Methods and compositions for treating sickness behavior or cachexia

Inhibiting prostaglandins, blocking receptors, and using omega-3 PUFAs with a low-fat diet addresses cachexia in cancer patients with LKB1 mutations, improving survival and quality of life by targeting metabolic reprogramming.

WO2026236367A1PCT designated stage Publication Date: 2026-11-12NEW YORK UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/US2026/026908
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-08-25
Filing Date
2026-05-06
Publication Date
2026-11-12

AI Technical Summary

Technical Problem

Current treatments for cancer-associated cachexia, which affects up to half of lung cancer patients, are ineffective, leading to significant morbidity and mortality due to anorexia and involuntary loss of lean and fat mass, with the underlying mechanisms largely unknown.

Method used

Inhibiting prostaglandin synthesis and activity, blocking prostaglandin receptors, and suppressing sensory neurons, combined with omega-3 PUFAs and a low-fat diet, to treat cachexia and sickness behavior in cancer patients with LKB1 mutations.

Benefits of technology

This approach effectively reduces cachexia-related symptoms and improves quality of life and survival in cancer patients by targeting the underlying metabolic reprogramming associated with LKB1 mutations.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure IMGF000013_0001
    Figure IMGF000013_0001
  • Figure IMGF000115_0001
    Figure IMGF000115_0001
  • Figure IMGF000123_0001_TABLE
    Figure IMGF000123_0001_TABLE
Patent Text Reader

Abstract

This invention relates to methods of treating cachexia and / or sickness behavior in a subject (e.g., a subject having cancer) and (i) a mutation in a liver kinase B1 (LKB1) gene and / or (ii) suppression of LKB1-mediated signaling. The invention also relates to inhibitors of one or more prostaglandins or its receptors, and / or sensory neurons as well as combinations of said inhibitors with one or more omega-3 PUFAs and / or a low-fat diet. The invention further relates to compositions comprising inhibitors of one or more prostaglandins or its receptors, and / or sensory neurons as well as methods of producing and using said inhibitors of one or more prostaglandins or its receptors, and / or sensory neurons, optionally in combination with one or more omega-3 PUFAs and / or a low-fat diet.
Need to check novelty before this filing date? Find Prior Art

Description

Attorney Docket No: 243735.000512METHODS AND COMPOSITIONS FOR TREATING SICKNESS BEHAVIOR OR CACHEXIACROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This application claims priority to U. S. Provisional Application Nos. 63 / 800,657 filed May 6, 2025, and 63 / 869,697 filed on August 25, 2025, the contents of which are incorporated herein by reference in their entireties.SEQUENCE LISTING

[0002] The instant application contains a Sequence Listing which has been submitted electronically in XML format and is hereby incorporated by reference in its entirety. Said XML copy, created on April 29. 2026, is named 243735_000512_SL.xml and is 57,274 bytes in size.FIELD OF THE INVENTION

[0003] This invention relates to methods of treating cachexia and / or sickness behavior in a subject (e.g., a subject having cancer) and (i) a mutation in a liver kinase Bl (LKB1) gene and / or (ii) suppression of LKB1 -mediated signaling. The invention also relates to inhibitors of one or more prostaglandins or its receptors, and / or sensory neurons as well as combinations of said inhibitors with one or more omega-3 PUFAs and / or a low-fat diet. The invention further relates to compositions comprising inhibitors of one or more prostaglandins or its receptors, and / or sensory neurons as well as methods of producing and using said inhibitors of one or more prostaglandins or its receptors, and / or sensory neurons, optionally in combination with one or more omega-3 PUFAs and / or a low-fat diet.BACKGROUND

[0004] Sickness behaviors are seen in cancer cachexia and affect up to half of lung cancer patients1,2, yet why certain patients develop this devastating syndrome remains largely unknown.

[0005] C ancer-associated cachexia (CAC) represents a paraneoplastic syndrome characterized by anorexia and / or the involuntary loss of lean and / or fat mass (including, without limitation, the loss of muscle mass with or without the loss of fat mass)1’9. This dramatic reprogramming of systemic metabolism leads to significant morbidity and mortality in cancer patients, and there are1328856447vlAttorney Docket No: 243735.000512currently no effective interventions to treat CAC. As development of cachexia is associated with impaired quality of life, decreased tolerance to therapy, and reduced overall survival, there is an urgent need to understand the mechanisms that promote cachexia in translationally relevant animal models to develop effective treatments for this syndrome.SUMMARY OF THE INVENTION

[0006] As specified in the Background section above, there is a need in the art to exploit approaches to develop effective treatments for treating sickness behavior and / or cachexia. The present application addresses these and other needs.

[0007] In one aspect, provided herein is a method of treating cachexia and / or sickness behavior in a subject having a cancer and (i) a mutation in a liver kinase Bl (LKB1) gene and / or (ii) suppression of LKBl-mediated signaling, wherein the method comprises a) inhibiting synthesis and / or activity and / or function of one or more prostaglandins; b) inhibiting one or more prostaglandin receptors; and / or c) inhibition of sensory neurons.

[0008] In some embodiments, the cancer comprises a lung cancer, a pancreatic cancer, a cervical cancer, and / or a cholangiocarcinoma.

[0009] In some embodiments, the cancer is non-small cell lung cancer.

[0010] In some embodiments, the LKB1 mutation comprises a loss of function mutation.

[0011] In some embodiments, the LKB1 mutation comprises a point mutation, a frameshift mutation, a splice mutation, an insertion mutation, a deletion mutation, a missense mutation, a nonsense mutation, a chromosomal arm deletion, and / or a focal deletion.

[0012] In some embodiments, the LKB1 mutation comprises a G251V mutation, a G251R mutation, a G251C mutation, a S216F mutation, a D194H mutation, a D194Y mutation, a G242W mutation, a G242V mutation, a W239C mutation, a Q220* mutation, a R86* mutation, a Y60* mutation, a E165* mutation, a P281Rfs*6 mutation, a L282Afs*3 mutation, a K84* mutation, a E223* mutation, a E33* mutation, D53Tfs*ll mutation, a K78N mutation, a E199* mutation, a G56V mutation, a E57Kfs*7 mutation, a D53Gfs*110 mutation, a G56W mutation, a E70* mutation, a K62* mutation, a A43Pfs*8 mutation, a E65* mutation, a Y60* mutation, a K146* mutation, a KI 75* mutation, a K262* mutation, a K235* mutation, a K78E mutation, a T250Rfs*37 mutation, a N259Kfs*28 mutation, a D176A mutation, a L228Rfs*33 mutation, a D30Gfs*133 mutation, a E265Gfs*19 mutation, a S69* mutation, a K108* mutation, a E138*2328856447vlAttorney Docket No: 243735.000512mutation, a V77Sfs*19 mutation, a Q37Pfs*123 mutation, a Q220Pfs*46 mutation, a M136K mutation, a M136I mutation, a STK11-ARHGAP45 Fusion mutation, a STK11-SRFBP1 Fusion mutation, a ARHGAP45-STK11 Fusion mutation, a TNRC6B-STK11 Fusion mutation, a Q137H mutation, a L245F mutation, a H168R mutation, a Q170P mutation, a Y118H mutation, a M129I mutation, a I224V mutation, a X200_splice mutation, a X155_splice mutation, a X245_splice mutation, a X288_splice mutation, and / or a X97_splice mutation.

[0013] In some embodiments, the suppression of LKB1 -mediated signaling includes a mutation in a salt-inducible kinase (SIK) gene.

[0014] In some embodiments, the SIK is SIK1, SIK2, and / or SIK3.

[0015] In some embodiments, the SIK mutation comprises a loss of function mutation.

[0016] In some embodiments, the prostaglandin is prostaglandin E2 (PGE2).

[0017] In some embodiments, the synthesis of the one or more prostaglandins is inhibited by decreasing activity and / or function of a prostaglandin synthase.

[0018] In some embodiments, the prostaglandin synthase is a cyclooxygenase (COX) enzyme, phospholipase A2, and / or prostaglandin E synthase (PTGES).

[0019] In some embodiments, the COX enzyme is COX-1 or COX-2.

[0020] In some embodiments, the activity and / or function of the COX enzyme is decreased by administering a therapeutic agent.

[0021] In some embodiments, the therapeutic agent that decreases the activity and / or function of the COX enzyme comprises a competitive inhibitor, a non-competitive inhibitor, an uncompetitive inhibitor, a reversible inhibitor, and / or an irreversible inhibitor.

[0022] In some embodiments, the therapeutic agent comprises a small molecule.

[0023] In some embodiments, the small molecule comprises a COX-1 inhibitor and / or a COX-2 inhibitor.

[0024] In some embodiments, the COX-1 inhibitor is a selective COX-1 inhibitor or a non-selective COX-1 inhibitor.

[0025] In some embodiments, the COX-2 inhibitor is a selective COX-2 inhibitor or a non-selective COX-2 inhibitor, optionally wherein the selective COX-2 inhibitor comprises celecoxib (Celebrex), NS-398 (N-[2-(cyclohexyloxy)-4-nitrophenyl]-methanesulfonamide), and / or valdecoxib (Bextra).3328856447vlAttorney Docket No: 243735.000512

[0026] In some embodiments, the therapeutic agent that decreases the activity and / or function of the COX enzyme comprises a non-steroidal anti-inflammatory drug (NSAID).

[0027] In some embodiments, the NSAID is ibuprofen or acetylsalicylic acid.

[0028] In some embodiments, the therapeutic agent that decreases the activity and / or function of the COX enzyme is an antibody.

[0029] In some embodiments, the therapeutic agent that decreases the activity and / or function of the COX enzyme comprises a polyunsaturated fatty acid (PUFA).

[0030] In some embodiments, the PUFA comprises an omega-3 PUFA.

[0031] In some embodiments, the PUFA comprises eicosapentaenoic acid (EPA) and / or docosahexaenoic acid (DHA).

[0032] In some embodiments, the EPA is administered in an amount of 250 mg / day to 3000 mg / day.

[0033] In some embodiments, the DHA is administered in an amount of 250 mg / day to 3000 mg / day.

[0034] In some embodiments, the ratio of EPA to DHA is 2:1.

[0035] In some embodiments, the prostaglandin synthase is prostaglandin E synthase (PTGES).

[0036] In some embodiments, the PTGES is microsomal PTGES.

[0037] In some embodiments, the activity and / or function of PTGES is decreased by administering a therapeutic agent.

[0038] In some embodiments, the therapeutic agent that decreases the activity and / or function of PTGES is a small molecule.

[0039] In some embodiments, the therapeutic agent that decreases the activity and / or function of PTGES is a small molecule selected from crisdesalazine (AAD-2004), compound III (N-cyclopentyl-l-[5,6-dimethyl-l-(l-methylethyl)-lH-benzimidazol-2-yl]-4-piperidinecarboxamide; mPGES-1 Inhibitor III), LY3023703 (2-(difluoromethyl)-5-[[(2-methyl-l-oxopropyl)amino]methyl]-N-[4-methyl-5-[4-(trifluoromethyl)phenyl]-lH-imidazol-2-yl]-3-pyridinecarboxamide), AF3485 (N-[9-(2-hydroxyethyl)-9H-carbazol-3-yl]-2-(trifluoromethyl)-benzamide), MF63 (2-(6-chloro-lH-phenanthro[9,10-d]imidazol-2-yl)-isophthalonitrile), AF3442 (N-(9-ethyl-9H-carbazol-3-yl)-2-(trifluoromethyl)benzamide), PF-9184 (N-(3’,4'-dichloro[l,l'-biphenyl]-4-yl)-4-hydroxy-2H-l,2-benzothiazine-3-carboxamide 1,1-dioxide), PF-4693627 (l-[5-chloro-6-(4-chlorophenyl)-2-benzoxazolyl]-N-[(lS,3S)-3-(hydroxymethyl)cyclohexyl]-4-4328856447vlAttorney Docket No: 243735.000512piperidinecarboxamide), EY3031207 (2-chloro-N-(lH-imidazol-2-yl)-5- (pivalamidomethyl)benzamide), YS121 (2-(4-chloro-6-(2,3-dimethylphenylamino)pyrimidin-2-ylthio)octanoic acid), MK-886 (l-[(4-chlorophenyl)methyl]-3-[(l.l-dimethylethyl)thio]-alpha,alpha-dimethyl-5-(l-methylethyl)-lH-indole-2-propanoic acid), and dexamethasone, or derivative(s) thereof.

[0040] In some embodiments, the therapeutic agent that decreases the activity and / or function of PTGES is an antibody.

[0041] In some embodiments, the activity and / or function of a prostaglandin is inhibited by increasing activity and / or function of a different prostaglandin.

[0042] In some embodiments, the activity and / or function of PGE2 is inhibited by increasing activity and / or function of prostaglandin E3 (PGE3), optionally by administering a PUFA, preferably an omega-3 PUFA, alone or in combination with a low-fat diet, for example simultaneously with a meal of the low-fat diet, before a meal of the low-fat diet, or after a meal of the low-fat diet.

[0043] In some embodiments, the PUFA comprises eicosapentaenoic acid (EPA) and / or docosahexaenoic acid (DHA).

[0044] In some embodiments, the EPA is administered in an amount of 250 mg / day to 3000 mg / day.

[0045] In some embodiments, the DHA is administered in an amount of 250 mg / day to 3000 mg / day.

[0046] In some embodiments, the ratio of EPA to DHA is 2:1.

[0047] In some embodiments, the therapeutic agent is administered in combination with a PUFA, preferably an omega-3 PUFA.

[0048] In some embodiments, the PUFA comprises eicosapentaenoic acid (EPA) and / or docosahexaenoic acid (DHA).

[0049] In some embodiments, the EPA is administered in an amount of 250 mg / day to 3000 mg / day.

[0050] In some embodiments, the DHA is administered in an amount of 250 mg / day to 3000 mg / day.

[0051] In some embodiments, the ratio of EPA to DHA is 2:1.5328856447vlAttorney Docket No: 243735.000512

[0052] In some embodiments, the therapeutic agent, optionally in combination with the PUFA, is administered with a low-fat diet.

[0053] In some embodiments, the therapeutic agent, optionally in combination with the PUFA, is administered simultaneously with a meal of the low-fat diet, before a meal of the low-fat diet, or after a meal of the low-fat diet.

[0054] In some embodiments, the one or more prostaglandin receptors are selected from the group consisting of prostaglandin E2 receptor 1 (EPl), prostaglandin E2 receptor 2 (EP2), prostaglandin E2 receptor 3 (EP3), and prostaglandin E2 receptor 4 (EP4).

[0055] In some embodiments, the one or more prostaglandin receptors are EPl receptors.

[0056] In some embodiments, the activity and / or function of the one or more prostaglandin receptors is inhibited by an antagonist.

[0057] In some embodiments, the antagonist is a competitive antagonist, a non-competitive antagonist, an uncompetitive antagonist, a reversible antagonist, and / or an irreversible antagonist.

[0058] In some embodiments, the antagonist is a small molecule.

[0059] In some embodiments, the one or more prostaglandin receptors are EPl receptors and the antagonist comprises SC-51322, GW-848687X, SC- 19220, SC-51089, ONO-8713, ONO-8130, and / or ONO-8711.

[0060] In some embodiments, the one or more prostaglandin receptors are EP2 receptors and the antagonist comprises PF-04418948, TG6-10-1, and / or TG8-260.

[0061] In some embodiments, the one or more prostaglandin receptors are EP3 receptors and the antagonist comprises DG-041, L798-106, and / or ONO-AE3-240.

[0062] In some embodiments, the one or more prostaglandin receptors are EP4 receptors and the antagonist comprises ONO-AE3-208, LY3127760, Grapiprant, AH6809, and / or RQ-15986.

[0063] In some embodiments, the antagonist is an antibody.

[0064] In some embodiments, the antagonist is administered in combination with a PUFA, preferably an omega-3 PUFA.

[0065] In some embodiments, the PUFA comprises eicosapentaenoic acid (EPA) and / or docosahexaenoic acid (DHA).

[0066] In some embodiments, the EPA is administered in an amount of 250 mg / day to 3000 mg / day.6328856447vlAttorney Docket No: 243735.000512

[0067] In some embodiments, the DHA is administered in an amount of 250 mg / day to 3000 mg / day.

[0068] In some embodiments, the ratio of EPA to DHA is 2:1.

[0069] In some embodiments, the antagonist, optionally in combination with the PUFA, is administered with a low-fat diet.

[0070] In some embodiments, the antagonist, optionally in combination with the PUFA, is administered simultaneously with a meal of the low-fat diet, before a meal of the low-fat diet, or after a meal of the low-fat diet.

[0071] In some embodiments, the sensory neurons are inhibited by a chemogenetic compound, blocking or stimulating a vagal nerve in the subject, or by vagotomy.

[0072] In some embodiments, the sensory neurons are adjacent to the cancer in the subject.

[0073] In some embodiments, the sensory neurons are in a lung of the subject.

[0074] In some embodiments, the chemogenetic compound comprises clozapine-N-oxide (CNO).

[0075] In some embodiments, the vagotomy is unilateral.

[0076] In some embodiments, blocking the vagal nerve comprises an intermittent vagal blockade, optionally via an implanted device.

[0077] In some embodiments, the vagal nerve is stimulated via an implanted device.

[0078] In some embodiments, the method further comprises(i) administering a therapeutic agent according to the method of the present disclosure, (ii) increasing activity and / or function of the different prostaglandin according to the method of the present disclosure, and / or(iii) administering an antagonist according to the method of the present disclosure.

[0079] In some embodiments, the subject is a mammal.

[0080] In some embodiments, the subject is a human.BRIEF DESCRIPTION OF THE DRAWINGS

[0081] Figs. 1A-1I depict that loss of Lkbl promotes cachexia in autochthonous models of lung cancer. Fig. 1A depicts a schematic illustrating timeline for genetically-engineered mouse model (GEMM) experiments. Tumors were initiated in animals and allowed to progress for 10 weeks before mice were placed into metabolic cages for 1 week. Fig. IB depicts representative7328856447vlAttorney Docket No: 243735.000512hematoxylin and eosin (H& E) images of tumor burden in lungs collected from p53 (KP), Cdkn2a / 2b (KCC), or Lkbl (KL) mice 11 weeks post tumor initiation, with quantification of tumor burden (tumor area / total lung area). Values are mean ± s.e.m.; n=14 KP, z?=12 KCC, zt=16 KL mice. One-way analysis of variance (ANOVA) with Tukey’s multiple comparison test. P-0.8024 (KP vs KCC); P-0.2987 (KP vs KL); P-0.1035 (KCC vs KL). Mice were placed in metabolic cages for 7 days, with the first two days excluded to allow mice to adjust to new environment. Values are mean ± s.e.m.; n-4 mice per group. One-way ANOVA with Tukey’s multiple comparison test of final day in metabolic cages (Day 5). Fig. 1C depicts relative weight of mice normalized to first day of measurement. P-0.8395 (KP vs KCC); P-0.0341 (KP vs KL); P-0.0142 (KCC vs KL). Fig. ID depicts cumulative food intake (grams) of mice in metabolic cages. P-0.1754 (KP vs KCC); P-0.0055 (KP vs KL); P-0.0011 (KCC vs KL). Fig. IE depicts cumulative water intake (grams) of mice in metabolic cages. P-0.2310 (KP vs KCC); P<0.0001 (KP vs KL); P-0.0002 (KCC vs KL). KP= circle, KCC= diamond, KL =square. Fig. IF depicts cumulative locomotive activity (cumulative beam breaks) of mice in metabolic cages. P= 0.4713 (KP vs KCC); P-0.0003 (KP vs KL); P-0.0011 (KCC vs KL). KP- circle, KCC= diamond, KL =square. Figs. 1G-1I depict dual-energy X-ray absorptiometry (DEXA) scans measuring the total (Fig. 1G), fat (Fig. 1H), and lean (Fig. II) mass of genetically-engineered mouse models (GEMMs) at 11 weeks post tumor initiation. Values are mean ± s.e.m.; n=5 mice per group. Oneway ANOVA with Tukey’s multiple comparison test. Fig. 1G, Total mass: P-0.0172 (KP vs KCC); P<0.0001 (KP vs KL); P-0.0169 (KCC vs KL). Fig. 1H, Fat mass: P-0.1987 (KP vs KCC); P-0.0008 (KP vs KL); P-0.0197 (KCC vs KL). Fig. II. P-0.0431 (KP vs KCC); P-0.0003 (KP vs KL); P-0.0399 (KCC vs KL). *P<0.05, **P<0.01, ***P<0.001, ***P<0.0001; ns: not significant. Schematic in Fig. 1A created at BioRender.com.

[0082] Figs. 2A-2K depict that high-fat diets exacerbate cachexia in Lkbl -mutant lung adenocarcinoma (LUAD). Fig. 2A depicts a schematic demonstrating timeline for dietary interventions in Tm-GEMMs. Tumors were initiated in animals and allowed to progress for 4 weeks before mice were placed on high-fat diet (HFD), ketogenic diet, or maintained on chow.Fig. 2B depicts relative weight of Kras-GEMMs normalized to weights at time of diet swap. Values are mean ± s.e.m.; n= 13 KP chow, n= 14 KP HFD, «=15 KCC chow / HFD, w-12 KL chow, n=9 KL HFD. One-way ANOVA with Tukey’s multiple comparison test. P<0.0001 (KP Chow vs HFD); P<0.0001 (KCC Chow vs HFD): P-0.0092 (KL Chow vs HFD); P<0.0001 (KP HFD vs8328856447vlAttorney Docket No: 243735.000512KL HFD); P <0.0001 (KCC HFD vs KL HFD). Figs.2C-2E depict survival curves for each Kras-GEMM placed on HFD, ketogenic diet, or maintained on chow after 4 weeks of tumor progression. Log-rank (Mantel-Cox) test. Fig. 2C, 77=17 KL chow, 77=15 KL Keto, 77=15 KL HFD. P<0.0001 (KL Chow vs HFD); P<0.0001 (KL Chow vs Keto); P=0.8703 (KL Keto vs HFD). Fig.2D, 77=15 KCC chow, 77= 13 KCC Keto, 77=14 KCC HFD. P=0.0067 (KCC Chow vs HFD); P=0.6615 (KCC Chow vs Keto); P=0.0163 (KCC Keto vs HFD). Fig. 2E, 77=11 KP chow, 77=13 KP Keto. 77=13 KP HFD. P=0.0644 (KP Chow vs HFD); P=0.5973 (KCC Chow vs Keto); P=0.2352 (KCC Keto vs HFD). Figs. 2F-2I depict that mice were placed in metabolic cages for 20 days, with the first two days excluded to allow mice to adjust to new environment. After 7 days, mice were swapped to HFD or maintained on normal chow. Values are mean ± s.e.m.; 77=4 mice per group. A mean daily change in parameter (days 8-20) was calculated based on baseline data from days 2-7 from each mouse. Two-tailed unpaired t-test. Fig. 2F, Relative weight of KL GEMMs normalized to first day diet swap. P=0.0091. Fig. 2G, Relative food intake of KL GEMMs fed chow or HFD; P=0.002. Fig. 2H, Relative water intake of KL GEMMs fed chow or HFD; P=0.0006. Fig. 21, Relative locomotive activity (beam breaks) of KL GEMMs fed chow or HFD. P=0.0041. Figs.2J-2K depict immunostaining of Fos Proto-oncogene (FOS) in the area postrema (AP) and nucleus tractus solitarii (NTS) from KL GEMMs collected 2 weeks post-diet swap. Quantification of FOS-positive neurons (FOS+nuclei / total nuclei). Values are mean ± s.e.m.; 77=8 AP Chow, 77=9 AP HFD, 77= 5 Chow NTS, 77=5 HFD NTS. Two-tailed unpaired t-test. P=0.0035. *P<0.05, **P<0.01, ***P<0.001, ***P<0.0001; ns: not significant. Schematic in Fig. 2A created at BioRender.com.

[0083] Figs.3A-3J depict that localized eicosanoid signaling promotes cachexia in KL GEMMs fed HFD. Fig. 3A depicts a biosynthetic pathway of omega-6 (co-6) eicosanoids (PGE2) including relevant biosynthetic enzymes and inhibitors. Fig. 3B depicts levels of PGE2 in bronchoalveolar lavage fluid from KL GEMMs 3 days post diet swap. P=0.0013. Two-tailed unpaired t-test. Values are mean ± s.e.m.; 77=5 mice per group. Fig. 3C depicts Ptges expression (normalized to Actb) in sorted tumor cells from Lkbl wildtype or mutant GEMMs. Values are mean ± s.e.m.; 77=4 WT and 77=3 Lkbl^. P=0.0011. Fig.3D depicts Ptges expression (normalized to Actb) in sorted tumor cells from Lkbl -mutant GEMMs fed chow or HFD 3-weeks post diet swap (7 weeks post-initiation). Values are mean ± s.e.m.; n=3 chow and n=4 HFD. P=0.0013. Figs. 3E-3F depict that tumors were initiated in KL GEMMs and allowed to develop for 4 weeks before animals were treated daily with acetylsalicylic acid (ASA or aspirin) (100 mg / kg, IP) or vehicle (PBS). Following 29328856447vlAttorney Docket No: 243735.000512days of pretreatment, animals were switched to HFD or maintained on chow. Values are mean ± s.e.m.; n=6 (chow), 7 (HFD; HFD+ASA). A mean daily change in parameter was calculated based on baseline data from each mouse. One-way ANOVA with Tukey’s multiple comparison test. Fig.3E depicts relative food intake of KL GEMMs fed chow or HFD (treated with vehicle or ASA); P=0.0008 (Chow vs HFD); P=0.8893 (Chow vs HFD+ASA); P=0.0002 (HFD vs HFD+ASA).Fig. 3F depicts relative water intake of KL GEMMs fed chow or HFD (treated with vehicle or ASA); P<0.0001 (Chow vs HFD); P=0.5062 (Chow vs HFD+ASA); P<0.0001 (HFD vs HFD+ASA). Fig. 3G depicts normalized levels of significantly changed polyunsaturated fatty acids (PUFA) species from bronchoalveolar lavage fluid from KL GEMMs fed chow or HFD 3 days post-diet swap, n-5 mice per condition. P=0.0001 (PGE3); P=0.0033 (PGD3); P=0.0148 (LTB5); P=0.0174 (RvDi & AT- RvDi). In the heatmap, normalized values from -1 to 0 are represented by a gradient from darker to lighter shades, whereas values from 0 to 2 are represented by a gradient from lighter to darker shades. Fig. 3H depicts a biosynthetic pathway of omega-3 (ro-3) eicosanoids including relevant biosynthetic enzymes and inhibitors. Fig. 31 depicts that tumors were initiated in KL GEMMs and allowed to progress for 4 weeks before animals were swapped to traditional HFD, fish oil HFD, or maintained on chow, and measurements of body weight recorded. Values are mean ± s.e.m.; n=5 mice per group. One-way ANOVA with Tukey’s multiple comparison test. P=0.0001 (Chow vs HFD); P=0.3110 (Chow vs fish oil HFD); P=0.0008 (HFD vs fish oil HFD). Fig.3J depicts survival curves for each KL GEMMs placed on traditional HFD, fish oil HFD, or maintained on chow after 4 weeks of tumor progression. Logrank (Mantel-Cox) test. n=5 mice per group. P=0.0021 (Chow vs HFD); P=0.0157 (Chow vs fish oil HFD); P=0.0021 (HFD vs fish oil HFD). P=0.0035. *P<0.05, **P<0.01, ***P<0.001, ***P<0.0001; ns: not significant.

[0084] Figs. 4A-4G depict that signaling through vagal sensory neurons contribute to diet-induced cachexia. Fig. 4A depicts a schematic illustrating the timeline of unilateral cervical vagotomy and diet swap in KL GEMMs. Tumors were allowed to progress for 2 weeks after which the right vagus nerve was transected. Animals were then allowed to recover for 2 weeks before swap to HFD or maintained on chow. Figs. 4B-4C depict a mean daily change in intake was calculated based on baseline data from each mouse. Values are mean ± s.e.m.; n=5 mice per group.2 chow mice had to be excluded from water intake studies due to leaking water bottles. One-way ANOVA with Tukey’s multiple comparison test. Fig. 4B depicts relative food intake of KL10328856447vlAttorney Docket No: 243735.000512GEMMs fed chow or HFD (sham vs vagotomy). P=0.0002 (Chow vs HFD); P=0.0459 (Chow vs HFD+Vagotomy); P=0.0157 (HFD vs HFD+Vagotomy). Fig.4C depicts relative water intake of KE GEMMs fed chow or HFD (sham vs vagotomy). P=0.0046 (Chow vs HFD); P=0.2485 (Chow vs HFD+Vagotomy); P=0.0385 (HFD vs HFD+Vagotomy). Fig. 4D depicts a schematic illustrating the timeline of designer receptors exclusively activated by designer drugs (DREADD) experiment and diet swap in KE GEMMs. Tumors were allowed to progress for 2 weeks after which animals were intratracheally administered virus. Animals were then allowed to recover for 2 weeks before 1 day pretreatment with clozapine-N-oxide (CNO) (EP. 1 mg / kg administered 30 minutes prior to dark cycle and orally in drinking water at 5 ag / mL) or vehicle (PBS). Animals were then swapped to HFD or maintained on chow with daily treatment of CNO (EP. 1 mg / kg administered 30 minutes prior to dark cycle and orally in drinking water at 5 p.g / mL). Figs.4E-4F depict a mean daily change in intake was calculated based on baseline data from each mouse. Values are mean ± s.e.m.; n=5 (chow and HFD) and 7 (HFD +CNO). One-way ANOVA with Tukey’s multiple comparison test. Fig. 4E depicts relative food intake of KL GEMMs fed chow or HFD (vehicle or CNO). P=0.0002 (Chow vs HFD); P=0.2384 (Chow vs HFD+CNO); P=0.0017 (HFD vs HFD+CNO). Fig. 4F depicts relative water intake of KL GEMMs fed chow or HFD (vehicle or CNO). P<0.0001 (Chow vs HFD); P=0.9936 (Chow vs HFD+CNO); P=0.0001 (HFD vs HFD+CNO). P=0.0035. Fig. 4G depicts a model of sensory-neuron mediated cachexia in context of high-fat diet. *P<0.05, **P<0.01, ***P<0.001, ***P<0.0001; ns: not significant. Schematics in Figs.4A, 4D, and 4G created at BioRender.com.

[0085] Figs. 5A-5G depict that loss of Lkbl leads to loss of lean and fat mass in non-small cell lung cancer (NSCLC). Fig. 5A depicts a schematic of V / Y / . V-GEMMS with viral constructs to generate genetic subtypes of NSCLC. Figs. 5B-5D depict the total (Fig. 5B), fat (Fig. 5C), and lean (Fig. 5D) mass of KP, KC, and KL GEMMs. Figs. 5E-5F depict relative total weight of inguinal white adipose tissue (iWAT) (Fig. 5E) and gastrocnemius (Fig. 5F) normalized to total body weight. Values are mean ± s.e.m.; zz=8 mice per condition. One-way ANOVA with Tukey’s multiple comparison test. Fig. 5E, P-0.9803 (KP vs KCC); P=0.0013 (KP vs KL); P-0.0008 (KCC vs KL). Fig. 5F, P=0.4074 (KP vs KCC); P=0.0081 (KP vs KL); P=0.0004 (KCC vs KL).Fig. 5G depicts energy expenditure (adjusted by lean mass using ANCOVA) in animals whose tumors were initiated and allowed to progress for 10 weeks before mice were placed into metabolic cages for 1 week. Values are mean ± s.e.m.; / ?=4 mice per condition. P=0.1427 (KP vs KCC);11328856447vlAttorney Docket No: 243735.000512P=0.2417 (KP vs KL); P=0.0011 (KCC vs KL). One-way ANOVA with Tukey’s multiple comparison test. *P<0.05, **P<0.01, ***P<0.001, ***P<0.0001; ns: not significant. Schematic in Fig. 5A created at BioRender.com.

[0086] Figs. 6A-6L depict that energy dense diets promote weight loss and decreased survival in KL GEMMs in a tumor non-autonomous manner. Figs. 6A-6B depict macronutrient composition and caloric density of the three diets used in dietary interventions in GEMMs. Data in (Fig. 6A) are presented as proportion of total calories. Fig. 6C depicts relative weight of Kras-GEMMs normalized to weights at time of diet swap. Values are mean ± s.e.m.: 77=13 KP chow, 77=10 KP Keto, 77=15 KCC chow, 77=13 KCC Keto, 77=12 KL chow, 77=11 KL Keto. One-way ANOVA with Tukey’s multiple comparison test. P=0.9830 (KP Chow (open diamond with solid line) vs Keto (closed diamond with dashed line)); P=0.7763 (KCC Chow (open circle with solid line) vs Keto (closed circle with dashed line)); P- 0.0005 (KL Chow (open square with solid line) vs Keto (closed square with dashed line)); P<0.0001 (KP Keto vs KL Keto); P<0.0001 (KCC Keto vs KL Keto). Figs.6D-6E depict survival curves for male and female KL GEMMs placed on HFD (Fig. 6D), ketogenic diet (Fig. 6E), or maintained on chow after 4 weeks of tumor progression. Log-rank (Mantel-Cox) test. Fig.6D, 77=10 KL female chow, 77=12 KL female HFD, 77=13 KL male chow. 77=12 KL male HFD. P<0.0001 (KL female Chow vs HFD); P<0.0001 (KL male chow vs HFD); P=0.7066 (KL male HFD vs female HFD). Fig. 6E, 77=9 KL female chow, 77=10 KL female keto. n=9 KL male chow. 77=8 KL male HFD. P<0.0001 (KL female Chow vs keto); P<0.0001 (KL male Chow vs Keto); P=0.4260 (KL male keto vs female keto). Figs. 6F-6L depict that systemic metabolic changes in KL mice occur in a tumor non-autonomous manner.Figs.6F-6G depict blood ketone (Fig.6F) or glucose levels (Fig.6G) in KL GEMMs 1 week post dietary intervention. Values are mean ± s.e.m.; 77=16 (chow), 77=13 (HFD), 77=15 (keto). Fig. 6F, P<0.0001 (chow vs keto), P=0.9902 (chow vs HFD), P<0.0001 (Keto vs HFD). Fig.6G, P<0.0001 (chow vs keto), P=0.7794 (chow vs HFD), P<0.0001 (Keto vs HFD). Figs. 6H-6I depict blood ketone (Fig. 6H) or glucose levels (Fig. 61) in KP GEMMs 1 week post dietary intervention. Values are mean ± s.e.m.; 77=13 (chow), 77=14 (HFD and keto). Fig.6H, P<0.0001 (chow vs keto), P=0.9014 (chow vs HFD), P<0.0001 (Keto vs HFD). Fig.61, P=0.0002 (chow vs keto), P=0.9599 (chow vs HFD), P=0.0004 (Keto vs HFD). Figs. 6J-6K depict blood ketone (Fig. 6J) or glucose levels (Fig.6K) in KCC GEMMs 1 week post dietary intervention. Values are mean ± s.e.m.; 77=15 (chow), 77=14 (HFD), 77=13 (keto). Fig. 6J, P<0.0001 (chow vs keto), P=0.9446 (chow vs HFD),12328856447vlAttorney Docket No: 243735.000512P<0.0001 (Keto vs HFD). Fig.6K, P=0.0002 (chow vs keto), P<0.0001 (chow vs HFD), P=0.0004 (Keto vs HFD). Fig. 6L depicts representative H& E images of lungs (right) from KL GEMMs 3 weeks post diet swap, with quantification calculated as tumor area over total lung area. Values are mean ± s.e.m.; n-8 (chow and HFD),10( keto). P-0.2581 (chow vs keto), P =0.7749 (chow vs HFD), P=0.6473 (Keto vs HFD). P-values for Figs. 6F-6L were calculated using one-way ANOVA with Tukey’s multiple comparison test. *P<0.05, **P<0.01, ***P<0.001, ***P<0.0001; ns: not significant.

[0087] Figs. 7A-7I depict physiological changes in KL GEMMs fed HFD. Figs. 7A-7B depict energy expenditure (adjusted by lean mass using ANCOVA) (Fig. 7A) in KL GEMMs whose tumors were initiated and allowed to progress for 3 weeks before mice were placed into metabolic cages. After 1 week, animals were swapped to HFD or maintained on chow. Values are mean ± s.e.m.; n=4 mice per condition. Two-tailed unpaired t-test. Fig. 7A, =0.2944 (chow (dark) vs HFD (light)). Fig. 7B, P<0.0001 (chow vs HFD). Figs. 7B-7C depict that tumors were initiated in KrasLSL (’l2l)'+p53fl / fland Rosa26LSL’Cas9GFP / LSL’Cas9GFPanimals with lentiviruses constitutively expressing Cre-recombinase and either non-targeting sgRNAs (KP) or sgRNAs targeting Lkbl (KPL). After 4 weeks, animals were swapped to HFD or maintained on chow. A mean daily change in intake was calculated based on baseline data from each mouse. Values are mean ± s.e.m.; n=5 mice per group. One-way ANOVA with Tukey’s multiple comparison test. Fig.7B, Relative food intake of KP or KPL GEMMs fed chow or HFD; P=0.0002 (KP chow (open circle with dashed line) vs KP HFD (closed square with dashed line)), P< 0.0001 (KPL Chow (closed circle with solid line) vs KPL HFD (closed square with solid line)). P<0.0001 (KP HFD vs KPL HFD). Fig. 7C, Relative water intake of KP or KPL GEMMs fed chow or HFD; P=0.9998 (KP chow (open circle with dashed line) vs KP HFD (closed square with dashed line)), P<0.0001 (KPL Chow (closed circle with solid line) vs KPL HFD (closed square with solid line)), P<0.0001 (KP HFD vs KPL HFD). Figs. 7D-7F depict percent weight (Fig. 7D), Ucpl and Dio2 expression (Fig. 7E), and adipocyte size (Fig. 7F) of inguinal white adipose tissue (iWAT) isolated from KL GEMMS or littermate, non-tumor bearing controls (WT) on chow or HFD 3-weeks post diet swap. Values are mean ± s.e.m. One-way ANOVA with Tukey’s multiple comparison test. Fig. 7D, iWAT weight normalized to total mouse weight. n=8 (WT chow), n= 10 (WT HFD), «=13 (KL chow), n=15 (KL HFD). P<0.0001 (WT chow vs WT HFD), P=0.6596 (WT chow vs KL chow), P<0.0001 (WT HFD vs KL HFD), P=0.0040 (KL chow vs KL HFD). Fig.7E, Relative expression normalized to13328856447vlAttorney Docket No: 243735.000512Actb of Ucpl and Dio2. n=4 (WT chow and HFD), 77=8 (KL chow and HFD). Fig.7F, Adipocyte size of iWAT. P<0.0001 (WT chow vs WT HFD), P<0.0001 (WT chow vs KL chow), P<0.0001 (WT HFD vs KL HFD), P<0.0001 (KL chow vs KL HFD). Figs. 7G-7I depict percent weight (Fig. 7G), gene expression (Fig. 7H), and muscle fiber size (Fig. 71) of gastrocnemius isolated from KL GEMMS or littermate, non-tumor bearing controls (WT) on chow or HFD 3-weeks post diet swap. Values are mean ± s.e.m. One-way ANOVA with Tukey’s multiple comparison test.Fig. 7G, Gastrocnemius weight normalized to total mouse weight. 77=8 (WT chow), n= 10 (WT HFD), 77=13 (KL chow), 77=15 (KL HFD). P=0.3125 (WT chow vs WT HFD), P=0.9848 (WT chow vs KL chow), P=0.9776 (WT HFD vs KL HFD), P=0.1374 (KL chow vs KL HFD). Fig.7H, Relative expression normalized to Actb of Trim63, Mstn, Foxo3 and Fbxo32 for WT chow, WT HFD, KL chow, and KL HFD in the order of appearance. 77=4 (WT chow and HFD), 77=8 (KL chow and HFD). Fig.71, Muscle fiber size of gastrocnemius. P<0.0001 (WT chow vs WT HFD), P=0.0005 (WT chow vs KL chow), P<0.0001 (WT HFD vs KL HFD). P=0.4081 (KL chow vs KL HFD). *P<0.05, **P<0.01, ***P<0.001, ***P<0.0001; ns: not significant.

[0088] Fig. 8A-8J depict that interleukin 6 (IL-6) and Growth Differentiation Factor 15 (GDF- 15) are dispensable for HFD induced cachexia. Fig. 8A depicts the results of enzyme-linked immunosorbent assay (ELISA) of IL-6 in plasma from WT, KL, or KP GEMMs 3 weeks following dietary swap to HFD or maintenance on chow. Values are mean ± s.e.m.; 77=6 (WT mice), 77=14 (KL mice), 77=8 (KP mice). One-way ANOVA with Tukey’s multiple comparison test. P=0.0266 (WT chow vs KL chow), P<0.0001 (WT HFD vs KL HFD), P<0.0001 (KL chow vs KL HFD), P<0.0001 (KP HFD vs KL HFD), P=0.0048 (KL chow vs KP chow). Figs. 8B-8C depict food (Fig. 8B) and water (Fig. 8C) intake from KL GEMMs maintained on chow, switched to HFD, or switched to HFD and treated with anti-IL-6 antibody (100 gg I. P. daily). A mean daily change in intake was calculated based on baseline data from each mouse. Values are mean ± s.e.m.; n=5 mice per group. One-way ANOVA with Tukey’s multiple comparison test. Fig. 8B depicts normalized food intake in vehicle treated or anti-IL-6 treated animals. P<0.0001 (Chow vs HFD), P=0.0007 (Chow vs HFD+anti-IL6), P=0.1696 (HFD vs HFD+anti-IL6). Fig. 8C depicts normalized water intake in vehicle treated or anti-IL-6 treated animals. P<0.0001 (Chow vs HFD), P<0.0001 (Chow vs HFD+anti-IL6), P=0.8526 (HFD vs HFD+anti-IL6). Fig. 8D depicts the results of ELISA of GDF-15 in plasma from WT, KL, or KP GEMMs 3 weeks following dietary swap to HFD or maintenance on chow. Values are mean ± s.e.m.; 77=6 (WT mice). 77=14 (KL14328856447vlAttorney Docket No: 243735.000512mice), M=8 (KP mice). One-way ANOVA with Tukey’s multiple comparison test. P=0.2114 (WT chow vs WT HFD), P=0.0180 (WT chow vs KL chow), P<0.0001 (WT HFD vs KL HFD), P<0.0001 (KL chow vs KL HFD), P<0.0001 (KP HFD vs KL HFD). Fig. 8E depicts a schematic of KrasLSL'12D / +' Gdfl5‘ / _mice with viral constructs expressing Cas9-Cre and an sgRNA targeting Lkbl to generate Kras-GDF15-Lkbl mutant GEMMs. Figs.8F-8I depict that tumors were initiated in Kras-GDF15-Lkbl mutant GEMMs and allowed to develop for 8 weeks, after which mice were swapped to HFD or maintained on normal chow. Fig. 8J depicts the results of ELISA of IL-6 in broncheoalveolar lavage in vehicle treated or anti-IL-6 animals. n=4 per group. Values are mean ± s.e.m.; n=6 mice per group. Two-tailed unpaired t-test. Fig. 8F, Food intake, P<0.0001. Fig.8G, Water intake. P<0.0001. Fig. 8H, Relative weight normalized to weight at diet swap; P=0.0015.Fig.81. Survival of Kras-GDF15-Lkbl mutant GEMMs on chow or HFD. Log-rank (Mantel-Cox) test; =0.0016. *P<0.05, **P<0.01, ***P<0.001, ***P<0.0001; ns: not significant. Schematic in Fig.8E created at BioRender.com.

[0089] Figs. 9A-9G depict cytokine profiling of bronchoalveolar lavage fluid in KL GEMMs. Luminex profiling of bronchoalveolar lavage fluid collected from KL GEMMs 3 days post diet swap. Values are mean ± s.e.m.; n=8 (chow). n=10 (HFD); Two-tailed unpaired t-test. Fig. 9A, P<0.0001 (IL-6), Fig.9B, P=0.0824 (TNFa), Fig.9C, P=0.5848 (IL-lp), Fig.9D, P=0.7313 (IL-la). Fig.9E. P=0.9308 (IFNy), Fig.9F. P=0.9316 (CCL2), Fig.9G, P=0.1183 (LIF). P=0.0016. *P<0.05, **P<0.01, ***P<0.001, ***P<0.0001; ns: not significant.

[0090] Figs. 10A-10F depict that Lkbl regulates eicosanoid production in NSCLC. Fig. 10A depicts gene expression of PTGES in LU AD patients based on the Cancer Genomic Atlas (TCGA) study. Figs. 10B-10C depict that gene expression of prostaglandin synthesis enzymes normalized to Actb in H2009 or H358 LKB1-WT NSCLC human cell lines transfected with Cas9 and a nontargeting sgRNA (sgTOM) or sgRNA targeting LKBL Fig. 10B, PTGES expression in H2009 NSCLC-cell lines, P=0.0001 (sgTOM vs sgLKBl.l), P<0.0001 (sgTOM vs sgLKB1.2). PTGS2 expression in 2009 NSCLC-cell lines. P=0.0062 (sgTOM vs sgLKBl.l), P=0.0022 (sgTOM vs sgLKB1.2). Fig. 10C, PTGES expression in H358 NSCLC-cell lines, P=0.0005 (sgTOM vs sgLKBl.l), P<0.0001 (sgTOM vs sgLKB1.2), PTGS1 expression in 2009 NSCLC-cell lines, P<0.0001 (sgTOM vs sgLKBl.l or sgLKB1.2), PTGS2 expression in 2009 NSCLC-cell lines, P=0.0012 (sgTOM vs sgLKBl.l), P<0.0001 (sgTOM vs sgLKB1.2). Figs. 10D-10E depict that gene expression of prostaglandin synthesis enzymes normalized to Actb in A549 or H23 LKB1-15328856447vlAttorney Docket No: 243735.000512mutant NSCLC human cell lines transfected with luciferase, LKB1 cDNA (LKB1 WT), or kinase-dead LKB1 (LKB1 KD). Fig. 10D, PTGES and PTGS2 expression in A549 cell lines, P<0.0001 (LK. B1 WT vs Luciferase or LKB1 KD). Fig. 10E, PTGES expression in H23 cell lines, P<0.0001 (LKB1 WT vs Luciferase or LKB1 KD). Fig. 10F depicts enzyme-linked immunosorbent assay (ELISA) of PGE2 in cell-culture supernatant in Kras-P53-LkW mouse NSCLC cell-lines treated for 24 hours with 3mM linoleic acid. P=0.0010 (395; control vs linoleic acid). P=0.0067 (454, control vs linoleic acid). Figs. 10B-10F, Values are mean ± s.e.m.; n=3 replicates per condition.Figs. 10B-10E, One-way ANOVA with Tukey’s multiple comparison test. Fig. 10F, Two-tailed unpaired t-test. *P<0.05, **P<0.01, ***P<0.001, ***P<0.0001; ns: not significant.

[0091] Figs. 11A-11G depict disruptions in prostaglandin signaling in KL GEMMs fed HFD.Figs. 11A-11B depict the results of enzyme-linked immunosorbent assay (ELISA) of PGE2 in bronchoalveolar lavage fluid from KL GEMMs treated with acetylsalicylic acid (ASA) (Fig. 11 A) or ibuprofen (Fig. 11B) following dietary swap to HFD or maintenance on chow. Values are mean ± s.e.m.; One-way ANOVA with Tukey’s multiple comparison test. Fig. 11A, n=6 (chow), 7=8 (HFD), n- 7 (HFD+ASA), P=0.0092 (Chow vs HFD), P=0.9881 (Chow vs HFD+ASA), P=0.0048 (HFD vs HFD+ASA). Fig. 11B, n=5 per group: P=0.0017 (Chow vs HFD), P=0.6833 (Chow vs HFD+ibuprofen), P=0.0075 (HFD vs HFD+ibuprofen). Figs. 11C-11D depict that tumors were initiated in KL GEMMs and allowed to develop for 4 weeks before animals were treated daily with ibuprofen (5 mg / ml, drinking water) or vehicle (saline). Following 3 days of pretreatment, animals were switched to HFD or maintained on chow. Values are mean ± s.e.m.; n=7 (chow; HFD), n= (HFD+ibuprofen). A mean daily change in parameter was calculated based on baseline data from each mouse. One-way ANOVA with Tukey’s multiple comparison test. Fig.11C depicts relative food intake of KL GEMMs fed chow or HFD (treated with vehicle or ibuprofen); P<0.0001 (Chow vs HFD); P=0.0010 (Chow vs HFD+ibuprofen); P=0.0181 (HFD vs HFD+ibuprofen). Fig. 11D, Relative water intake of KL GEMMs fed chow or HFD (treated with vehicle or ibuprofen); P=0.0059 (Chow vs HFD); P=0.5573 (Chow vs HFD+ibuprofen); P=0.0435 (HFD vs HFD+ibuprofen). Figs.11E-11F depict macronutrient composition and caloric density of the three diets used in dietary interventions used in Figs.3G-3H. Data in (Fig. HE) are presented as proportion of total calories. Fig. 11G, Lipid species comparison between lard, the main component of standard HFD, and fish oil, presented as proportion of total lipid species. *P<0.05, **P<0.01, ***P<0.001, ***P<0.0001; ns: not significant.16328856447vlAttorney Docket No: 243735.000512

[0092] Figs. 12A-12B depict the results of studies performed to identify the prostaglandin receptor mediating the sickness behavior.

[0093] Figs. 13A-13I demonstrate that localized eicosanoid signaling promotes cachexia in KL GEMMs fed HFD. Fig. 13A depicts the results of ELISA of PGE2 in bronchoalveolar lavage fluid from KL, KP, or KCC GEMMs 3 days following dietary swap to HFD or maintenance on chow. n=5 mice per group. Fig. 13B depicts the results of immunostaining of Ptges of KL and KP tumors 3 days after switch to HFD or maintained on chow Fig. 13C depicts H-score quantification of Ptges staining intensity of KL, KP, and KCC tumors. n=12 KL, n= 10 KP, «=10 KCC tumors.Fig. 13D shows biosynthetic pathway of n-6 eicosanoids (PGE2) including relevant biosynthetic enzymes and inhibitors. Fig. 13E shows a schematic of Kras-GEMMs with viral constructs to generate Lkbl knockout and Lkbl / Ptges double-knockout tumor. Fig. 13F depicts the results of ELISA of PGE2 in bronchoalveolar lavage fluid from Lkbl knockout or Lkbl / Ptges doubleknockout GEMMs 3 days following dietary swap to HFD or maintenance on chow. n=6 mice per group. Fig. 13G, Relative weight of Lkbl knockout and Lkbl / Ptges double-knockout GEMMs normalized to weights at time of diet swap. n= 10 sgLkbl / sgNeo Chow, n=l 1 sgLkbl / sgNeo HFD, n=ll sgLkbl / sgPtges Chow, n=!2 sgLkbl / sgPtges HFD. Figs. 13H-13I, Mice were placed 6 weeks after diet swap in metabolic cages for 7 days, with the first two days excluded to allow mice to adjust to new environment and (Fig. 13H) cumulative food intake and (Fig. 131) cumulative water intake was recorded. n=4 mice per group. (Figs. 13A, 13C, and 13F-13I) One-way ANOVA with Tukey’s multiple comparison test.

[0094] Figs.l4A-14B depict relative weights and survival curves of KrasLSL~G12D / +; Rosa26LSL" cas9 P2A GFP / LSL caS9 P2A GFPm^ceintratracheally infected with lentiviral particles containing constitutively active Cre recombinase and a sgRNA cassettes targeting Sikl and Sik3. Tumors were initiated in animals and allowed to progress for 4 weeks before mice were placed on HFD or maintained on chow. (Fig. 14 ) Relative weight of KrasG12D', sgSikl / 3 GEMMs normalized to weights at time of diet swap. n=l 1 mice per group. Two-tailed unpaired t-test. (Fig. 14B) Survival curves of KrasG12D', •> Sikl / 3 GEMMs fed HFD or maintained on chow. n=ll mice per group. Values are mean ± s.e.m. *P<0.05, **P<0.01, ***P<0.001, ***P<0.0001; ns: not significant.

[0095] Figs. 15A-15H depict that common circulating cachexia-causing factors are not elevated in KL GEMMs fed HFD. (Figs. 15A-15F) Luminex profiling of isolated plasma from healthy (WT) or tumor bearing animals (KL) 3 weeks following dietary swap to HFD or17328856447vlAttorney Docket No: 243735.000512maintenance on chow. 77=4 WT, n=5 KL. (Figs. 15G-15H) ELISA of PThRP (Fig. 15G) or LCN2 (Fig. 15H) in plasma from WT or KL mice 3 weeks following dietary swap to HFD or maintenance on chow. 77=5 (Fig. 15G) or 8 (Fig. 15H) (WT mice). 77=8 (KL chow), 77=12 (Fig. 15G) or 8 (Fig.15H) (KL HFD). One-way ANOVA with Tukey’s multiple comparison test. Values are mean ± s.e.m.*P<0.05, **P<0.01, ***P<0.001, ***P<0.0001; ns: not significant.

[0096] Figs.1 A-1 K depict that Lkbl regulates eicosanoid production in NSCLC. (Fig. 16A) Body mass index (BMI) changes of NSCLC patients for cancer cachexia-anorexia syndrome stratification (Fig. 16B) ELISA of PGE2 in bronchoalveolar lavage fluid of cachectic (CACS) and non-cachectic (NCACS) patients (Fig. 16C) Gene set enrichment analysis of prostaglandin signaling comparing tumor RNA sequencing from NCACS and CACS tumors (Fig. 16D) Ptges expression (normalized to Aab) in sorted tumor cells from Lkbl wildtype or mutant GEMMS. Values are mean + s.e.m.; 77=3 sgNeo and 7=4 sgLkbl. (Figs. 16E and 16F) Expression of Ptges, Ptgsl, and Ptgs2 (normalized to Actb) in sorted tumor cells from Lkbl -mutant GEMMs fed chow or HFD 3-weeks post diet swap (7-weeks post initiation).; 77=3 chow and 77=4 HFD. (Fig. 16G) Immunostaining of Ptges of KL and KP tumors 3 days after switch to HFD or maintained on chow.(Fig. 16H) ELISA of PGE2 in cell culture supernatant of EGFR-mutated (PC9 and H1975) and Kras / p53-mutated (H2009) NSCLC human cell lines transfected with CasO and non-targeting sgRNA (sgTOM) or sgRNA targeting LKB1 treated for 24hr with 30pM linoleic acid. 77=3 (Fig.161) Ptges expression (normalized to Actb) in 1234 p53-mutant cells transfected with Cas9 and a non-targeting sgRNA (sgTOM), sgRNA targeting Lkbl or sgRNA targeting Sikl / 3. n=3 per group.(Fig. 16J) ELISA of PGE2 in cell-culture supernatant of Kras-P53-. S7k / / j mouse NSCLC celllines treated for 24hr with 30pM linoleic acid. 77=3. (Fig. 16K) Comparison of PTGES gene expression from The Cancer Genome Atlas (TCGA) LU AD tumors with or without mutations in STK11 / LKB1 and / or Kras and normal lung tissue. 77=46 normal, n=266 WT, n=104 Kras-mut, n=32 STKll-mut, and 33 Kras / STKll-mut. (Figs. 16D-16F, 16H, and 16J) Two-tailed unpaired t-test. (Figs. 161 and 16K) One-way ANOVA with Tukey’s multiple comparison test. Values are mean ± s.e.m.*P<0.05, **P<0.01, ***P<0.001, ***P<0.0001.

[0097] Figs. 17A-17F depict disruptions in prostaglandin signaling in KL GEMMs fed HFD.(Fig. 17A) Normalized levels of eicosanoids from bronchoalveolar lavage fluid from KL and KP GEMMs fed chow or HFD 3 days post-diet swap. 77=5 mice per condition. (Fig. 17B) Normalized levels of PUFA from bronchoalveolar lavage fluid from KCC GEMMs fed chow or HFD 3 days18328856447vlAttorney Docket No: 243735.000512post-diet swap. n=3 mice per condition. (Figs. 17C-17F) KE GEMMs 3 days after switched to Fish Oil HFD or maintained on regular chow, n-3 mice per group. (Fig. 17C) EEISA of PGE2 in bronchoalveolar lavage fluid, (Fig. 17D) immunostaining of Ptges, and (Fig. 17E) h-score quantification, and (Fig.17F) normalized levels of PUFA species from bronchoalveolar lavage fluid (Figs. 17A, 17B, and 17F) In the heatmap, normalized values from -1 to 0 are represented by a gradient from darker to lighter shades, whereas values from 0 to 2 are represented by a gradient from lighter to darker shades. (Figs. 17C and 17E) Two-tailed unpaired t-test. Values are mean ± s.e.m.. *P<0.05, **P<0.01, ***P<0.001, ***P<0.0001; ns: not significant.

[0098] Fig. 18 depicts relative weight of Kras-GEMMs normalized to weights at infection. It shows that animals with Lkbl mutant tumors lose weight rapidly and to significantly greater extent than control group.

[0099] Fig. 19 depicts that decreases in food and water intake occurs rapidly upon HFD, only in Lkbl mutant tumors.

[0100] Fig. 20 depicts that consumption of HFD induces changes in levels of bioactive lipids locally in the lung.

[0101] Figs. 21A-21I demonstrate that tumor prostaglandin synthesis drives cachexia. (Fig.21A) Immunostaining of Ptges in Lkbl knockout and Lkbl / Ptges double-knockout GEMMs (Fig.21B) Quantification of tumor burden (tumor area / total lung area) in Lkbl knockout An Lkb l / Ptges double-knockout GEMMs fed HFD. n=9 sgEkbl / sgNeo and n=6 sgLkbl / sgPtges. Two-tailed unpaired t-test. (Fig. 21C) Survival curves for Lkbl knockout and Lkbl / Ptges double-knockout GEMMs placed on HFD or maintained on chow after 4 weeks of tumor progression. / ?=!() sgLkbl / sgNeo Chow, n=11 sgLkbl / sgNeo HFD, n=11 sgLkbl / sgPtges Chow, n=12 sgLkbl / sgPtges HFD. Log-rank (Mantel-Cox) test (Figs. 21D-21F) (Fig. 21D) Total body mass, (Fig. 21E) fat mass and (Fig. 21F) lean mass at 6 weeks after diet swap. N=4 mice per group.(Figs.21G and 21H) Mice were placed 6 weeks after diet swap in metabolic cages for 7 days, with the first two days excluded to allow mice to adjust to new environment and (Fig. 21G) travelled distance and (Fig. 21H) energy expenditure was recorded. n=4 mice per group. (Fig. 211) Normalized levels of PUFA species from bronchoalveolar lavage fluid from Lkbl knockout and Lkbl / Ptges double-knockout GEMMs or HFD 12 weeks post-diet swap. n=5 mice per condition. In the heatmap, normalized values from -1 to 0 are represented by a gradient from darker to lighter shades, whereas values from 0 to 4 are represented by a gradient from lighter to darker shades.19328856447vlAttorney Docket No: 243735.000512(Figs. 21D-21H) One-way ANOVA with Tukey’s multiple comparison test. Values are mean ± s.e.m.. *P<0.05, **P<0.01, ***P<0.001, ***P<0.0001; ns: not significant.DETAILED DESCRIPTION

[0102] Cachexia is believed to be driven by diverse mediators released from cancer cells and components of the tumor microenvironment, with a host of preclinical studies utilizing allografts of tumor cell lines identifying circulating factors that promote cachexia5,8 10 12.

[0103] These factors may travel through circulation to induce their catabolic effects in metabolic tissues or signal to the brain to induce neurobehavioral changes such as anorexia1,3,8-io,i3-i8 circulating levels of factors implicated in cachexia, such as IL-6 and GDF-15, have been correlated to the mutational status of genes frequently mutated in cancer, such as LKBl / STKll ~24. yet the contribution of common mutations in cancer to the development of cachexia is not well characterized. Additionally, locally produced signals have been demonstrated to act on sensory neurons and drive weight loss and reductions in food intake in infection models25,26, yet whether detection of inflammatory signals by sensory neurons contributes to the development of cachexia is not understood.

[0104] The combination of hypercatabolism and reduced caloric intake drives weight-loss in cachexia, with dietary interventions serving as first- line treatments to restore caloric and nutritional deficiencies and mitigate weight-loss1,2. However, in some patients, skeletal muscle and adipose tissue loss can continue to occur despite provision of adequate nutrients1,2and dietary interventions can worsen cachexia in some animal models27. With a lack of studies investigating the factors that promote response to nutritional interventions, it remains largely unknown how nutritional interventions promote or prevent CAC.

[0105] The present disclosure demonstrates that among the most common cancer mutations, mutations in the tumor suppressor Lkbl promote a dramatic reduction in food intake and the development of cachexia in pre-clinical models of lung cancer (Fig. 1). In an attempt to improve caloric intake by placing tumor bearing animals on high-fat, energy dense diets, a dramatic exacerbation in anorexia and cachexia was paradoxically observed only in animals harboring L^Z-mutant tumors (Fig. 2). The invention of the present disclosure demonstrates that this cachexia (including, without limitation, diet-induced cachexia) is mediated in part through local, tumor cell-dependent production of prostaglandin E2 (PGE2) rather than circulating factors (Fig.20328856447vlAttorney Docket No: 243735.0005123) as genetic and pharmacological inhibition of prostaglandin synthesis or tumor-derived PGE2 improves sickness and cachexia in multiple models (Figs. 3E-3F and 11C-11D). Preventing the production of PGE2 by enriching the diet in omega-3 fatty acids or by deletion of key prostaglandin enzymes in the tumor alleviates cachexia. Importantly, the present disclosure demonstrates that the abrogation of lung sensory neuron signaling through vagotomy and chemogenetic inhibition also improves cachexia by preventing PGE2-dependent cachexia associated sickness in the tumor models illustrated herein. The study as described herein establishes a role for localized signals to sensory neurons rather than circulating signals in the development of cachexia and highlights a potential novel role of the peripheral nervous system for sensory neurons in cancer-promoted sickness behaviors in cachexia.

[0106] In the studies illustrated herein, the inventors investigated the interaction between common mutations in lung cancer and dietary interventions to the development of cachexia. Using pre-clinical genetically engineered mouse models of lung cancer, it was demonstrated that mutations in Lkbl promote cachexia and anorexia, which is severely exacerbated upon consumption of high-fat diets. The observed anorexia and cachexia are mediated in part by prostaglandin E2 (including, without limitation, tumor-derived PGE2), omega-6 eicosanoids, and signaling through sensory neurons. The present disclosure sheds new light on the interplay between tumor mutational status and dietary interventions and demonstrates a role for sensory neurons in the development of cachexia.Definitions

[0107] To facilitate an understanding of the principles and features of the various embodiments of the invention, various illustrative embodiments are explained below. Although exemplary embodiments of the invention are explained in detail, it is to be understood that other embodiments are contemplated. Accordingly, it is not intended that the invention is limited in its scope to the details of construction and arrangement of components set forth in the following description or examples. The invention is capable of other embodiments and of being practiced or carried out in various ways. Also, in describing the exemplary embodiments, specific terminology will be resorted to for the sake of clarity.

[0108] Unless otherwise defined herein, scientific, and technical terms used in connection with the present invention shall have the meanings that are commonly understood by those of ordinary21328856447vlAttorney Docket No: 243735.000512skill in the art. Further, unless otherwise required by context, singular terms shall include pluralities and plural terms shall include the singular. Generally, nomenclatures used in connection with, and techniques of, cell and tissue culture, molecular biology, immunology, microbiology, genetics and protein and nucleic acid chemistry and hybridization described herein are those well-known and commonly used in the art.

[0109] The methods and techniques of the present invention are generally performed according to conventional methods well known in the art and as described in various general and more specific references that are cited and discussed throughout the present specification unless otherwise indicated. See, e.g., Sambrook et al.. Molecular Cloning: A Laboratory Manual, 2d ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N. Y. (1989) and Ausubel et al., Current Protocols in Molecular Biology, Greene Publishing Associates (1992), and Harlow and Lane Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N. Y. (1990), which are incorporated herein by reference. Enzymatic reactions and purification techniques are performed according to manufacturer’s specifications, as commonly accomplished in the art, or as described herein. The nomenclatures used in connection with, and the laboratory procedures and techniques of, analytical chemistry, synthetic organic chemistry, and medicinal and pharmaceutical chemistry described herein are those well-known and commonly used in the art. Standard techniques are used for chemical syntheses, chemical analyses, pharmaceutical preparation, formulation, and delivery, and treatment of patients.

[0110] The terms “inhibit” and “inhibition” as used herein refer to reducing synthesis, function, and / or activity to an extent sufficient to achieve a desired biological or physiological effect. Inhibition may be complete or partial.

[0111] The phrase “pharmaceutically acceptable”, as used in connection with compositions described herein, refers to molecular entities and other ingredients of such compositions that are physiologically tolerable and do not typically produce untoward reactions when administered to a mammal (e.g., a human). Preferably, the term “pharmaceutically acceptable” means approved by a regulatory agency of the Federal or a state government or listed in the U. S. Pharmacopeia or other generally recognized pharmacopeia for use in mammals, and more particularly in humans.

[0112] As used herein, “pharmaceutically acceptable carrier” or “pharmaceutical acceptable excipient” includes any material which, when combined with an active ingredient, allows the ingredient to retain biological activity and is non-reactive with the subject’s immune system.22328856447vlAttorney Docket No: 243735.000512Compositions comprising such carriers are formulated by well-known conventional methods (see, for example. Remington’s Pharmaceutical Sciences, 18thedition, A. Gennaro, ed., Mack Publishing Co., Easton, Pa.. 1990; and Remington, The Science and Practice of Pharmacy 20thEd. Mack Publishing, 2000).

[0113] The term “treating”, as used herein, unless otherwise indicated, means reversing, alleviating, inhibiting the progress of, delaying the progression of, delaying the onset of, or preventing the disorder or condition to which such term applies, or one or more symptoms of such disorder or condition. The term “treatment”, as used herein, unless otherwise indicated, refers to the act of treating as “treating” is defined immediately above. The term “treating” also includes adjuvant and neo-adjuvant treatment of a subject. For the avoidance of doubt, reference herein to “treatment” includes reference to curative, palliative, and prophylactic treatment.

[0114] The phrase “effective amount” or “therapeutically effective amount” as used herein refers to an amount necessary (at dosages and for periods of time and for the means of administration) to achieve the desired therapeutic result. An effective amount is at least the minimal amount, but less than a toxic amount, of an active agent which is necessary to impart therapeutic benefit to a subject.

[0115] The phrase “effective amount” or “therapeutically effective amount” as used herein refers to an amount necessary (at dosages and for periods of time and for the means of administration) to achieve the desired therapeutic result. An effective amount is at least the minimal amount, but less than a toxic amount, of an active agent which is necessary to impart therapeutic benefit to a subject.

[0116] The terms “patient”, “individual”, “subject”, and “animal” are used interchangeably herein and refer to mammals, including, without limitation, human and veterinary animals (e.g., cats, dogs, cows, horses, sheep, pigs, etc.) and experimental animal models. In a preferred embodiment, the subject is a human.

[0117] The term “about” or “approximately” means within a statistically meaningful range of a value. Such a range can be within an order of magnitude, preferably within 50%, more preferably within 20%, still more preferably within 10%, and even more preferably within 5% of a given value or range. The allowable variation encompassed by the term “about” or “approximately” depends on the particular system under study, and can be readily appreciated by one of ordinary skill in the art.23328856447vlAttorney Docket No: 243735.000512

[0118] It must also be noted that, as used in the specification and the appended claims, the singular forms “a,” “an,” and “the” include plural references, unless the context clearly dictates otherwise. For example, reference to a component is intended also to include composition of a plurality of components. References to a composition containing “a” constituent is intended to include other constituents in addition to the one named. In other words, the terms “a,” “an,” and “the” do not denote a limitation of quantity, but rather denote the presence of “at least one” of the referenced item.

[0119] Also, in describing the exemplary embodiments, terminology will be resorted to for the sake of clarity. It is intended that each term contemplates its broadest meaning as understood by those skilled in the art and includes all technical equivalents that operate in a similar manner to accomplish a similar purpose.

[0120] It is also to be understood that the mention of one or more method steps does not preclude the presence of additional method steps or intervening method steps between those steps expressly identified. Similarly, it is also to be understood that the mention of one or more components in a composition does not preclude the presence of additional components than those expressly identified.

[0121] The materials described hereinafter as making up the various elements of the present invention are intended to be illustrative and not restrictive. Many suitable materials that would perform the same or a similar function as the materials described herein are intended to be embraced within the scope of the invention. Such other materials not described herein can include, but are not limited to, materials that are developed after the time of the development of the invention, for example. Any dimensions listed in the various drawings are for illustrative purposes only and are not intended to be limiting. Other dimensions and proportions are contemplated and intended to be included within the scope of the invention.Methods of the inventionMethods of treating cachexia and / or sickness behavior

[0122] Provided herein are methods of treating cachexia and / or sickness behavior in a subject. In some embodiments, provided herein are methods of treating cachexia and / or sickness behavior in a subject having cancer. In some embodiments, the present disclosure provides a method of treating cachexia and / or sickness behavior in a subject having Peutz-Jeghers syndrome (PJS).24328856447vlAttorney Docket No: 243735.000512Sickness behavior includes anorexia and decreased motility in response to a malignant growth. Cachexia includes progressive weight loss and persistent erosion of body mass in response to a malignant growth. The fundamental physiological instability can be related to a decrease in food intake relative to energy expenditure. The cachectic state can cause most cancer morbidity and mortality. The extensive wasting which is associated with cancer, and other diseases, is known as “cachexia” (Kern, et al., {J. Parent. Enter. Nutr. 12:286-298 (1988)). Cachexia is observed in the most aggressive cancers and impacts approximately 80% of cancer patients. Cachexia is associated with a multitude of morbidities encompassing functional, metabolic, and immune disorders. LKB1 mutations can increase incidence of cachexia (Goncalves et al., PNAS 2018; Iyengar et al., JCI Insight, 2023). Genetic and dietary factors that impact cachexia remain largely unknown.

[0123] In one aspect, provided herein is a method of treating cachexia and / or sickness behavior in a subject, wherein the method comprises inhibiting (a) one or more prostaglandins, (b) one or more prostaglandin receptors, and / or (c) sensory neurons. The subject of the present disclosure may include, but is not limited to, a subject having germline mutations in Peutz-Jeghers syndrome (PJS), or a cancer, or a risk of developing cancer.

[0124] In one aspect, the present disclosure provides a method of treating cachexia and / or sickness behavior in a subject, the subject having a mutation in a liver kinase Bl (LKB1; also known as serine / threonine kinase 11 or STK11) gene, wherein the method comprises inhibiting (a) one or more prostaglandins, (b) one or more prostaglandin receptors, and / or (c) sensory neurons. The subject of the present disclosure may include, but is not limited to, a subject having germline mutations in Peutz-Jeghers syndrome (PJS), or a cancer, or a risk of developing cancer.

[0125] In one aspect, the present disclosure provides a method of treating cachexia and / or sickness behavior in a subject having a cancer and a mutation in a liver kinase Bl (LKB1; also known as serine / threonine kinase 11 or STK11) gene.

[0126] In one aspect, provided herein is a method of treating cachexia and / or sickness behavior in a subject having a mutation in a liver kinase Bl (LKB1) gene, wherein the method comprises inhibiting (a) one or more prostaglandins, (b) one or more prostaglandin receptors, and / or (c) sensory neurons.

[0127] In one aspect, provided herein is a method of treating cachexia and / or sickness behavior in a subject having a cancer and a mutation in a liver kinase B 1 (LKB 1) gene, wherein the method25328856447vlAttorney Docket No: 243735.000512comprises inhibiting (a) one or more prostaglandins, (b) one or more prostaglandin receptors, and / or (c) sensory neurons.

[0128] The terms “LKB1 mutant” and “LKB 1 deficient” can be used interchangeably with LKB 1 / STK11 deficient or mutant, STK11 deficient and STK11 mutant. All refer to a loss of function mutation in the gene, or a defect in the function of the protein, including, but not limited to signaling mediated by LKB1. The nucleotide sequence of human LKB 1 (also referred to as STK11) is available under Accession No. NM_007460 (SEQ ID NO:1), and the amino acid sequence of the human protein STK11 is available under Accession No. NP 000446 (SEQ ID NO:2) from GenBank. All nucleotide sequences described herein, their RNA and DNA equivalents, and complimentary sequences are included in this disclosure. All polynucleotide and amino acid sequences associated with GenBank accession numbers (or other similar databases) described in this disclosure are incorporated herein by reference as those sequences are listed in the database as of the priority filing date of this application or patent.SEQ ID NO:2 MEVVDPQQLGMFTEGELMSVGMDTFIHRIDSTEVIYQPRRKRAKLIGKYLMGDLLGEGSYGKV KEVLDSETLCRRAVKILKKKKLRRIPNGEANVKKEIQLLRRLRHKNVIQLVDVLYNEEKQKMYM VMEYCVCGMQEMLDSVPEKRFPVCQAHGYFCQLIDGLEYLHSQGIVHKDIKPGNLLLTTGGTLK ISDLGVAEALHPFAADDTCRTSQGSPAFQPPEIANGLDTFSGFKVDIWSAGVTLYNITTGLYPFEG DNIYKLFENIGKGSYAIPGDCGPPLSDLLKGMLEYEPAKRFSIRQIRQHSWFRKKHPPAEAPVPIPP SPDTKDRWRSMTVVPYLEDLHGADEDEDLFDIEDDIIYTQDFTVPGQVPEEEASHNGQRRGLPK AVCMNGTEAAQLSTKSRAEGRAPNPARKACSASSKIRRLSACKQQ

[0129] LKB 1 mutant cells may be identified by detecting at the nucleic acid level or at the protein level. The loss of function may be due to nucleic acid that is translated or transcribed at a detectably lower level in a cancer cell, in comparison to a normal cell. The loss of function may be due to gene deletion, mutation of a gene rendering the gene non-functional with respect to transcription or translation, transcription, post transcriptional processing, translation, post-translational processing, cellular localization (e.g., organelle, cytoplasm, nucleus, cell surface), or RNA and protein stability, as compared to a control, or a protein with significantly less activity compared to a control. Loss of function may be manifested as underexpression and can be detected using conventional techniques for detecting mRNA (z.e., RT-PCR, PCR, and hybridization) or proteins (z.<?., ELISA, immunoblotting, and immunohistochemical techniques). Underexpression can be 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or less in comparison to a control.26328856447vlAttorney Docket No: 243735.000512

[0130] Cells (e.g., cancer cells) may be tested for the presence of LKB1 deficiency such as a loss-of-function mutation. The loss-of-function testing can be carried out on any biological sample, including sections of tissues such as biopsy samples and frozen sections prepared from tissues taken for histologic purposes. Samples may include tumor tissue samples, blood, and blood fractions (e.g., serum, platelets, red blood cells, and the like), sputum, bronchoalveolar lavage, cultured cells, e.g., primary cultures, explants, transformed cells, stool, urine, and the like. A biological sample is typically obtained from a mammal, such as a human, but may be obtained from a farm animal or a domesticated animal. A biopsy may be obtained by standard techniques including, excisional biopsy, incisional biopsy, needle biopsy, surgical biopsy, and bone marrow biopsy. Biopsy techniques are described in in Harrison’s Principles of Internal Medicine, Kasper, etal., eds., 16thed„ 2005).

[0131] As illustrated herein, among the most common cancer mutations, mutations in the tumor suppressor Lkbl promote a dramatic reduction in food intake and the development of cachexia in pre-clinical models of lung cancer.

[0132] In one aspect, the present disclosure provides a method of treating cachexia and / or sickness behavior in a subject having suppression of LKB1 -mediated signaling.

[0133] In one aspect, the present disclosure provides a method of treating cachexia and / or sickness behavior in a subject having a cancer and suppression of LKB1 -mediated signaling.

[0134] In one aspect, provided herein is a method of treating cachexia and / or sickness behavior in a subject having (i) a mutation in a liver kinase Bl (LKB1) gene and / or (ii) suppression of LKB1 -mediated signaling, wherein the method comprises inhibiting (a) one or more prostaglandins, (b) one or more prostaglandin receptors, and / or (c) sensory neurons.

[0135] In one aspect, provided herein is a method of treating cachexia and / or sickness behavior in a subject having a cancer and (i) a mutation in a liver kinase Bl (LKB1) gene and / or (ii) suppression of LKBl-mediated signaling, wherein the method comprises inhibiting (a) one or more prostaglandins, (b) one or more prostaglandin receptors, and / or (c) sensory neurons.

[0136] The LKBl-mediated signaling includes an activation of salt-inducible kinase (SIK). In some embodiments, the suppression of LKBl-mediated signaling includes an inhibition of SIK. Salt-inducible kinases (SIKs) are from a group of serine / threonine kinases from the adenosine monophosphate-activated protein kinase (AMPK) family. SIK exists in three isoforms: SIK1, SIK2, and SIK3. SIKs are crucial in various physiological processes. Based on the data it was27328856447vlAttorney Docket No: 243735.000512found that inhibiting the signaling cascade of LKB1 and the downstream kinases SIK1, SIK2, or SIK3 produces the same effects in terms of cachexia and sickness as a mutation in the LKB1 gene.

[0137] In some embodiments, the suppression of LKBl-mediated signaling includes a mutation in a SIK gene. In some embodiments, the SIK is SIK1, SIK2, and / or SIK3. In some embodiments, the SIK mutation comprises a loss of function mutation.

[0138] Any mutation or signaling that inhibits the LKB1-AMPK pathway could mimic the mutational loss of LKB1. The LKB1 mutation may include, but is not limited to, a point mutation, a frameshift mutation, a splice mutation, an insertion mutation, a deletion mutation, a missense mutation, a nonsense mutation, a chromosomal arm deletion, and / or a focal deletion. In some embodiments, the LKB1 mutation includes a G251V mutation, a G251R mutation, a G251C mutation, a S216F mutation, a D194H mutation, a D194Y mutation, a G242W mutation, a G242V mutation, a W239C mutation, a Q220* mutation, a R86* mutation, a Y60* mutation, a E165* mutation, a P281Rfs*6 mutation, a L282Afs*3 mutation, a K84* mutation, a E223* mutation, a E33* mutation, D53Tfs*ll mutation, a K78N mutation, a E199* mutation, a G56V mutation, a E57Kfs*7 mutation, a D53Gfs*110 mutation, a G56W mutation, a E70* mutation, a K62* mutation, a A43Pfs*8 mutation, a E65* mutation, a Y60* mutation, a K146* mutation, a K175* mutation, a K262* mutation, a K235* mutation, a K78E mutation, a T250Rfs*37 mutation, a N259Kfs*28 mutation, a D176A mutation, a L228Rfs*33 mutation, a D30Gfs*133 mutation, a E265Gfs*19 mutation, a S69* mutation, a K108* mutation, a E138* mutation, a V77Sfs*19 mutation, a Q37Pfs*123 mutation, a Q220Pfs*46 mutation, a M136K mutation, a M136I mutation, a STK11-ARHGAP45 Fusion mutation, a STK11-SRFBP1 Fusion mutation, a ARHGAP45-STK11 Fusion mutation, a TNRC6B-STK11 Fusion mutation, a Q137H mutation, a E245F mutation, a H168R mutation, a Q170P mutation, a Y118H mutation, a M129I mutation, a I224V mutation, a X200_splice mutation, a X155_splice mutation, a X245_splice mutation, a X288_splice mutation, and / or a X97_splice mutation.

[0139] In some embodiments, the method of treating cachexia and / or sickness behavior in a subject further comprises supplementing with a polyunsaturated fatty acid, preferably an omega-3 polyunsaturated fatty acid (also known as omega-3 PUFA or n-3 PUFA). In some embodiments, the method of treating cachexia and / or sickness behavior in a subject further comprises administering an omega-3 PUFA, alone or in combination with a therapeutic agent or antagonist as described herein, and optionally further in combination with a low-fat diet as described herein.28328856447vlAttorney Docket No: 243735.000512In some embodiments, supplementing with an omega-3 PUFA includes feeding a subject a diet enriched in an omega-3 PUFA.

[0140] In some embodiments, the method of treating cachexia and / or sickness behavior in a subject having a cancer further comprises supplementing with a polyunsaturated fatty acid, preferably an omega-3 polyunsaturated fatty acid (also known as omega-3 PUFA or n-3 PUFA). In some embodiments, the method of treating cachexia and / or sickness behavior in a subject having a cancer further comprises administering an omega-3 PUFA, alone or in combination with a therapeutic agent or antagonist as described herein, and optionally further in combination with a low-fat diet as described herein. In some embodiments, supplementing with an omega-3 PUFA includes feeding a subject a diet enriched in an omega-3 PUFA.

[0141] In some embodiments, the method of treating cachexia and / or sickness behavior in a subject having (i) a mutation in a liver kinase Bl (LKB1) gene and / or (ii) suppression of LKB1-mediated signaling further comprises supplementing with a polyunsaturated fatty acid, preferably an omega-3 polyunsaturated fatty acid (also known as omega-3 PUFA or n-3 PUFA). In some embodiments, the method of treating cachexia and / or sickness behavior in a subject having (i) a mutation in a liver kinase Bl (LKB1) gene and / or (ii) suppression of LKB1 -mediated signaling further comprises administering an omega-3 PUFA, alone or in combination with a therapeutic agent or antagonist as described herein, and optionally further in combination with a low-fat diet as described herein.

[0142] In some embodiments, the method of treating cachexia and / or sickness behavior in a subject having a cancer and (i) a mutation in a liver kinase B 1 (LKB 1) gene and / or (ii) suppression of LKB 1 -mediated signaling further comprises supplementing with a polyunsaturated fatty acid, preferably an omega-3 PUFA (n-3 PUFA). In some embodiments, the method of treating cachexia and / or sickness behavior in a subject having a cancer and (i) a mutation in a liver kinase B 1 (LKB 1) gene and / or (ii) suppression of LKBI-mediated signaling further comprises administering an omega-3 PUFA, alone or in combination with a therapeutic agent or antagonist as described herein, and optionally further in combination with a low-fat diet as described herein.

[0143] In some embodiments, supplementing with an omega-3 PUFA includes feeding a subject a diet enriched in an omega-3 PUFA. In some embodiments, supplementing with an omega-3 PUFA includes feeding a subject a diet enriched in omega-3 PUFA. In some29328856447vlAttorney Docket No: 243735.000512embodiments, the diet enriched in omega-3 PUFA includes an isocaloric high-fat diet derived from fish oil.

[0144] Non-limiting examples of omega-3 PUFAs include eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). EPA and DHA are precursors to eicosanoids. Omega-3 derived eicosanoids generally have anti-inflammatory properties. In some embodiments, the PUFA comprises eicosapentaenoic acid (EPA) and / or docosahexaenoic acid (DHA). In some embodiments, an omega-3 PUFA is administered or supplemented in an amount of 250 mg to 3000 mg. In some embodiments, an omega-3 PUFA is administered or supplemented in an amount of 250 mg / day to 3000 mg / day.

[0145] In some embodiments, EPA is administered or supplemented in an amount of 250 mg to 3000 mg. In some embodiments, EPA is administered or supplemented in an amount of 250 mg / day to 3000 mg / day. In some embodiments, DHA is administered or supplemented in an amount of 250 mg to 3000 mg. In some embodiments, DHA is administered or supplemented in an amount of 250 mg / day to 3000 mg / day. When the combination of EPA and DHA is used for the treatment as described herein, the ratio of EPA to DHA is 2: 1.

[0146] In some embodiments, the method of treating cachexia and / or sickness behavior in a subject further comprises supplementing with a low-fat diet. In some embodiments, the method of treating cachexia and / or sickness behavior in a subject having a cancer further comprises supplementing with a low-fat diet. In some embodiments, the diet comprises a low-fat diet in combination with supplement(s) that contain a high level of fish oil.

[0147] In some embodiments, the method of treating cachexia and / or sickness behavior in a subject having (i) a mutation in a liver kinase Bl (LKB1) gene and / or (ii) suppression of LKB1-mediated signaling further comprises supplementing with a low-fat diet. In some embodiments, the method of treating cachexia and / or sickness behavior in a subject having a cancer and (i) a mutation in a liver kinase Bl (LKB1) gene and / or (ii) suppression of LKB1 -mediated signaling further comprises supplementing with a low-fat diet. In some embodiments, the diet comprises a low-fat diet in combination with supplement(s) that contain a high level of fish oil.

[0148] In some embodiments, a method of treating cachexia and / or sickness behavior in a subject having (i) a mutation in a liver kinase Bl (LKB1) gene and / or (ii) suppression of LKB1-mediated signaling comprises inhibiting the synthesis and / or activity and / or function of one or more prostaglandins in combination with supplementing with one or more omega-3 PUFA and / or30328856447vlAttorney Docket No: 243735.000512a low-fat diet. In some embodiments, a method of treating cachexia and / or sickness behavior in a subject having (i) a mutation in a liver kinase Bl (LKB1) gene and / or (ii) suppression of LKB1-mediated signaling comprises inhibiting one or more prostaglandin receptors in combination with supplementing with one or more omega-3 PUFA and / or a low-fat diet. In some embodiments, a method of treating cachexia and / or sickness behavior in a subject having (i) a mutation in a liver kinase Bl (LKB1) gene and / or (ii) suppression of LK. B1 -mediated signaling comprises inhibiting sensory neurons in combination with supplementing with one or more omega-3 PUFA and / or a low-fat diet. In some embodiments, a method of treating cachexia and / or sickness behavior in a subject comprises inhibiting sensory neurons in combination with supplementing with one or more omega-3 PUFA and / or a low-fat diet. In some embodiments, a method of treating cachexia and / or sickness behavior in a subject having a cancer and (i) a mutation in a liver kinase Bl (LKB1) gene and / or (ii) suppression of LKBl-mediated signaling comprises inhibiting the synthesis and / or activity and / or function of one or more prostaglandins in combination with supplementing with one or more omega-3 PUFA and / or a low-fat diet. In some embodiments, a method of treating cachexia and / or sickness behavior in a subject having a cancer and (i) a mutation in a liver kinase Bl (LKB1) gene and / or (ii) suppression of LKBl-mediated signaling comprises inhibiting one or more prostaglandin receptors in combination with supplementing with one or more omega-3 PUFA and / or a low-fat diet. In some embodiments, a method of treating cachexia and / or sickness behavior in a subject having a cancer and (i) a mutation in a liver kinase Bl (LKB1) gene and / or (ii) suppression of LKBl-mediated signaling comprises inhibiting sensory neurons in combination with supplementing with one or more omega-3 PUFA and / or a low-fat diet. In some embodiments, a method of treating cachexia and / or sickness behavior in a subject having a cancer comprises inhibiting sensory neurons in combination with supplementing with one or more omega-3 PUFA and / or a low-fat diet. In some embodiments, the diet comprises a low-fat diet in combination with supplement(s) that contain a high level of fish oil.

[0149] In some embodiments, a method of treating cachexia and / or sickness behavior in a subject having (i) a mutation in a liver kinase Bl (LKB1) gene and / or (ii) suppression of LKBl-mediated signaling comprises administering one or more prostaglandin inhibitors {e.g., therapeutic agents described herein) and one or more omega-3 PUFA, optionally in combination with supplementing with a low-fat diet. In some embodiments, a method of treating cachexia and / or sickness behavior in a subject having (i) a mutation in a liver kinase Bl (LKB1) gene and / or (ii)31328856447vlAttorney Docket No: 243735.000512suppression of LKB1 -mediated signaling comprises administering one or more prostaglandin receptor inhibitors (e.g., receptor antagonists described herein) and one or more omega-3 PUFA, optionally in combination with supplementing with a low-fat diet. In some embodiments, a method of treating cachexia and / or sickness behavior in a subject having (i) a mutation in a liver kinase Bl (LKB1) gene and / or (ii) suppression of LKB1 -mediated signaling comprises administering one or more chemogenetic compounds optionally in combination with altering vagal nerve activity and administering one or more omega-3 PUFA, optionally in combination with supplementing a low-fat diet. In some embodiments, a method of treating cachexia and / or sickness behavior in a subject having (i) a mutation in a liver kinase Bl (LKB1) gene and / or (ii) suppression of LK. B1 -mediated signaling comprises administering one or more chemogenetic compounds optionally in combination with altering vagal nerve activity and one or more omega-3 PUFA, optionally in combination with supplementing a low-fat diet. In some embodiments, a method of treating cachexia and / or sickness behavior in a subject having a cancer and (i) a mutation in a liver kinase Bl (LKB1) gene and / or (ii) suppression of LKB1 -mediated signaling comprises administering one or more prostaglandin inhibitors (e.g., therapeutic agents described herein) and one or more omega-3 PUFA, optionally in combination with supplementing with a low-fat diet. In some embodiments, a method of treating cachexia and / or sickness behavior in a subject having a cancer and (i) a mutation in a liver kinase Bl (LKB1) gene and / or (ii) suppression of LKBl-mediated signaling comprises administering one or more prostaglandin receptor inhibitors (e.g., receptor antagonists described herein) and one or more omega-3 PUFA, optionally in combination with supplementing with a low-fat diet. In some embodiments, a method of treating cachexia and / or sickness behavior in a subject having a cancer and (i) a mutation in a liver kinase B 1 (LKB 1) gene and / or (ii) suppression of LKBl-mediated signaling comprises administering one or more chemogenetic compounds optionally in combination with altering vagal nerve activity and administering one or more omega-3 PUFA, optionally in combination with supplementing a low-fat diet. In some embodiments, a method of treating cachexia and / or sickness behavior in a subject having a cancer comprises administering one or more chemogenetic compounds optionally in combination with altering vagal nerve activity and one or more omega-3 PUFA, optionally in combination with supplementing a low-fat diet. In some embodiments, the diet comprises a low-fat diet in combination with supplement(s) that contain a high level of fish oil.32328856447vlAttorney Docket No: 243735.000512

[0150] In some embodiments, an omega-3 PUFA and an inhibitor (e.g., a therapeutic agent, a receptor antagonist, and / or a chemogenetic compound described herein) of the present disclosure are administered concurrently to the subject. In some embodiments, an omega-3 PUFA is administered before administering an inhibitor (e.g., a therapeutic agent and / or a receptor antagonist described herein, and / or a chemogenetic compound described herein) to the subject. In some embodiments, an omega-3 PUFA is administered after administering an inhibitor (e.g., a therapeutic agent and / or a receptor antagonist described herein, and / or a chemogenetic compound described herein) to the subject.

[0151] In some embodiments, an inhibitor (e.g., a therapeutic agent and / or a receptor antagonist and / or a chemogenetic compound described herein) of the present disclosure and an omega-3 PUFA, optionally in combination with a meal of the low-fat diet, are given concurrently to the subject. In some embodiments, an inhibitor (e.g., a therapeutic agent and / or a receptor antagonist and / or a chemogenetic compound described herein) is administered before administering an omega-3 PUFA, optionally in combination with a meal of the low-fat diet. In some embodiments, an inhibitor (e.g., a therapeutic agent and / or a receptor antagonist and / or a chemogenetic compound described herein) of the present disclosure is administered after administering an omega-3 PUFA, optionally in combination with a meal of the low-fat diet.

[0152] In some embodiments, an omega-3 PUFA is administered with one or more meals. In some embodiments, the meal is a meal of the low-fat diet. In some embodiments, an omega-3 PUFA is given with each meal.Methods of the invention comprising inhibiting one or more prostaglandins

[0153] In one aspect, a method of treating cachexia and / or sickness behavior in a subject having (i) a mutation in a liver kinase Bl (LKB1) gene and / or (ii) suppression of LKB1 -mediated signaling comprises inhibiting one or more prostaglandins. In some embodiments, inhibiting one or more prostaglandins involves inhibiting the synthesis, activity, and / or function of one or more prostaglandins.

[0154] In one aspect, a method of treating cachexia and / or sickness behavior in a subject having a cancer and (i) a mutation in a liver kinase Bl (LKB1) gene and / or (ii) suppression of LKB 1-mediated signaling comprises inhibiting one or more prostaglandins. In some embodiments, inhibiting one or more prostaglandins involves inhibiting the synthesis, activity, and / or function of one or more prostaglandins.33328856447vlAttorney Docket No: 243735.000512

[0155] In some embodiments, inhibiting one or more prostaglandins includes administering one or more prostaglandin inhibitors (e.g., therapeutic agents described herein). In some embodiments, inhibiting one or more prostaglandins further includes administering one or more n-3 PUFA and optionally in combination with supplementing a low-fat diet. In some embodiments, the synthesis, activity, and / or function of a prostaglandin is inhibited by increasing synthesis, activity, and / or function of a different prostaglandin.

[0156] In some embodiments, the prostaglandin is prostaglandin E2 (PGE2). PGE2 is known as a strong pro-inflammatory mediator. It is also known to induce fever, inflammation, and pain. In some embodiments, a method of treating cachexia and / or sickness behavior in a subject having (i) a mutation in a liver kinase Bl (LKB1) gene and / or (ii) suppression of LKB1 -mediated signaling comprises inhibiting PGE2. In some embodiments, a method of treating cachexia and / or sickness behavior in a subject having a cancer and (i) a mutation in a liver kinase Bl (LKB1) gene and / or (ii) suppression of LKB1 -mediated signaling comprises inhibiting PGE2. In some embodiments, inhibiting PGE2 involves inhibiting the activity, and / or function of PGE2. In some embodiments, inhibiting PGE2 includes administering an inhibitor (e.g., a therapeutic agent described herein) of PGE2.

[0157] In some embodiments, inhibiting PGE2 includes activating prostaglandin E3 (PGE3). In some embodiments, inhibiting the activity and / or function of PGE2 includes increasing activity and / or function of PGE3, optionally by administering a PUFA, preferably an omega-3 PUFA, alone or in combination with a low-fat diet.

[0158] In some embodiments, inhibiting one or more prostaglandins involves decreasing an activity and / or function of one or more prostaglandin synthases. Non-limiting examples of prostaglandin synthase are cyclooxygenase (COX) enzyme, phospholipase A2, prostaglandin E synthase (PGES or PTGES), and any combinations thereof. In some embodiments, the prostaglandin synthase is a cyclooxygenase (COX) enzyme. In some embodiments, the COX enzyme is cyclooxygenase 1 (COX-1) or cyclooxygenase 2 (COX-2).

[0159] The isoforms of COX enzyme, COX-1 and COX-2, also known as prostaglandin endoperoxide synthase 1 and 2, are key enzymes in the conversion of arachidonic acid to prostaglandins, thromboxanes, and other eicosanoids. COX-1 and COX-2 may have different physiologic functions due to prominent differences in their tissue expression and regulation. COX-1 is a constitutive enzyme that is responsible for the production of cytoprotective prostaglandins34328856447vlAttorney Docket No: 243735.000512important for homeostatic functions, such as maintaining the integrity of the gastric mucosa, mediating normal platelet function, and regulating renal blood flow. COX-2 is a rapidly inducible form of cyclooxygenase that leads to one or more pro-inflammatory prostaglandin production. The expression of COX-2 is highly restricted under basal conditions.

[0160] In some embodiments, a method of treating cachexia and / or sickness behavior in a subject having (i) a mutation in a liver kinase Bl (LKB1) gene and / or (ii) suppression of LKB1-mediated signaling comprises inhibiting one or more COX enzymes. In some embodiments, a method of treating cachexia and / or sickness behavior in a subject having a cancer and (i) a mutation in a liver kinase Bl (LK. B1) gene and / or (ii) suppression of LKB1 -mediated signaling comprises inhibiting one or more COX enzymes. In some embodiments, inhibiting one or more COX enzymes involves inhibiting the synthesis, activity, and / or function of one or more COX enzymes. In some embodiments, inhibiting COX enzyme includes administering an inhibitor (e.g., a therapeutic agent described herein) of a COX enzyme. In some embodiments, the COX enzyme inhibitor is a therapeutic agent. Non-limiting examples of a therapeutic agent that inhibits the synthesis, activity, and / or function of a COX enzyme include a competitive inhibitor, a noncompetitive inhibitor, an uncompetitive inhibitor, a reversible inhibitor, and / or an irreversible inhibitor of one or more COX enzymes.

[0161] In some embodiments, the prostaglandin synthase is prostaglandin E synthase (PTGES). The PTGES may include, but is not limited to, microbial Ptges (mPGES). In some embodiments, microbial Ptges is microsomal prostaglandin E2 synthase- 1 (mPGES- 1) or microsomal prostaglandin E2 synthase-2 (mPGES-2). In some embodiments, a method of treating cachexia and / or sickness behavior in a subject having (i) a mutation in a liver kinase Bl (LKB1) gene and / or (ii) suppression of LKB1 -mediated signaling comprises inhibiting PTGES. In some embodiments, a method of treating cachexia and / or sickness behavior in a subject having a cancer and (i) a mutation in a liver kinase Bl (LKB1) gene and / or (ii) suppression of LKB1 -mediated signaling comprises inhibiting PTGES. In some embodiments, inhibiting PTGES involves inhibiting the synthesis, activity, and / or function of PTGES. In some embodiments, inhibiting PTGES includes administering an inhibitor e.g., a therapeutic agent described herein) of PTGES. In some embodiments, the inhibitor of PTGES is a direct inhibitor or an indirect inhibitor. In some embodiments, the inhibitor of PTGES inhibits the activity and / or function of another protein. In some embodiments, the PTGES inhibitor is a therapeutic agent, a small molecule, and / or an35328856447vlAttorney Docket No: 243735.000512antibody. Non-limiting examples of a therapeutic agent that inhibits the synthesis, activity, and / or function of PTGES includes zaloglanstat (ISC-27864; GRC-27864). Non-limiting examples of a therapeutic agent that inhibits the synthesis, activity, and / or function of mPGES-1 include crisdesalazine (also known as AAD-2004), compound III (CIII; also known as N-cyclopentyl-1-[5,6-dimethyl-l-(l-methylethyl)-lH-benzimidazol-2-yl]-4-piperidinecarboxamide; mPGES-1 Inhibitor III), LY3023703 (also known as 2-(difluoromethyl)-5-[[(2-methyl-l-oxopropyl)amino]methyl]-N-[4-methyl-5-[4-(trifluoromethyl)phenyl]-lH-imidazol-2-yl]-3-pyridinecarboxamide), AF3485 (also known as N-[9-(2-hydroxyethyl)-9H-carbazol-3-yl]-2-(trifluoromethyl)-benzamide), MF63 (also known as 2-(6-chloro-lH-phenanthro[9,10-d]imidazol-2-yl)-isophthalonitrile), AF3442 (also known as N-(9-ethyl-9H-carbazol-3-yl)-2-(trifluoromethyl)benzamide), PF-9184 (also known as N-(3',4'-dichloro[l,l'-biphenyl]-4-yl)-4-hydroxy-2H-l,2-benzothiazine-3-carboxamide 1,1 -dioxide), PF-4693627 (also known as l-[5-chloro-6-(4-chlorophenyl)-2-benzoxazolyl]-N-[(lS,3S)-3-(hydroxymethyl)cyclohexyl]-4-piperidinecarboxamide), and LY3031207 (also known as 2-chloro-N-(lH-imidazol-2-yl)-5-(pivalamidomethyl)benzamide). In some embodiments, the small molecule functions as a dual inhibitor of two proteins (e.g., a prostaglandin synthase and an oxygenase enzyme). Non-limiting examples of dual inhibitors include YS121 (also known as 2-(4-chloro-6-(2,3-dimethylphenylamino)pyrimidin-2-ylthio)octanoic acid) and MK-886 (also known as l-[(4-chlorophenyl)methyl]-3-[(l,l-dimethylethyl)thio]-alpha,alpha-dimethyl-5-(l-methylethyl)-lH-indole-2-propanoic acid) or derivative(s) thereof. A non-limiting example of a small molecule that inhibits mPGES-1 indirectly is dexamethasone or derivative(s) thereof.

[0162] In some embodiments, a method of treating cachexia and / or sickness behavior in a subject having (i) a mutation in a liver kinase Bl (LKB1) gene and / or (ii) suppression of LKB1-mediated signaling comprises administering one or more prostaglandin inhibitors (e.g., therapeutic agents described herein) in combination with supplementing with an omega-3 PUFA and / or a low-fat diet. In some embodiments, a method of treating cachexia and / or sickness behavior in a subject having a cancer and (i) a mutation in a liver kinase Bl (LKB1) gene and / or (ii) suppression of LKBl-mediated signaling comprises administering one or more prostaglandin inhibitors (e.g., therapeutic agents described herein) in combination with supplementing with an omega-3 PUFA and / or a low-fat diet. In some embodiments, a method of treating cachexia and / or sickness behavior in a subject having (i) a mutation in a liver kinase B 1 (LKB 1) gene and / or (ii) suppression36328856447vlAttorney Docket No: 243735.000512of LKBl-mediated signaling comprises administering one or more prostaglandin inhibitors (e.g., therapeutic agents described herein) and an omega-3 PUFA, optionally in combination with a low-fat diet. In some embodiments, a method of treating cachexia and / or sickness behavior in a subject having a cancer and (i) a mutation in a liver kinase Bl (LKB1) gene and / or (ii) suppression of LKBl-mediated signaling comprises administering one or more prostaglandin inhibitors (e.g., therapeutic agents described herein) and an omega-3 PUFA, optionally in combination with a low-fat diet. Any of the various prostaglandin inhibitors or prostaglandin synthase inhibitors described herein can be used according to the methods of the present disclosure. In some embodiments, a prostaglandin inhibitor or a prostaglandin synthase inhibitor is a therapeutic agent.

[0163] In some embodiments, a method of treating cachexia and / or sickness behavior in a subject having (i) a mutation in a liver kinase Bl (LKB1) gene and / or (ii) suppression of LKBl-mediated signaling comprises administering one or more prostaglandin synthase inhibitors e.g., therapeutic agents described herein) in combination with supplementing with an omega-3 PUFA and / or a low-fat diet. In some embodiments, a method of treating cachexia and / or sickness behavior in a subject having (i) a mutation in a liver kinase B 1 (LKB 1) gene and / or (ii) suppression of LKBl-mediated signaling comprises administering one or more prostaglandin synthase inhibitors (e.g., therapeutic agents described herein) and an omega-3 PUFA optionally in combination with a low-fat diet. In some embodiments, a method of treating cachexia and / or sickness behavior in a subject having a cancer and (i) a mutation in a liver kinase Bl (LKB1) gene and / or (ii) suppression of LKBl-mediated signaling comprises administering one or more prostaglandin synthase inhibitors (e.g., therapeutic agents described herein) in combination with supplementing with an omega-3 PUFA and / or a low-fat diet. In some embodiments, a method of treating cachexia and / or sickness behavior in a subject having a cancer and (i) a mutation in a liver kinase Bl (LKB1) gene and / or (ii) suppression of LKBl-mediated signaling comprises administering one or more prostaglandin synthase inhibitors (e.g., therapeutic agents described herein) and an omega-3 PUFA optionally in combination with a low-fat diet. Any of the various prostaglandin inhibitors or prostaglandin synthase inhibitors described herein can be used according to the methods of the present disclosure. In some embodiments, a prostaglandin inhibitor or a prostaglandin synthase inhibitor is a therapeutic agent.

[0164] In some embodiments, a method of treating cachexia and / or sickness behavior in a subject having (i) a mutation in a liver kinase Bl (LKB1) gene and / or (ii) suppression of LKB1-37328856447vlAttorney Docket No: 243735.000512mediated signaling comprising administering a therapeutic agent. In some embodiments, a method of treating cachexia and / or sickness behavior in a subject having (i) a mutation in a liver kinase Bl (LKB1) gene and / or (ii) suppression of LKB1 -mediated signaling comprises administering a therapeutic agent in combination with supplementing with an omega-3 PUFA and / or a low-fat diet. In some embodiments, a method of treating cachexia and / or sickness behavior in a subject having (i) a mutation in a liver kinase Bl (LKB1) gene and / or (ii) suppression of LKB1 -mediated signaling comprises administering a therapeutic agent and an omega-3 PUFA, optionally in combination with a low-fat diet. In some embodiments, a method of treating cachexia and / or sickness behavior in a subject having a cancer and (i) a mutation in a liver kinase Bl (LK. B1) gene and / or (ii) suppression of LKB1 -mediated signaling comprising administering a therapeutic agent. In some embodiments, a method of treating cachexia and / or sickness behavior in a subject having a cancer and (i) a mutation in a liver kinase Bl (LKB1) gene and / or (ii) suppression of LKB1-mediated signaling comprises administering a therapeutic agent in combination with supplementing with an omega-3 PUFA and / or a low-fat diet. In some embodiments, a method of treating cachexia and / or sickness behavior in a subject having a cancer and (i) a mutation in a liver kinase Bl (LKB1) gene and / or (ii) suppression of LKBl-mediated signaling comprises administering a therapeutic agent and an omega-3 PUFA, optionally in combination with a low-fat diet.

[0165] In some embodiments, the therapeutic agent is a protein, a nucleic acid, or a compound e.g., a small molecule or an antibody) that inhibits one or more prostaglandins and / or one or more prostaglandin synthases (e.g., by delaying, binding, decreasing, partially or totally blocking, partially or totally preventing, partially or totally inactivating, desensitizing, or down-regulating synthesis, activity, and / or function, e.g., any prostaglandin activity and / or function including a COX enzyme activity and / or function, PTGES activity and / or function, and the like).

[0166] In some embodiments, the therapeutic agent is a COX inhibitor. Non-limiting examples of therapeutic agents include drugs that are able to inhibit the formation of PGE2, including, but not limited to, “coxibs” (selective COX-2 inhibitors) and “NSAIDs” (non-steroidal antiinflammatory drugs). These drugs primarily act by an inhibition of COX-1 and / or COX-2, thereby reducing the formation of PGE2. The contribution of COX-2 and the elevated production of prostaglandins are linked with a variety of diseases and disorders, including, but not limited to, cancers.38328856447vlAttorney Docket No: 243735.000512

[0167] In some embodiments, the COX inhibitor is a selective inhibitor or a non-selective inhibitor. In some embodiments, the COX inhibitor comprises a COX-1 inhibitor and / or a COX-2 inhibitor. In some embodiments, the COX-1 inhibitor is a selective COX-1 inhibitor or a non-selective COX-1 inhibitor. In some embodiments, the COX-2 inhibitor is a selective COX-2 inhibitor or a non-selective COX-2 inhibitor.

[0168] In some embodiments, the therapeutic agent that that inhibits the activity, and / or function of a COX enzyme comprises a non-steroidal anti-inflammatory drug (NSAID). Nonlimiting examples of NSAIDs include ibuprofen, acetylsalicylic acid (ASA), diclofenac, diflunisal, etodolac, fenoprofen, flurbiprofen, indomethacin, ketoprofen, ketorolac, mefenamic acid, meloxicam, nabumetone, naproxen, oxaprozin, piroxicam, sulindac, tolmetin, and any combinations thereof. In some embodiments, a non-selective COX inhibitor is an NSAID.

[0169] Non-limiting examples of selective COX-2 inhibitors include valdecoxib (Bextra), celecoxib (Celebrex), rofecoxib, NS-398 (also known as N-[2-(cyclohexyloxy)-4-nitrophenyl]-methanesulfonamide). and any combinations thereof. In some embodiments, a selective COX-2 inhibitor is selected from valdecoxib (Bextra), celecoxib (Celebrex), rofecoxib, and any combinations thereof.

[0170] In some embodiments, the therapeutic agent is a PTGES inhibitor. Non-limiting examples of a therapeutic agent that inhibits the synthesis, activity, and / or function of PTGES include zaloglanstat (ISC-27864; GRC-27864).

[0171] In some embodiments, the therapeutic agent that inhibits the activity and / or function of a COX enzyme comprises a polyunsaturated fatty acid (PUFA). In some embodiments, the therapeutic agent that inhibits the activity and / or function of a PTGES comprises a polyunsaturated fatty acid (PUFA). In some embodiments, the PUFA comprises an omega-3 PUFA. In some embodiments, the PUFA comprises eicosapentaenoic acid (EPA) and / or docosahexaenoic acid (DHA). In some embodiments, an omega-3 PUFA is administered or supplemented in an amount of 250 mg to 3000 mg. In some embodiments, an omega-3 PUFA is administered or supplemented in an amount of 250 mg / day to 3000 mg / day.

[0172] In some embodiments, EPA is administered or supplemented in an amount of 250 mg to 3000 mg. In some embodiments, EPA is administered or supplemented in an amount of 250 mg / day to 3000 mg / day. In some embodiments, DHA is administered or supplemented in an amount of 250 mg to 3000 mg. In some embodiments, DHA is administered or supplemented in39328856447vlAttorney Docket No: 243735.000512an amount of 250 mg / day to 3000 mg / day. When the combination of EPA and DHA is used for the treatment as described herein, the ratio of EPA to DHA is 2: 1.

[0173] In some embodiments, the therapeutic agent that decreases the activity and / or function of the COX enzyme is an antibody. In some embodiments, the therapeutic agent that decreases the activity and / or function of the PTGES is an antibody. An antibody may include an intact antibody, an antigen-binding (Fab) fragment, an Fab’ fragment, an (Fab’)2fragment, an Fd, an Fv, a dAb, a single domain fragment or single monomeric variable antibody domain, a single-chain Diabody (scDb), a single-chain variable fragment (scFv), a monoclonal antibody, a monovalent antibody, a bivalent antibody, a multivalent antibody, a Bi-specific T-cell engager (BiTE), a bispecific killer cell engager (BiKE), and / or a CrossMab.

[0174] In some embodiments, the present disclosure provides an antibody that decreases the activity and / or function of the COX enzyme or PTGES that is conjugated to a diagnostic or the other therapeutic agent. The diagnostic agent may comprise a radioactive or non-radioactive label, a contrast agent (such as for magnetic resonance imaging, computed tomography, or ultrasound), and the radioactive label can be a gamma-, beta-, alpha-, Auger electron-, or positron-emitting isotope. A diagnostic agent is a molecule which is administered conjugated to an antibody moiety, i.e., antibody or antibody fragment, or sub-fragment, and is useful in diagnosing or detecting a disease by locating the cells containing the antigen.Methods of the invention comprising inhibiting one or more prostaglandin receptors

[0175] In one aspect, a method of treating cachexia and / or sickness behavior in a subject having (i) a mutation in a liver kinase Bl (LKB1) gene and / or (ii) suppression of LKB1 -mediated signaling comprises inhibiting one or more prostaglandin receptors. Non-limiting examples of prostaglandin receptors include prostaglandin E2 receptor 1 (EPl), prostaglandin E2 receptor 2 (EP2), prostaglandin E2 receptor 3 (EP3), and prostaglandin E2 receptor 4 (EP4). In certain embodiments, a method of treating cachexia and / or sickness behavior in a subject having (i) a mutation in a liver kinase Bl (LKB1) gene and / or (ii) suppression of LKB1 -mediated signaling comprises inhibiting the prostaglandin EPl receptor.

[0176] In one aspect, a method of treating cachexia and / or sickness behavior in a subject having a cancer and (i) a mutation in a liver kinase Bl (LKB1) gene and / or (ii) suppression of LKBl-mediated signaling comprises inhibiting one or more prostaglandin receptors. Non-limiting examples of prostaglandin receptors include prostaglandin E2 receptor 1 (EPl), prostaglandin E240328856447vlAttorney Docket No: 243735.000512receptor 2 (EP2), prostaglandin E2 receptor 3 (EP3), and prostaglandin E2 receptor 4 (EP4). In certain embodiments, a method of treating cachexia and / or sickness behavior in a subject having a cancer and (i) a mutation in a liver kinase Bl (LKB1) gene and / or (ii) suppression of LKB1-mediated signaling comprises inhibiting the prostaglandin EPl receptor.

[0177] In some embodiments, inhibiting one or more prostaglandin receptors involves decreasing an activity and / or a function of one or more prostaglandin receptors. In some embodiments, a method of treating cachexia and / or sickness behavior in a subject having (i) a mutation in a liver kinase Bl (LKB1) gene and / or (ii) suppression of LKBl-mediated signaling comprising administering a prostaglandin receptor inhibitor (e.g., a receptor antagonist described herein). In some embodiments, a method of treating cachexia and / or sickness behavior in a subject having (i) a mutation in a liver kinase Bl (LKB1) gene and / or (ii) suppression of LKBl-mediated signaling comprising administering a prostaglandin receptor antagonist. In some embodiments, a method of treating cachexia and / or sickness behavior in a subject having a cancer and (i) a mutation in a liver kinase B 1 (LKB 1) gene and / or (ii) suppression of LKB 1 -mediated signaling comprising administering a prostaglandin receptor inhibitor (e.g., a receptor antagonist described herein). In some embodiments, a method of treating cachexia and / or sickness behavior in a subject having a cancer and (i) a mutation in a liver kinase Bl (LKB1) gene and / or (ii) suppression of LKBl-mediated signaling comprising administering a prostaglandin receptor antagonist. The prostaglandin receptor antagonists may include, but are not limited to, a competitive antagonist, a non-competitive antagonist, an uncompetitive antagonist, a reversible antagonist, and an irreversible antagonist.

[0178] In some embodiments, the prostaglandin receptor antagonist is a protein, a nucleic acid, or a small molecule. In certain embodiments, the prostaglandin receptor antagonist is a small molecule. Non-limiting examples of the prostaglandin receptor antagonist include SC-51322, GW-848687X, SC-19220, SC-51089. ONO-8713. ONO-8130. ONO-8711, PF-04418948. TG6-10-1, TG8-260, DG-041, L798-106, ONO-AE3-240, ONO-AE3-208, LY3127760, Grapiprant, AH6809, RQ-15986, and any combinations thereof. (Pain. 2011 Jun;152(6):1373-1381. doi: 10.1016 / j.pain.2011.02.019. Epub 2011 Mar 10.)

[0179] In certain embodiments, the prostaglandin receptor is an EPl receptor. In some embodiments, the EPl receptor antagonist is selected from SC-51322, GW-848687X, SC- 19220, SC-51089, ONO-8713, ONO-8130, ONO-8711, and any combination thereof.41328856447vlAttorney Docket No: 243735.000512

[0180] In certain embodiments, the prostaglandin receptor is an EP2 receptor. In some embodiments, the EP2 receptor antagonist is selected from PF-04418948, TG6-10-1, TG8-260, and any combination thereof.

[0181] In certain embodiments, the prostaglandin receptor is an EP3 receptor. In some embodiments, the EP3 receptor antagonist is selected from DG-041, L798-106, ONO-AE3-240, and any combination thereof.

[0182] In certain embodiments, the prostaglandin receptor is an EP4 receptor. In some embodiments, the EP4 receptor antagonist is selected from ONO-AE3-208, LY3127760, Grapiprant, AH6809, RQ- 15986, and any combination thereof.

[0183] In some embodiments, the receptor antagonist is a protein, a nucleic acid, or a compound that inhibits one or more prostaglandin receptors (e.g.. by delaying, binding, decreasing, partially or totally blocking, partially or totally preventing, partially or totally inactivating, desensitizing, or down-regulating synthesis, activity, and / or function, e.g., any prostaglandin receptor).

[0184] In some embodiments, the prostaglandin receptor antagonist is an antibody. An antibody may include an intact antibody, an antigen-binding (Fab) fragment, an Fab’ fragment, an Fab’ fragment, an (Fab’)2fragment, an Fd, an Fv, a dAb, a single domain fragment or single monomeric variable antibody domain, a single-chain Diabody (scDb), a single-chain variable fragment (scFv), a monoclonal antibody, a monovalent antibody, a bivalent antibody, a multivalent antibody, a Bi-specific T-cell engager (BiTE), a bispecific killer cell engager (BiKE), and / or a CrossMab.

[0185] In some embodiments, the present disclosure provides an antibody that decreases the activity and / or function of the prostaglandin receptor is conjugated to a diagnostic or the therapeutic agent. The diagnostic agent may comprise a radioactive or non-radioactive label, a contrast agent (such as for magnetic resonance imaging, computed tomography, or ultrasound), and the radioactive label can be a gamma-, beta-, alpha-, Auger electron-, or positron-emitting isotope. A diagnostic agent is a molecule which is administered conjugated to an antibody moiety, i.e., antibody or antibody fragment, or sub-fragment, and is useful in diagnosing or detecting a disease by locating the cells containing the antigen.

[0186] In some embodiments, a method of treating cachexia and / or sickness behavior in a subject having (i) a mutation in a liver kinase Bl (LKB1) gene and / or (ii) suppression of LKB1-42328856447vlAttorney Docket No: 243735.000512mediated signaling comprises administering a prostaglandin receptor inhibitor (e.g., a prostaglandin receptor antagonist as described herein) in combination with supplementing with an omega-3 PUFA and / or a low-fat diet. In some embodiments, a method of treating cachexia and / or sickness behavior in a subject having (i) a mutation in a liver kinase Bl (LKB1) gene and / or (ii) suppression of LKBl-mediated signaling comprises administering a prostaglandin receptor inhibitor (e.g., a prostaglandin receptor antagonist as described herein) and an omega-3 PUFA, optionally in combination with a low-fat diet. In some embodiments, a method of treating cachexia and / or sickness behavior in a subject having a cancer and (i) a mutation in a liver kinase B 1 (LKB 1) gene and / or (ii) suppression of LKBl-mediated signaling comprises administering a prostaglandin receptor inhibitor (e.g., a prostaglandin receptor antagonist as described herein) in combination with supplementing with an omega-3 PUFA and / or a low-fat diet. In some embodiments, a method of treating cachexia and / or sickness behavior in a subject having a cancer and (i) a mutation in a liver kinase Bl (LKB1) gene and / or (ii) suppression of LKBl-mediated signaling comprises administering a prostaglandin receptor inhibitor (e.g., a prostaglandin receptor antagonist as described herein) and an omega-3 PUFA, optionally in combination with a low-fat diet. Nonlimiting examples of omega-3 PUFAs that can be used in the methods of the present disclosure are various omega-3 PUFAs that are described herein.Methods of the inven tion comprising inhibiting sensory neurons

[0187] In one aspect, a method of treating cachexia and / or sickness behavior in a subject comprises inhibiting sensory neurons. In another aspect, a method of treating cachexia and / or sickness behavior in a subject having (i) a mutation in a liver kinase Bl (LKB1) gene and / or (ii) suppression of LKBl-mediated signaling comprises inhibiting sensory neurons. In another aspect, a method of treating cachexia and / or sickness behavior in a subject having a cancer comprises inhibiting sensory neurons. In another aspect, a method of treating cachexia and / or sickness behavior in a subject having a cancer and (i) a mutation in a liver kinase Bl (LKB1) gene and / or (ii) suppression of LKBl-mediated signaling comprises inhibiting sensory neurons. In some embodiments, the sensory neurons are present adjacent to the cancer in the subject. The sensory neurons may include, but are not limited to, vagal neurons and dorsal root ganglion (DRG) neurons.

[0188] In some embodiments, the sensory neurons are present in a lung of the subject. In some embodiments, inhibiting sensory neurons includes administering one or more chemogenetic43328856447vlAttorney Docket No: 243735.000512compounds optionally in combination with altering vagal nerve activity. Non-limiting examples of a chemogenetic compound include clozapine-N-oxide (CNO). In some embodiments, the chemogenetic compound is delivered in combination with a gene therapy.

[0189] In some embodiments, inhibiting sensory neurons involves vagus nerve stimulation.68In some embodiments, inhibiting sensory neurons involves vagotomy such as unilateral vagotomy or intermittent vagal blockade.67

[0190] Vagus nerve stimulation comprises the use of a device to send electrical impulses to the vagus nerve. The vagus nerve is the main nerve of the system. The vagus nerve controls heart rate, digestion, and other vital functions. When the device fires, the device sends electrical impulses to different areas of the brain. This changes brain activity to treat conditions including the conditions or diseases disclosed herein.

[0191] In some embodiments, a method of treating cachexia and / or sickness behavior in a subject comprises administering one or more chemogenetic compounds optionally in combination with altering vagal nerve activity in combination with supplementing with an omega-3 PUFA and / or a low-fat diet. In some embodiments, a method of treating cachexia and / or sickness behavior in a subject comprises administering one or more chemogenetic compounds optionally in combination with altering vagal nerve activity and an omega-3 PUFA optionally with a low-fat diet. In some embodiments, a method of treating cachexia and / or sickness behavior in a subject having a cancer comprises administering one or more chemogenetic compounds optionally in combination with altering vagal nerve activity in combination with supplementing with an omega-3 PUFA and / or a low-fat diet. In some embodiments, a method of treating cachexia and / or sickness behavior in a subject having a cancer comprises administering one or more chemogenetic compounds optionally in combination with altering vagal nerve activity and an omega-3 PUFA optionally with a low-fat diet.

[0192] In some embodiments, a method of treating cachexia and / or sickness behavior in a subject having (i) a mutation in a liver kinase Bl (LKB1) gene and / or (ii) suppression of LKB1-mediated signaling comprises administering one or more chemogenetic compounds optionally in combination with altering vagal nerve activity in combination with supplementing with an omega-3 PUFA and / or a low-fat diet. In some embodiments, a method of treating cachexia and / or sickness behavior in a subject having (i) a mutation in a liver kinase B 1 (LKB 1) gene and / or (ii) suppression of LKB1-mediated signaling comprises administering one or more chemogenetic compounds44328856447vlAttorney Docket No: 243735.000512optionally in combination with altering vagal nerve activity and an omega-3 PUFA optionally with a low-fat diet. In some embodiments, a method of treating cachexia and / or sickness behavior in a subject having a cancer and (i) a mutation in a liver kinase B 1 (LKB 1) gene and / or (ii) suppression of LKB 1 -mediated signaling comprises administering one or more chemogenetic compounds optionally in combination with altering vagal nerve activity in combination with supplementing with an omega-3 PUFA and / or a low-fat diet. In some embodiments, a method of treating cachexia and / or sickness behavior in a subject having a cancer and (i) a mutation in a liver kinase B 1 (LKB 1) gene and / or (ii) suppression of LKBl-mediated signaling comprises administering one or more chemogenetic compounds optionally in combination with altering vagal nerve activity and an omega-3 PUFA optionally with a low-fat diet.

[0193] Non-limiting examples of omega-3 PUFAs that can be used in the methods of the present disclosure are the various omega-3 PUFAs that are described herein.

[0194] In some embodiments, a method of treating cachexia and / or sickness behavior in a subject comprises vagotomy (e.g., unilateral vagotomy) in combination with supplementing with omega-3 PUFAs and / or a low-fat diet. In some embodiments, a method of treating cachexia and / or sickness behavior in a subject comprises vagotomy (e.g., unilateral vagotomy) and administering an omega-3 PUFA optionally in combination with a low-fat diet. In some embodiments, a method of treating cachexia and / or sickness behavior in a subject having a cancer comprises vagotomy (e.g., unilateral vagotomy) in combination with supplementing with omega-3 PUFAs and / or a low-fat diet. In some embodiments, a method of treating cachexia and / or sickness behavior in a subject having a cancer comprises vagotomy (e.g., unilateral vagotomy) and administering an omega-3 PUFA optionally in combination with a low-fat diet.

[0195] In some embodiments, a method of treating cachexia and / or sickness behavior in a subject having (i) a mutation in a liver kinase Bl (LKB1) gene and / or (ii) suppression of LKBl-mediated signaling comprises vagotomy (e.g., unilateral vagotomy) in combination with supplementing with omega-3 PUFAs and / or a low-fat diet. In some embodiments, a method of treating cachexia and / or sickness behavior in a subject having (i) a mutation in a liver kinase B 1 (LKB1) gene and / or (ii) suppression of LKBl-mediated signaling comprises vagotomy (e.g., unilateral vagotomy) and administering an omega-3 PUFA optionally in combination with a low-fat diet. In some embodiments, a method of treating cachexia and / or sickness behavior in a subject having a cancer and (i) a mutation in a liver kinase Bl (LKB1) gene and / or (ii) suppression of45328856447vlAttorney Docket No: 243735.000512LKB 1 -mediated signaling comprises vagotomy {e.g., unilateral vagotomy) in combination with supplementing with omega-3 PUFAs and / or a low-fat diet. In some embodiments, a method of treating cachexia and / or sickness behavior in a subject having a cancer and (i) a mutation in a liver kinase Bl (LKB1) gene and / or (ii) suppression of LKB 1 -mediated signaling comprises vagotomy {e.g., unilateral vagotomy) and administering an omega-3 PUFA optionally in combination with a low-fat diet.

[0196] Non-limiting examples of omega-3 PUFAs that can be used in the methods of the present disclosure are the various omega-3 PUFAs that are described herein.Inhibitors of the invention

[0197] In one aspect, the present disclosure provides an inhibitor that inhibits synthesis and / or activity and / or function of (i) one or more prostaglandins, (ii) one or more prostaglandin receptors, and / or (iii) sensory neurons. The inhibitors may decrease an activity and / or function of its target receptor or protein or a cell, e.g., by delaying, binding, decreasing, partially or totally blocking, partially or totally preventing, partially or totally inactivating, desensitizing, or down-regulating activity and / or function of its target receptor or protein or a cell.

[0198] In some embodiments, the inhibitor is a therapeutic agent, a receptor antagonist, and / or a chemogenetic compound. In some embodiments, the inhibitor is a protein, a nucleic acid, or a compound that inhibits a receptor or a protein or a cell {e.g., by delaying, binding, decreasing, partially or totally blocking, partially or totally preventing, partially or totally inactivating, desensitizing, or down-regulating activity and / or function, e.g., prostaglandin activity and / or function, prostaglandin synthase activity and / or function, COX enzyme activity and / or function, prostaglandin receptor activity and / or function, sensory neuron activity and / or function, and the like).

[0199] In some embodiments, the inhibitor {e.g., a therapeutic agent, a receptor antagonist, and / or a chemogenetic compound described herein) is a protein. The protein as disclosed herein may include an isolated peptide, an antibody or antigen-binding fragment thereof, or derivatives and combinations thereof.

[0200] In one embodiment, the present invention provides a method for identifying an inhibitor that inhibits the synthesis and / or activity and / or function of (i) one or more prostaglandins, (ii) one or more prostaglandin receptors, and / or (iii) sensory neurons, said method comprising: (a) contacting a first cell with an inhibitor for a time period sufficient to allow the cell to respond to46328856447vlAttorney Docket No: 243735.000512said contact with the test compound; (b) determining in the cell prepared in step (a) the synthesis and / or activity and / or function of (i) one or more prostaglandins, (ii) one or more prostaglandin receptors, and / or (iii) sensory neurons; and (c) comparing the synthesis and / or activity and / or function of (i) one or more prostaglandins, (ii) one or more prostaglandin receptors, and / or (iii) sensory neurons determined in step (b) to the synthesis and / or activity and / or function of (i) one or more prostaglandins, (ii) one or more prostaglandin receptors, and / or (iii) sensory neurons in a second (control) cell that has not been contacted with the inhibitor of the present invention; wherein a detectable change in the synthesis and / or activity and / or function of (i) one or more prostaglandins, (ii) one or more prostaglandin receptors, and / or (iii) sensory neurons in the first cell in response to contact with the inhibitor compared to the synthesis and / or activity and / or function of (i) one or more prostaglandins, (ii) one or more prostaglandin receptors, and / or (iii) sensory neurons in the second cell that has not been contacted with the inhibitor, indicates that the inhibitor modulates the synthesis and / or activity and / or function of (i) one or more prostaglandins, (ii) one or more prostaglandin receptors, and / or (iii) sensory neurons and is a candidate inhibitor.

[0201] To develop effective therapeutics to treat cachexia and / or sickness behavior based on the inhibitor(s) of the present disclosure, candidate inhibitors can be first tested in vitro, e.g., by testing their ability to inhibit the synthesis and / or activity and / or function of (i) one or more prostaglandins, (ii) one or more prostaglandin receptors, and / or (iii) sensory neurons. Therapeutics which produce satisfactory effects in in vitro assays can be further tested in vivo in various animal models of cachexia and / or sickness behavior. In these models, the activity of the novel therapeutics in inhibiting the synthesis and / or activity and / or function of (i) one or more prostaglandins, (ii) one or more prostaglandin receptors, and / or (iii) sensory neurons can be determined using various methods known in the art.

[0202] The inhibitors which show strong effects in vitro and in animal models can be further optimized (e.g., by increasing the efficiency of their targeting to (i) one or more prostaglandins, (ii) one or more prostaglandin receptors, and / or (iii) sensory neurons, increasing their specificity to (i) one or more prostaglandins, (ii) one or more prostaglandin receptors, and / or (iii) sensory neurons).Antibodies and Isolated Peptides

[0203] In some embodiments, the inhibitor (e.g., a therapeutic agent, a receptor antagonist, and / or a chemogenetic compound described herein) is an antibody. An antibody may include an47328856447vlAttorney Docket No: 243735.000512‘intact antibody, an antigen-binding (Fab) fragment, an Fab’ fragment, an Fab’ fragment, an (Fab’)2fragment, an Fd, an Fv, a dAb, a single domain fragment or single monomeric variable antibody domain, a single-chain Diabody (scDb), a single-chain variable fragment (scFv), a monoclonal antibody, a monovalent antibody, a bivalent antibody, a multivalent antibody, a Bispecific T-cell engager (BiTE), a bispecific killer cell engager (BiKE), and / or a CrossMab.

[0204] The present disclosure provides antibodies, or antigen-binding fragments thereof, that specifically bind to one or more prostaglandins or one or more prostaglandin receptors. In some embodiments, the antibody, or antigen-binding fragment thereof of the present disclosure is an anti-PGE2 or antigen-binding fragment thereof. In some embodiments, the antibody, or antigenbinding fragment thereof of the present disclosure is an anti-COXl or antigen-binding fragment thereof. In some embodiments, the antibody, or antigen-binding fragment thereof of the present disclosure is an anti-COX2 or antigen-binding fragment thereof. In some embodiments, the antibody, or antigen-binding fragment thereof of the present disclosure is an anti-PTGES or antigen-binding fragment thereof. In some embodiments, the antibody, or antigen-binding fragment thereof of the present disclosure is an anti-EPl or antigen-binding fragment thereof. In some embodiments, the antibody, or antigen-binding fragment thereof of the present disclosure is an anti-EP2 or antigen-binding fragment thereof. In some embodiments, the antibody, or antigenbinding fragment thereof of the present disclosure is an anti-EP3 or antigen-binding fragment thereof. In some embodiments, the antibody, or antigen-binding fragment thereof of the present disclosure is an anti-EP4 or antigen-binding fragment thereof.

[0205] In some embodiments, the present disclosure provides an antibody that decreases the activity and / or function of its target receptor or protein is conjugated to a diagnostic or therapeutic agent. The diagnostic agent may comprise a radioactive or non-radioactive label, a contrast agent (such as for magnetic resonance imaging, computed tomography, or ultrasound), and the radioactive label can be a gamma-, beta-, alpha-, Auger electron-, or positron-emitting isotope. A diagnostic agent is a molecule which is administered conjugated to an antibody moiety, i.e., antibody or antibody fragment, or sub-fragment, and is useful in diagnosing or detecting a disease by locating the cells containing the antigen.

[0206] In certain embodiments, the antibody or antigen-binding fragment comprises one or more amino acid substitutions. In certain embodiments, amino acid substitutions of an antibody or portion thereof are those which: (1) reduce susceptibility to proteolysis, (2) reduce susceptibility48328856447vlAttorney Docket No: 243735.000512to oxidation, (3) alter binding affinity for forming protein complexes, or (4) confer or modify other physicochemical or functional properties. For example, single or multiple amino acid substitutions (preferably conservative amino acid substitutions) may be made in the naturally occurring sequence.

[0207] A conservative amino acid substitution should not substantially change the structural characteristics of the parent sequence. Examples of art-recognized polypeptide secondary and tertiary structures are described in Proteins, Structures and Molecular Principles (Creighton, Ed., W. H. Freeman and Company, New York (1984)); Introduction to Protein Structure (C. Branden and J. Tooze, eds., Garland Publishing, New York, N. Y. (1991)); and Thornton et al., Nature 354:105 (1991), which are each incorporated herein by reference.

[0208] As used herein, the twenty naturally occurring amino acids and their abbreviations follow conventional usage. See Immunology — A Synthesis (2ndEdition, E. S. Golub and D. R. Green, Eds., Sinauer Associates, Sunderland, Mass. (1991)), which is incorporated herein by reference.

[0209] In some embodiments, the antibody or antigen-binding fragment is recombinant. In certain embodiments, the antibody or antigen-binding fragment is a human antibody, a humanized antibody, a chimeric antibody, a murine antibody, a monoclonal antibody, a single chain antibody, a bispecific antibody or antigen-binding fragment thereof, a bi-epitopic antibody or antigenbinding fragment thereof, a Fab, a Fab’, a F(ab’)2, a Fv, a scFv, a VH domain, or a nanobody.

[0210] In some embodiments, the antibodies or antigen-binding fragments described herein are humanized antibodies. In some embodiments, the antibodies or antigen-binding fragments described herein are chimeric antibodies. In some embodiments, the antigen-binding fragment is a Fab. In some embodiments, the antigen-binding fragment is a scFv.

[0211] In some embodiments, an antibody or antigen-binding fragment thereof can be a bispecific antibody or antigen-binding fragment thereof. In some embodiments, the bispecific antibody or antigen-binding fragment thereof can comprise at least one antigen-binding domain. An antigen-binding domain can include any portion of an antigen-binding molecule (z.e., a molecule that is capable of specific binding to an antigen) which can specifically bind to an antigen. As a non-limiting example, an antigen-binding domain may be a portion of an antigenbinding fragment such as, without limitation, a Fab, an scFv, or a VH domain. In some embodiments, the bispecific antibody of antigen- binding fragment can comprise a first antigenbinding domain and a second antigen-binding domain.49328856447vlAttorney Docket No: 243735.000512

[0212] In some embodiments, an antibody or antigen-binding fragment thereof as described herein has a suitable binding affinity for the target antigen (e.g., PGE2 protein or COX enzyme or PTGES or prostaglandin receptor) or antigenic epitopes thereof. As used herein, “binding affinity” refers to the apparent association constant or KA. The KA is the reciprocal of the dissociation constant (KD). In various embodiments, the antibody, or antigen-binding fragment thereof described herein, may have a binding affinity (KD) of at least about 1X10‘6M or less, about IxlO’7M or less, about IxlO’8M or less, about IxlO’9M or less, about lxlO’loM or less, about IxlO’11M or less, about IxlO12M or less, or about IxlO13M or less for the target antigen or antigenic epitope. An increased binding affinity corresponds to a decreased KD.

[0213] Binding affinity (or binding specificity) can be determined by a variety of methods including equilibrium dialysis, equilibrium binding, gel filtration, ELISA, biolayer interferometry (BLI), surface plasmon resonance (SPR), bead-based assay, radioimmunoassay, or spectroscopy (e.g., using a fluorescence assay). In certain embodiments, an antigen (e.g., PGE2 protein or COX enzyme or prostaglandin receptor), or derivative thereof, is coated onto a bead or onto the surface of an ELISA plate or other solid phase used for measurement. Examples of bead-based binding assays which may be used for measuring KD of the antibodies and / or antigen-binding fragments described herein are described in, e.g., Nishikori et al., J Mol Biol. 2012 Dec 14;424(5):391-9 (PMID 23041298) and Hattori et al., J Immunol Methods. 2021 Mar;490: 112952 (PMID 33358997). each of which is incorporated herein by reference in its entirety and for all purposes as if fully set forth herein.

[0214] These techniques can be used to measure the concentration of bound antibody or antigenbinding fragment as a function of target antigen concentration. Under certain conditions, the fractional concentration of bound antibody or antigen-binding fragment ([Bound] / [Total]) is generally related to the concentration of total target antigen ([Target]) by the following equation:[Bound] / [Total] = [Target] / (Ko+[Target])

[0215] It is not always necessary to make an exact determination of KD, though, since sometimes it is sufficient to obtain a quantitative measurement of affinity, e.g., determined using a method such as ELISA or FACS analysis, is proportional to KD, and thus can be used for comparisons, such as determining whether a higher affinity is, e.g., 2-fold higher, to obtain a qualitative measurement of affinity, or to obtain an inference of affinity, e.g., by activity in a functional assay, e.g., an in vitro or in vivo assay. In some cases, the in vitro binding assay is indicative of in vivo50328856447vlAttorney Docket No: 243735.000512activity. In other cases, the in vitro binding assay is not necessarily indicative of in vivo activity. In some cases, tight binding is beneficial, but in other cases tight binding is not as desirable in the in vivo setting, and an antibody with lower binding affinity is more desirable.

[0216] In some embodiments, the heavy chain of any of any of the antibodies as described herein further comprise a heavy chain constant region (CH) or a portion thereof (e.g., CHI, CH2, CH3, or a combination thereof). The heavy chain constant region can be of any suitable origin, e.g., human, mouse, rat, or rabbit. In some embodiments, the heavy chain constant region is from an IgD, IgE, IgG, IgA, or IgM class, or sub-class thereof. In some embodiments, the heavy chain constant region is from a human IgG (a gamma heavy chain) or any IgG subfamily as described herein. In some embodiments, the heavy chain constant region is from an IgGl, IgG2, IgG3, or IgG4 subclass.

[0217] In some embodiments, the heavy chain constant region of the antibodies described herein comprise a single domain (e.g., CHI, CH2, or CH3) or a combination of any of the single domains, of a constant region. In some embodiments, the light chain constant region of the antibodies described herein comprise a single domain (e.g., CL), of a constant region.

[0218] In some embodiments, the antibody or antigen-binding fragment described herein is of an IgGl subclass. In some embodiments, the antibody or antigen-binding fragment described herein is of an IgG2 subclass. In some embodiments, the antibody or antigen-binding fragment described herein is of an IgG4 subclass.

[0219] In some embodiments, antibodies or antigen-binding fragments described herein comprises a fragment crystallizable (Fc) region. In some embodiments, antibodies or antigenbinding fragment described herein comprises a modified Fc region.

[0220] In some embodiments, an Fc region described herein is altered by replacing at least one amino acid residue with a different amino acid residue to alter the effector function(s) of the antibody. For example, one or more amino acids selected from the following positions: 234, 235, 236, 237, 297, 318, 320, 322, 330, and / or 331 may be substituted with a different amino acid residue such that the antibody has an altered affinity for an effector ligand but retains the antigenbinding ability of the parent antibody. The effector ligand to which affinity is altered can be, for example, an Fc receptor or the Cl component of complement. See, e.g., U. S. Pat. Nos. 5,624,821 and 5,648,260, both of which are incorporated herein by reference in their entirety.51328856447vlAttorney Docket No: 243735.000512

[0221] In one embodiment, an Fc region described herein comprises one or more amino acids substitutions at amino acid residues 329, 331, and 322 such that the antibody has altered Clq binding and / or reduced or abolished complement dependent cytotoxicity (CDC). See, e.g., U. S. Pat. No. 6,194,551, which is incorporated herein by reference in its entirety.

[0222] In some examples, an Fc region described herein comprises one or more amino acid residues at amino acid positions 231 and / or 239 to alter the ability of the antibody to fix complement. See, e.g., PCT Publication WO 94 / 29351, which is incorporated herein by reference in its entirety.

[0223] In some examples, an Fc region described herein can be modified to decrease antibody dependent cellular cytotoxicity (ADCC) and / or to decrease the affinity for an Fey receptor by modifying one or more amino acids at the following positions: 234, 235, 236, 238. 239, 240, 241, 243, 244, 245, 247, 248, 249, 252, 254, 255, 256, 258, 262, 263, 264, 265, 267, 268, 269, 270, 272, 276, 278, 280, 283, 285, 286, 289, 290, 292, 293, 294, 295, 296, 298, 299, 301, 303, 305, 307, 309. 312. 313, 315, 320, 322, 324. 325. 326, 327, 329, 330, 331. 332. 333, 334, 335, 337, 338, 340, 360, 373, 376, 378, 382, 388, 389, 398, 414, 416, 419, 430, 433, 434, 435, 436, 437, 438 or 439. Exemplary substitutions include but are not limited to 236A, 239D, 239E, 268D, 267E, 268E, 268F, 324T, 332D, and 332E. Exemplary variants include but are not limited to 239D / 332E, 236A / 332E, 236A / 239D / 332E, 268F / 324T, 267E / 268F, 267E / 324T, and 267E / 268F / 324T. In some embodiments, an exemplary variant can comprise L234A / L235A / P329G (LALA-PG), e.g., as described in Lo et al., J Biol Chem. 2017 Mar 3;292(9):3900-3908 (PMID 28077575).

[0224] In some embodiments, an Fc region described herein include modifications that reduce or ablate binding to FcyR and / or complement proteins, thereby reducing or ablating Fc-mediated effector functions such as ADCC, ADCP, and CDC. Exemplary modifications include but are not limited to substitutions, insertions, and deletions at amino acid residues (EU numbering) 234, 235, 236, 237. 267, 269, 325. 328, 330, and / or 331. Exemplary substitutions include but are not limited to 234A, 235E, 236R, 237A, 267R, 269R, 325L, 328R, 330S, and 331S (e.g., 330S, and 331S). An exemplary Fc variant can comprise 236R / 328R. Other modifications for reducing FcyR and complement interactions include substitutions 297A, 234A, 235 A, 237 A, 318A, 228P, 236E, 268Q, 309L, 330S, 33 IS, 220S, 226S, 229S, 238S, 233P, and 234V, as well as removal of the glycosylation at position 297 by e.g., mutational or enzymatic means or by production in organisms such as bacteria that do not glycosylate proteins.52328856447vlAttorney Docket No: 243735.000512

[0225] In one embodiment, an Fc region described herein is a human IgGl.3 Fc constant region comprising L234A, L235E, and G237A substitutions. In one embodiment, an Fc region described herein is a IgGlfa. P238K (or IgGl. P238K) comprising a P238K substitution. In one embodiment, an Fc region described herein is a IgGl. If variant comprising L234A, L235E, G237A, A330S, and P331S substitutions.

[0226] In some embodiments, an Fc region described herein is modified to enhance affinity for an inhibitory receptor FcyRIIb. Such modification can provide an Fc fusion protein with immunomodulatory activities related to FcyRIIb cells, including for example B cells and monocytes. For example, the Fc variants may provide selectively enhanced affinity to FcyRIIb relative to one or more activating receptors. Modifications that alter binding to FcyRIIb include one or more modifications at a position (EU numbering) selected from the group consisting of 234, 235, 236, 237, 239, 266, 267, 268, 325, 326, 327, 328, 330, 331, and 332. Exemplary substitutions for enhancing FcyRIIb affinity include but are not limited to 234A, 234D, 234E, 234F, 234W, 235D, 235E. 235F, 235R, 235Y, 236D, 236N. 237A. 237D, 237N, 239D, 239E, 266M, 267D, 267E, 268D, 268E, 327D, 327E, 328F, 328W, 328Y, 330S, 331S, and 332E. Exemplary substitutions include 235Y, 236D, 239D, 266M, 267E, 268D, 268E, 328F, 328W, and 328Y. Other Fc variants for enhancing binding to FcyRIIb include 235Y / 267E, 236D / 267E, 239D / 268D, 239D / 267E, 267E / 268D, 267E / 268E, and 267E / 328F.

[0227] Other modifications for enhancing FcyR and complement interactions include but are not limited to substitutions 298A, 333A, 334A, 326A, 2471, 339D, 339Q, 280H, 290S, 298D, 298V, 243L, 292P, 300L, 396L, 3051, and 396L. These and other modifications are reviewed in Strohl, 2009, Current Opinion in Biotechnology 20:685-691. Fc modifications that increase binding to an Fey receptor include amino acid modifications at any one or more of amino acid positions (EU numbering) 238, 239, 248, 249, 252, 254, 255, 256, 258, 265, 267, 268, 269, 270, 272, 279, 280, 283, 285. 298. 289, 290, 292, 293, 294. 295. 296, 298, 301, 303, 305. 307. 312, 315, 324, 327, 329, 330, 335, 337, 338, 340, 360, 373, 376, 379, 382, 388, 389, 398, 414, 416, 419, 430, 434, 435, 437, 438 or 439 of the Fc region (see., Patent Publication No. WO 00 / 42072).

[0228] The affinities and binding properties of an Fc region for its ligand can be determined by a variety of in vitro methods (e.g., biochemical or immunological based assays) known in the art including but not limited to, equilibrium methods (e.g., enzyme-linked immunosorbent assay (ELISA), or radioimmunoassay (RIA)), or kinetics (e.g., BIACORE analysis), and other methods53328856447vlAttorney Docket No: 243735.000512such as indirect binding assays, competitive inhibition assays, fluorescence resonance energy transfer (FRET), gel electrophoresis and chromatography (e.g., gel filtration). These and other methods can utilize a label on one or more of the components being examined and / or employ a variety of detection methods including, but not limited to fluorescent, luminescent, chromogenic, or isotopic labels.

[0229] In some embodiments, the glycosylation of an antibody is altered. Glycosylation can be altered to, for example, increase the affinity of the antibody for antigen. Such carbohydrate modifications can be accomplished by, for example, altering one or more sites of glycosylation within the antibody sequence. For example, glycosylation of the constant region on N297 can be prevented or reduced by mutating the N297 residue to another residue, e.g., N297A, or N297D and / or by mutating an adjacent amino acid, e.g., 298. Additionally, one or more amino acid substitutions can be made that result in elimination of one or more variable region framework glycosylation sites to thereby eliminate glycosylation at that site. Such aglycosylation can increase the affinity of the antibody for antigen. See, e.g., U. S. Pat. Nos. 5.714,350 and 6,350,861. both of which are incorporated herein by reference in their entirety.

[0230] In some embodiments, the antibody can be modified to increase its biological half-life. For example, the Fc region can be modified to increase its binding affinity for FcRn, by mutating one or more of following residues: 252, 254, 256, 433, 435, 436 (see, e.g., U. S. Pat. No. 6,277,375, which is incorporated herein by reference in its entirety). Specific exemplary mutations include one or more of the following: T252L, T254S, and / or T256F. In some embodiments, the antibody can be modified within the CHI or CL region to contain a salvage receptor binding epitope taken from two loops of a CH2 domain of an Fc region of an IgG, as described in U. S. Pat. Nos.5,869,046 and 6,121,022, each of which is incorporated herein by reference in its entirety.

[0231] Other exemplary variants that increase Fc binding to FcRn include: 250E, 250Q, 428L, 428F. 250Q / 428L (Hinton et al. 2004, J. Biol. Chem. 279(8): 6213-6216; Hinton et al. 2006 Journal of Immunology 176:346-356, each of which is incorporated herein by reference in its entirety), 256A, 272A, 286A, 305A, 307A, 307Q, 311A, 312A, 376A, 378Q, 380A. 382A, 434A (Shields et al., Journal of Biological Chemistry, 2001, 276(9):6591-6604, which is incorporated herein by reference in its entirety), 252F, 252T, 252Y, 252W, 254T, 256S, 256R, 256Q, 256E, 256D, 256T, 309P, 31 IS, 433R, 433S. 4331, 433P. 433Q, 434H, 434F, 434Y, 252Y / 254T / 256E, 433K / 434F / 436H, 308T / 309P / 31 IS (Dall Acqua et al. Journal of Immunology, 2002, 169:5171-54328856447vlAttorney Docket No: 243735.0005125180, Dall’Acqua et al., 2006, Journal of Biological Chemistry 281:23514-23524, each of which is incorporated herein by reference in its entirety). Additional exemplary variants that increase binding to FcRn and / or improve pharmacokinetic properties include mutations at positions 259, 308, 428, and 434, including for example 2591, 308F, 428L, 428M, 434S, 434H. 434F, 434Y, and 434M. Further modifications for modulating FcRn binding include those described in Yeung et al., 2010. J Immunol, 182:7663-7671, which is incorporated herein by reference in its entirety.

[0232] In some embodiments, antibodies described herein are of hybrid IgG isotypes. In some embodiments, an IgGl / IgG2 hybrid variant can be constructed by substituting IgG2 positions in the CH2 and / or CH3 region with amino acids from IgGl at positions where the two isotypes differ. In some embodiments, a hybrid variant IgG antibody can be constructed that comprises one or more substitutions, e.g., one or more of the following amino acid substitutions: 233E, 234L, 235L, - 236G (referring to an insertion of a glycine at position 236), and 327A. In some embodiments, an IgGl / IgG3 hybrid variant can be constructed by substituting IgGl positions in the CH2 and / or CH3 region with the amino acids from IgG3 at positions where the two isotypes differ. In some embodiments, a hybrid variant IgG antibody can be constructed that comprises one or more substitutions, e.g., 274Q, 276K, 300F, 339T, 356E, 358M, 384S, 392N, 397M, 4221, 435R, and / or 436F.

[0233] Moreover, the binding sites on human IgGl for FcyRI, FcyRII, FcyRIII and FcRn have been mapped and variants with improved binding have been described (see Shields, R. L. et al. (2001) J. Biol. Chem. 276:6591-6604). Specific mutations at positions 256, 290, 298, 333, 334 and 339 were shown to improve binding to FcyRIII. Additionally, the following combination mutants were shown to improve FcyRIII binding: T256A / S298A, S298A / E333A, S298A / K224A and S298A / E333A / K334A, which has been shown to exhibit enhanced FcyRIIIa binding and ADCC activity (Shields et al.. 2001). Other IgGl variants with strongly enhanced binding to FcyRIIIa have been identified, including variants with S239D / I332E and S239D / I332E / A330L mutations that showed the greatest increase in affinity for FcyRIIIa, a decrease in FcyRIIb binding, and strong cytotoxic activity in cynomolgus monkeys (Lazar el al., 2006). Introduction of the triple mutations into antibodies such as alemtuzumab (CD52-specific), trastuzumab (HER2 / neu-specific), rituximab (CD20- specific), and cetuximab (EGFR-specific) translated into greatly enhanced ADCC activity in vitro, and the S239D / I332E variant showed an enhanced capacity to deplete B cells in monkeys (Lazar et al., 2006).55328856447vlAttorney Docket No: 243735.000512

[0234] In addition, IgGl mutants containing L235V, F243L, R292P, Y300L and P396L mutations which exhibited enhanced binding to FcyRIIIa and concomitantly enhanced ADCC activity in transgenic mice expressing human FcyRIIIa in models of B cell malignancies and breast cancer have been identified (Stavenhagen et al., 2007; Nordstrom et al., 2011). Other Fc mutants that can be used include: S298A / E333A / L334A, S239D / I332E, S239D / I332E / A330L, L235V / F243L / R292P / Y300L / P396L, and M428L / N434S.

[0235] In some embodiments, an Fc region described herein may have reduced binding to FcyRs. For example, the Fc region (e.g., IgGl Fc) with reduced FcyR binding may comprise the following three amino acid substitutions: L234A, L235E and G237A.

[0236] In some embodiments, an Fc region described herein may have reduced complement fixation. For example, the Fc region (e.g., IgGl Fc) with reduced complement fixation may have the following two amino acid substitutions: A330S and P331S.

[0237] In some embodiments, an Fc region described herein may have essentially no effector function, i.e., it has reduced binding to FcyRs and reduced complement fixation. For example, an “effectorless” Fc region (e.g., IgGl Fc) may comprise the following five mutations: L234A, L235E, G237A, A330S and P331S.

[0238] In some embodiments, an Fc region described herein may include mutations L234A and / or L235A (EU numbering), which can suppress FcyR binding, and / or a P329G mutation (EU numbering) to abolish complement Clq binding, e.g., to abolish all immune effector functions.

[0239] In some embodiments, an IgG4 Fc region described herein may include a S228P mutation, e.g., to stabilize stabilizes IgG4 molecules and suppress formation of half-antibodies. In some embodiments, an hIgG4 Fab described herein may comprise an exchange mutant sequence which may include a S228P mutation which can suppress Fab arm exchange.

[0240] In some embodiments, the Fc region may comprise a non-naturally occurring amino acid residue at additional and / or alternative positions as described in, e.g., PCT Patent Publications WO 00 / 42072; WO 01 / 58957; WO 02 / 06919; WO 04 / 016750; WO 04 / 029207; WO 04 / 035752; WO 04 / 063351; WO 04 / 074455; WO 04 / 099249: WO 05 / 040217; WO 05 / 070963; WO 05 / 092925 and WO 06 / 020114; and U. S. Pat. Nos. 5,624,821; 6,277,375; 6,737,056; 6,194,551; 7,317,091; 8,101,720; each of which is incorporated herein by reference in its entirety). Other suitable Fc modifications are described in WO 2016 / 081746 or WO 2017 / 087678, both of which are incorporated herein by reference in their entirety.56328856447vlAttorney Docket No: 243735.000512

[0241] In some embodiments, an antibody or antigen-binding fragment thereof described herein is capable of depleting target protein (e.g., PGE2 protein or COX enzyme or PTGES or prostaglandin receptor) from a tumor microenvironment of a subject.

[0242] In some embodiments, an antibody or antigen-binding fragment thereof described herein is capable of selectively recognizing a target protein (e.g., PGE2 protein or COX enzyme or prostaglandin receptor) in the tumor microenvironment (TME), that is, an antibody or antigenbinding fragment thereof described herein has a higher affinity to the target protein (e.g., PGE2 protein or COX enzyme or prostaglandin receptor) that is present in the TME than the target protein (e.g., PGE2 protein or COX enzyme or prostaglandin receptor) in healthy tissues. Such antibodies or antigen-binding fragments thereof described herein may exhibit higher safety. Reported antibody engineering technologies may be exploited for developing such antibodies or antigenbinding fragments thereof described herein.

[0243] In some embodiments, the isolated peptide described herein inhibits one or more prostaglandins, one or more prostaglandin synthases, one or more prostaglandin receptors, and / or sensory neurons. In some embodiments, inhibiting one or more prostaglandins comprises inhibiting the synthesis, activity, and / or function of the one or more prostaglandins.

[0244] In some embodiments, the isolated peptides of the present disclosure can be further modified to improve affinity of the peptides and / or metabolic stability. In some embodiments, the isolated peptides of the present disclosure may also be synthesized with additional chemical groups present at their N- and / or C-termini, to enhance the affinity, bioavailability, and / or stability of the peptides.

[0245] In some embodiments, N-terminal modifications can include, but not limited to acetylation (e.g., with acetic acid or a halogenated derivative thereof such as a-chloroacetic acid, a-bromoacetic acid, or a-iodoacetic acid), methylation (e.g., — NHCH3 or — N(CH3)2), adding a benzyloxycarbonyl (Cbz) group, or blocking the amino terminus with any blocking group containing a carboxylate functionality defined by RCOO — or sulfonyl functionality defined by R — SO2 —, where R is selected from alkyl, aryl, heteroaryl, and the like, and similar groups. One can also incorporate a desamino acid at the N-terminus (so that there is no N-terminal amino group) to decrease susceptibility to proteases or to restrict the conformation of the peptide. Alternatively or additionally, hydrophobic groups such as carbobenzoxyl, dansyl, or t-butyloxycarbonyl groups57328856447vlAttorney Docket No: 243735.000512can be added to the N-terminus. Similarly, an acetyl group or a 9-fluorenylmethoxy-carbonyl group can be placed at the N-terminus.

[0246] In some embodiments, C-terminal modifications can include but not limited to replacing the free acid with a carboxamide group or forming a cyclic lactam at the carboxy terminus to introduce structural constraints. The peptide inhibitors of the present disclosure can be cyclized, or a desamino or descarboxy residue can be incorporated at the termini of the peptide, so that there is no terminal amino or carboxyl group, to decrease susceptibility to proteases or to restrict the conformation of the peptide. C-terminal functional groups of the peptide inhibitors of the present disclosure include amide, amide lower alkyl, amide di(lower alkyl), lower alkoxy, hydroxy, and carboxy, and the lower ester derivatives thereof, and the pharmaceutically acceptable salts thereof. In some embodiments, the hydrophobic group, t-butyloxycarbonyl, or an amido group can be added to the C-terminus of the peptide inhibitors.

[0247] Non-limiting examples of non-natural modifications include incorporation of nonencoded a-amino acids, retroinversion by using D-amino acids, -amino acids, backbone reduction, photoreactive cross-linking amino acids, N-methylated amino acids, and C-terminal amidation and PEGylation.

[0248] Non-limiting examples of amino acid replacements include stereoisomers (e.g., D-amino acids) and unnatural amino acids such as, L-citrulline, L-homocysteine, L-homoserine, L-omithine. 3-sulfino-L-alanine, N-(L-arginino)succinate, 3,4-dihydroxy-L-phenylalanine, 3-iodo-L-tyrosine, 3,5-diiodo-L-tyrosine, triiodothyronine, L-selenocysteine, L-thyroxine, N-(L-arginino)taurine, 4-aminobutylate, (R, S)-3-amino-2-methylpropanoate, a,a-disubstituted amino acids. N-alkyl amino acids, lactic acid, -alanine, 3-pyridylalanine, 4-hydroxyproline. O-phosphoserine, N-acetylserine, N-formylmethionine, N-methylglycine, 3-methylhistidine, 5-hydroxy lysine, nor- leucine, and other similar amino acids and imino acids.

[0249] In some embodiments, the isolated peptides of the present disclosure may comprise one or more amino acid substitutions and / or insertions and / or deletions. Amino acid substitution encompasses a substitution of the amino acid residue for a replacement amino acid residue at the same position. Inserted amino acid residues can be inserted at any position and can be inserted such that some or all of the inserted amino acid residues are immediately adjacent one another or can be inserted such that none of the inserted amino acid residues is immediately adjacent another inserted amino acid residue.58328856447vlAttorney Docket No: 243735.000512

[0250] In some embodiments, the isolated peptides of the present disclosure may be about 10-50 amino acids in length. For example, the isolated peptides of the present disclosure may be 14 amino acids, 15 amino acids, 16 amino acids, 17 amino acids, 18 amino acids, 19 amino acids, 20 amino acids, 21 amino acids, 22 amino acids, 23 amino acids, 24 amino acids, 25 amino acids, 26 amino acids, 27 amino acids, 28 amino acids, 29 amino acids, or 30 amino acids in length. In some embodiments, the isolated peptides of the present disclosure are 25 amino acids in length. In some embodiments, the isolated peptides of the present disclosure are 24 amino acids in length.

[0251] In some embodiments, the isolated peptides of the present disclosure are fused or conjugated to one or more heterologous moieties. Non-limiting examples of heterologous moieties suitable for chemical conjugation and / or genetical fusion with the isolated peptides of the disclosure include, but are not limited to, nucleic acids, lipids, sugars, peptides, polypeptides, small molecules, polymers, etc. The heterologous moieties may be fused at the N- and / or C-terminus of the peptide.

[0252] In some embodiments, the isolated peptide of the present disclosure is fused to carbohydrate, protein, and / or lipid moiety. In some embodiments, the isolated peptide of the present disclosure is fused to lipid moiety. The fusion of the isolated peptide of the present disclosure to lipids may enhance concentration of said isolated peptide at the cell surface.

[0253] Non-limiting examples of heterologous peptides and polypeptides include, but are not limited to, an epitope (such as FLAG) or a tag sequence (such as hexa histidine (SEQ ID NO: 38), and the like) to allow for the detection and / or isolation of a fusion protein; a polypeptide or peptide which increases stability, such as an immunoglobulin constant region (e.g., an Fc domain); a half-life-extending sequence comprising a combination of two or more naturally occurring or non-naturally occurring charged and / or uncharged amino acids designed to form hydrophilic or hydrophobic fusion partner for a fusion protein; a ligand or a portion thereof which binds to a transmembrane receptor protein; an enzyme or portion thereof which is catalytically active: a polypeptide or peptide which promotes oligomerization, for example, a leucine zipper domain; a transmembrane receptor protein or a portion thereof, for example, an extracellular domain or a transmembrane and intracellular domain; afunctional or non-functional antibody e.g., an antibody that is specific for dendritic cells), or a heavy or light chain thereof; and a polypeptide which has an activity, such as a therapeutic activity, different from fusion proteins of the present disclosure. In some embodiments, the one or more heterologous moieties enhances an isolated peptide-59328856447vlAttorney Docket No: 243735.000512specific immune response in a subject. In some embodiments, the one or more heterologous moieties mediates isolated peptide delivery to a specific site within a subject.

[0254] In some embodiments, fusion proteins of the disclosure may comprise one or more affinity tags, e.g., to allow for affinity purification or coupling to another molecule. Examples of affinity tags include, but are not limited to, an Avi-tag, a biotin, a calmodulin tag, a hexahistidine tag (SEQ ID NO: 38), a hemagglutinin (HA) tag, a Myc tag, a GST tag, a green fluorescent protein (GFP), YFP, RFP, CFP, a MBP tag, a chitin binding protein tag, a FLAG tag, a V5 tag, a streptavidin binding tag, mCherry, tdTomato, SUMO tag, and Ubiquitin tag.Nucleic acids

[0255] In some embodiments, the inhibitor (e.g., a therapeutic agent, a receptor antagonist, and / or a chemogenetic compound described herein) is a nucleic acid. A nucleic acid molecule may include a small-interference RNA (siRNA), a short hairpin RNA (shRNA), an antisense oligonucleotide (ASO), a micro RNA (miRNA), or a site-specific nuclease.

[0256] siRNAs are a class of double-stranded RNA molecules, typically about 20-25 base pairs in length that target nucleic acids (e.g., mRNAs) for degradation via the RNA interference (RNAi) pathway in cells. Such siRNA molecules typically include a region of sufficient homology to the target region, and are of sufficient length in terms of nucleotides, such that the siRNA molecules down-regulate target nucleic acid. It is not necessary that there be perfect complementarity between the siRNA molecule and the target, but the correspondence must be sufficient to enable the siRNA molecule to direct sequence-specific silencing, such as by RNAi cleavage of the target RNA. In some embodiments, the sense strand need only be sufficiently complementary with the antisense strand to maintain the overall double-strand character of the molecule. Specificity of siRNA molecules may be measured via the binding of the antisense strand of the molecule to its target RNA. Effective siRNA molecules are often fewer than 30 to 35 base pairs in length, e.g., to prevent stimulation of non-specific RNA interference pathways in the cell by way of the interferon response, however longer siRNA may also be effective. In various embodiments, the siRNA molecules are 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 base pairs in length. In various embodiments, the siRNA molecules are about 35 to about 70 more base pairs in length. In some embodiments, the siRNA molecules are more than 70 base pairs in length. In some embodiments, the siRNA molecules are 8 to 40 base pairs in length, 10 to 20 base pairs in length, 10 to 30 base pairs in length, 15 to 20 base pairs in length, 19 to 23 base60328856447vlAttorney Docket No: 243735.000512pairs in length, 21 to 24 base pairs in length. In some embodiments, the sense and antisense strands of the siRNA molecules are each independently about 19 to about 24 nucleotides in length. In some embodiments, the sense strand of an siRNA molecule is 23 nucleotides in length and the antisense strand is 21 nucleotides in length. In some embodiments, both the sense strand and the antisense strand of an siRNA molecule are 21 nucleotides in length. After selection of a suitable target RNA sequence. siRNA molecules that comprise a nucleotide sequence complementary to all or a portion of the target sequence, i.e., an antisense sequence, may be designed and prepared using suitable methods (see, e.g., U. S. Patent Publication Nos. 2004 / 0077574 and 2008 / 0081791 and PCT Publication No. WO 2004 / 016735). In some embodiments, the siRNA molecule may be single-stranded (z.e., a ssRNA molecule comprising just an antisense strand) or double stranded (i.e., a dsRNA molecule comprising an antisense strand and a complementary sense strand that hybridizes to form the dsRNA). In various embodiments, the siRNA molecules may comprise a duplex, asymmetric duplex, hairpin, or asymmetric hairpin secondary structure, comprising self-complementary sense and / or antisense strands.

[0257] A “small hairpin RNA” or “short hairpin RNA” or “shRNA” described herein may include a short RNA sequence that makes a tight hairpin turn that can be used to silence gene expression via RNA interference. The shRNAs provided herein may be chemically synthesized or transcribed from a transcriptional cassette in a DNA plasmid. The shRNA hairpin structure may be cleaved by the cellular machinery into siRNA, which is then bound to the RNA-induced silencing complex (RISC). Non-limiting examples of shRNAs include a double-stranded polynucleotide molecule assembled from a single-stranded molecule, where the sense and antisense regions are linked by a nucleic acid-based or non-nucleic acid-based linker; and a doublestranded polynucleotide molecule with a hairpin secondary structure having self-complementary sense and antisense regions. In some embodiments, the sense and antisense strands of the shRNA are linked by a loop structure comprising from about 1 to about 25 nucleotides, from about 2 to about 20 nucleotides, from about 4 to about 15 nucleotides, from about 5 to about 12 nucleotides, or 1, 2, 3, 4, 5, 6, 7, 8, 9. 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, or more nucleotides.

[0258] A site-specific nuclease described herein may comprise a DNA nuclease such as an engineered (e.g., programmable or targetable) DNA nuclease to induce genome editing of a target DNA sequence. Any suitable DNA nuclease can be used including, but not limited to, CRISPR-61328856447vlAttorney Docket No: 243735.000512associated protein (Cas) nucleases, zinc finger nucleases (ZFNs), transcription activator-like effector nucleases (TALENs), meganucleases, other endo- or exo-nucleases, variants thereof, fragments thereof, and combinations thereof.

[0259] An antisense oligonucleotide (ASO) described herein can downregulate a target, for example, by steric hindrance of ribosomal activity, by causing RNase H endonuclease cleavage of a target RNA, or by altering splicing or by inhibiting 5'cap formation. An ASO can generally comprise a short nucleotide sequence which is substantially complementary to a target nucleotide sequence in a pre-mRNA molecule, an mRNA molecule, or a heterogeneous nuclear RNA (hnRNA). The degree of complementarity (or substantial complementarity) of the antisense sequence can be such that a molecule comprising the antisense sequence may form a stable doublestranded hybrid with the target nucleotide sequence in the RNA molecule. Without wishing to be bound by theory, “complementarity” of nucleic acids can mean that a nucleotide sequence in one strand of nucleic acid, e.g., due to orientation of its nucleobase groups, forms hydrogen bonds with another sequence on an opposing nucleic acid strand. The complementary bases in DNA are generally A paired with T and C paired with G. In RNA, the complementary bases are generally C with paired with G and U paired with A. Complementarity can be perfect or substantial / sufficient. Perfect complementarity between two nucleic acids means that the two nucleic acids can form a duplex in which every base within the duplex is bonded to a complementary base by Watson-Crick pairing. “Substantial” or “sufficient” complementarity means that a sequence in one strand is not completely and / or perfectly complementary to a sequence in an opposing strand but that sufficient bonding takes place between bases on the two strands to form a stable hybrid complex in set of hybridization conditions (e.g., temperature and / or salt concentration). Such conditions can be determined by, e.g., empirical determination of Tm(melting temperature) by employing routine methods in the art or by using the sequences and standard mathematical calculations to predict the Tmof hybridized strands. Tmcan include the temperature at which a population of hybridization complexes formed between two nucleic acid strands are 50% denatured (i.e., a population of double- stranded nucleic acid molecules becomes half dissociated into single strands). At a temperature below the Tm, formation of a hybridization complex can be favored, while at a temperature above the Tm, melting or separation of the strands in the hybridization complex can be favored. ASO can be synthetic and chemically modified.62328856447vlAttorney Docket No: 243735.000512Chimeric Antigen Receptors

[0260] In some embodiments, an inhibitor (e.g., a therapeutic agent, and / or a receptor antagonist described herein) is a chimeric antigen receptor (CAR), such as for producing chimeric antigen receptor T cells (e.g., CAR T cells) and CAR natural killer (NK) cells, and killer macrophages.

[0261] In embodiments, a CAR of the present disclosure comprises scFv that comprises heavy and light chains as described herein. As is known in the art for previously described CARs, the scFv is present in a contiguous polypeptide that further comprises a CD3zeta chain and a costimulatory domain. In embodiments, the costimulatory domain comprises a 4-IBB costimulatory domain or a CD28 costimulatory domain. A CAR may also contain a coreceptor hinge sequence, such as a CD8 a co-receptor hinge sequence.Antibody-drug conjugate

[0262] In some embodiments, an inhibitor e.g., a therapeutic agent, and / or a receptor antagonist, described herein) is an antibody-drug conjugate. In some embodiments, the present disclosure also provides an antibody-drug conjugate comprising the antibody or antigen-binding fragment described herein conjugated to a heterologous moiety. Non-limiting examples of a heterologous moiety include a cytotoxic agent, siRNA, an antisense oligonucleotide, a radionucleotide, a lysosome-targeting chimera (LYTAC), an immune checkpoint inhibitor, a cytokine, a tumor-associated antigen (TAA)- targeting agent, and an immune agonist. In some embodiments, an antibody- drug conjugate is an immune- stimulating antibody conjugate (ISAC) or an antibody-oligonucleotide conjugate (AOC).

[0263] In some embodiments, a cytotoxic agent can include, e.g., an anti-tubulin agent, a tubulin polymerization inhibitor, a DNA synthesis inhibitor, a DNA intercalating agent, a DNA alkylating agent, a DNA cross-linking agent, a DNA cleaving agent, a platinum-based agent, topoisomerase I inhibitor, topoisomerase II inhibitor, an anti-microtubule agent, an anti-mitotic agent, a taxane-related anti-neoplastic agent, an anti-metabolite, an anti-tumor plant alkaloid, and an RNA polymerase II inhibitor.

[0264] Non-limiting examples of cytotoxic agents are doxorubicin, nemorubicin, PNU- 159682, paclitaxel, docetaxel, auristatin E, auristatin F, dolastatin 10. dolastatin 15, monomethyl auristatin E (MMAE), monomethyl auristatin F (MMAF), monomethyl auristatin D (MMAD), maytansine, mertansine (DM1), maytansinoid DM4, calicheamicin, N-acetyl-calicheamicin,63328856447vlAttorney Docket No: 243735.000512vinblastine, vincristine, vindesine, vinorelbine, camptothecin, topotecan, irinotecan, SN-38, duocarmycin A, duocarmycin Bl, duocarmycin B2, duocarmycin CI, duocarmycin C2, duocarmycin D, duocarmycin SA, duocarmycin TM, duocarmycin MB, duocarmycin DM, mitomycin C, rachelmycin, epothilone A, epothilone B, epothilone C, tubulysin B, tubulysin M, pyrrolobenzodiazepine (PBD), bortezomib, ranpimase, hTNF, IL- 12, ranpimase, human ribonuclease (RNAse), Bovine pancreatic Rnase, pokeweed antiviral protein. Pseudomonas exotoxin A, gelonin, ricin-A, interferon- alpha, interferon-lambda, urease, amatoxin, alpha-amanitin, beta-amanitin, gamma-amanitin, epsilon- amanitin, bouganin, and staphylococcal enterotoxin.

[0265] Methods for making the antibody-drug conjugates disclosed herein is also contemplated as within the scope of this disclosure. In one aspect, provided herein is a method for making an antibody-drug conjugate described herein comprising(a) contacting the antibody or antigen-binding fragment with the heterologous moiety under the conditions favorable for conjugation of the antibody or antigen-binding fragment to the heterologous moiety; and(b) optionally, isolating the antibody-drug conjugate produced in step (a).

[0266] In order to facilitate the coupling between the heterologous moiety and the antibody, it is possible to directly conjugate the two agents, or to introduce a spacer molecule between them. Suitable spacers include poly(alkylene) glycols such as polyethylene glycol, and peptide linkers. Many suitable coupling techniques are well known in the art. Suitable agents allowing covalent, electrostatic or noncovalent binding of the moiety to the antibody include benzoquinone, carbodiimide and more particularly EDC (l-ethyl-3-[3-dimethyl-aminopropyl] -carbodiimide hydrochloride), dimaleimide, dithiobis-nitrobenzoic acid (DTNB), N-succinimidyl S-acetyl thioacetate (SATA), the bridging agents having one or more phenylazide groups reacting with the ultraviolets (U. V.) and preferably N-[-4-(azidosalicylamino)butyl]-3'-(2'-pyridyldithio)-propionamide (APDP), N-succinimid-yl 3-(2-25 pyridyldithio)propionate (SPDP), 6-hydrazino-nicotinamide (HYNIC). Another form of coupling, especially for the radioelements, includes the use of a bifunctional ion chelator. For example, chelates derived from EDTA or DTPA which have been developed for binding metals, especially radioactive metals, and immunoglobulins. Thus, DTPA and its derivatives can be substituted by different groups on the carbon chain in order to increase the stability and the rigidity of the ligand-metal complex, as is well known in the art.64328856447vlAttorney Docket No: 243735.000512

[0267] In some embodiments, conjugation of a heterologous moiety to an antibody or antigenbinding fragment described herein is carried out via the covalent-nature binding, or binding by the use of adapter molecules or linkers.

[0268] Covalent binding requires prior activation of the heterologous moieties. In some embodiments, covalent strategies occur via carbodiimide chemistry, maleimide chemistry or “click chemistry”, as discussed in detail below.Pharmaceutical Compositions

[0269] Pharmaceutical compositions comprising the inhibitors (e.g., therapeutic agents, receptor antagonists, and / or chemogenetic compounds described herein) of the present disclosure are within the scope of the present invention. Such pharmaceutical compositions can comprise a therapeutically effective amount of an inhibitor (e.g., a therapeutic agent, a receptor antagonist, and / or a chemogenetic compound described herein) in admixture with a pharmaceutically or physiologically acceptable formulation agent selected for suitability with the mode of administration. Acceptable formulation agents preferably are nontoxic to recipients at the dosages and concentrations employed.

[0270] Any of various compositions, e.g., compositions comprising any of the various prostaglandin inhibitors such as inhibitors of function and / or activity of one or more prostaglandins, or of one or more prostaglandin synthases (e.g., a PGE2 protein inhibitor or a COX enzyme inhibitor) described herein, can be present in a pharmaceutical composition (such as a formulation) that can includes other agents, excipients, or stabilizers. In various embodiments, a pharmaceutical composition described herein may further comprise (i) one or more prostaglandin receptor inhibitors, (ii) one or more chemogenetic compounds, and / or (iii) PGE3, with a pharmaceutically acceptable carrier and / or excipient.

[0271] Any of various compositions, e.g., compositions comprising any of the various prostaglandin receptor inhibitors such as inhibitors of function and / or activity of one or more prostaglandin receptors (e.g., EPl receptor antagonist, EP2 receptor antagonist, EP3 receptor antagonist, or EP4 receptor antagonist) described herein, can be present in a pharmaceutical composition (such as a formulation) that can includes other agents, excipients, or stabilizers. In various embodiments, a pharmaceutical composition described herein may further comprise (i)65328856447vlAttorney Docket No: 243735.000512one or more prostaglandin inhibitors, (ii) one or more chemogenetic compounds, and / or (iii) PGE3, with a pharmaceutically acceptable carrier and / or excipient.

[0272] Any of various compositions, e.g., compositions comprising any of the various sensory neuron inhibitors such as inhibitors of function and / or activity of one or more sensory neurons (e.g., a chemogenetic compound described herein) described herein, can be present in a pharmaceutical composition (such as a formulation) that can includes other agents, excipients, or stabilizers. In various embodiments, a pharmaceutical composition described herein may further comprise (i) one or more prostaglandin inhibitors, (ii) one or more prostaglandin receptor inhibitors, and / or (iii) PGE3, with a pharmaceutically acceptable carrier and / or excipient.

[0273] Any of various compositions, e.g., compositions comprising any of various PGE3 activators such as activators of function and / or activity of PGE3 can be present in a pharmaceutical composition (such as a formulation) that can includes other agents, excipients, or stabilizers. In various embodiments, a pharmaceutical composition described herein may comprise (i) one or more prostaglandin inhibitors, (ii) one or more prostaglandin receptor inhibitors, and / or (iii) one or more chemogenetic compounds, with a pharmaceutically acceptable carrier and / or excipient.

[0274] The prostaglandin inhibitor (e.g., therapeutic agents described herein) can be any of the various prostaglandin inhibitors described herein. In some embodiments, the prostaglandin inhibitor is a PGE2 inhibitor. In some embodiments, the prostaglandin inhibitor is a prostaglandin synthase inhibitor. In some embodiments, the prostaglandin inhibitor is a COX enzyme inhibitor. In some embodiments, the prostaglandin synthase inhibitor is a COX inhibitor described herein. In some embodiments, the prostaglandin synthase inhibitor is a COXI inhibitor and / or a COX2 inhibitor described herein.

[0275] Non-limiting examples of COX enzyme inhibitors are NSAIDs such as ibuprofen, acetylsalicylic acid (ASA), diclofenac, diflunisal, etodolac, fenoprofen, flurbiprofen, indomethacin, ketoprofen, ketorolac, mefenamic acid, meloxicam, nabumetone. naproxen, oxaprozin, piroxicam, sulindac, tolmetin, and any combinations thereof and / or valdecoxib (Bextra), celecoxib (Celebrex), rofecoxib, and any combinations thereof.

[0276] In some embodiments, the prostaglandin inhibitor is a PTGES inhibitor. Non-limiting examples of a therapeutic agent that inhibits the synthesis, activity, and / or function of PTGES include zaloglanstat (ISC-27864; GRC-27864).66328856447vlAttorney Docket No: 243735.000512

[0277] The prostaglandin receptor inhibitor (e.g., prostaglandin receptor antagonists described herein) can be any of the various prostaglandin inhibitors described herein. Non-limiting examples of the prostaglandin receptor antagonists include SC-51322, GW-848687X, SC- 19220. SC-51089, ONO-8713, ONO-8130, ONO-8711, PF-04418948, TG6-10-1, TG8-260, DG-041, L798-106, ONO-AE3-240, ONO-AE3-208, LY3127760, Grapiprant, AH6809, RQ-15986, and any combinations thereof. (Pain. 2011 Jun;152(6):1373-1381. doi: 10.1016 / j.pain.2011.02.019. Epub 2011 Mar 10.)

[0278] In some embodiments, the EPl receptor antagonist is selected from SC-51322, GW-848687X, SC-19220, SC-51089, ONO-8713, ONO-8130, ONO-8711, and any combination thereof. In some embodiments, the EP2 receptor antagonist is selected from PF-04418948, TG6-10-1, TG8-260, and any combination thereof. In some embodiments, the EP3 receptor antagonist is selected from DG-041, L798-106, ONO-AE3-240, and any combination thereof. In some embodiments, the EP4 receptor antagonist is selected from ONO-AE3-208, LY3127760, Grapiprant. AH6809, RQ-15986. and any combination thereof.

[0279] The sensory neuron inhibitor can be any of the various sensory neuron inhibitors described herein. In some embodiments, the sensory neuron inhibitor is a chemogenetic compound described herein. In some embodiments, the chemogenetic compound is clozapine-N-oxide.

[0280] The pharmaceutical composition can contain formulation agent(s) for modifying, maintaining, or preserving, for example, the pH, osmolarity, viscosity, clarity, color, isotonicity, odor, sterility, stability, rate of dissolution or release, adsorption, or penetration of the composition. Suitable formulation agents include, but are not limited to, amino acids (such as glycine, glutamine, asparagine, arginine, or lysine), antimicrobials, antioxidants (such as ascorbic acid, sodium sulfite, methionine or sodium hydrogen-sulfite), buffers (such as borate, bicarbonate, Tris-HC1, histidine, citrates, phosphates, or other organic acids), bulking agents (such as mannitol or glycine), chelating agents (such as ethylenediamine tetraacetic acid (EDTA)), complexing agents (such as caffeine, polyvinylpyrrolidone, beta-cyclodextrin, or hydroxypropyl-beta-cyclodextrin), fillers, monosaccharides, disaccharides, and other carbohydrates (such as glucose, mannose, or dextrins), proteins (such as serum albumin, gelatin, or immunoglobulins), coloring, flavoring and diluting agents, emulsifying agents, hydrophilic polymers (such as polyvinylpyrrolidone), low molecular weight polypeptides, salt-forming counterions (such as sodium), preservatives (such as benzalkonium chloride, benzoic acid, salicylic acid, thimerosal, phenethyl alcohol, methylparaben,67328856447vlAttorney Docket No: 243735.000512propylparaben, chlorhexidine, sorbic acid, or hydrogen peroxide), solvents (such as glycerin, propylene glycol, or polyethylene glycol), sugar alcohols (such as mannitol or sorbitol), suspending agents, surfactants or wetting agents (such as pluronics; PEG; sorbitan esters; polysorbates such as polysorbate 20 or polysorbate 80; triton; tromethamine; lecithin; cholesterol or tyloxapal), stability enhancing agents (such as sucrose or sorbitol), tonicity enhancing agents (such as alkali metal halides — preferably sodium or potassium chloride — or mannitol sorbitol), delivery vehicles, diluents, excipients and / or pharmaceutical adjuvants (see, e.g., Remington’s Pharmaceutical Sciences (18thEd., A. R. Gennaro, ed., Mack Publishing Company 1990), and subsequent editions of the same, incorporated herein by reference for any purpose).

[0281] The optimal pharmaceutical composition will be determined by a skilled artisan depending upon, for example, the intended route of administration, delivery format, and desired dosage (see, e.g., Remington’s Pharmaceutical Sciences, supra). Such compositions can influence the physical state, stability, rate of in vivo release, and rate of in vivo clearance of the inhibitors, (e.g., therapeutic agents, receptor antagonists, and / or chemogenetic compounds described herein).

[0282] The primary vehicle or carrier in a pharmaceutical composition can be either aqueous or non-aqueous in nature. For example, a suitable vehicle or carrier for injection can be water, physiological saline solution, or artificial cerebrospinal fluid, possibly supplemented with other materials common in compositions for parenteral administration. Neutral buffered saline or saline mixed with serum albumin are further exemplary vehicles. Other exemplary pharmaceutical compositions comprise Histidine or Tris buffer of about pH 6.0-8.5, which can further include sorbitol or a suitable substitute. In one embodiment of the present invention, compositions can be prepared for storage by mixing the selected composition having the desired degree of purity of the inhibitor (e.g., a therapeutic agent, a receptor antagonist, and / or a chemogenetic compound described herein) with optional formulation agents (Remington's Pharmaceutical Sciences, supra) in the form of an aqueous solution.

[0283] The pharmaceutical compositions can be selected for parenteral delivery. Alternatively, the compositions can be selected for inhalation or for delivery through the digestive tract, such as orally. The preparation of such pharmaceutically acceptable compositions is within the skill of the art. The formulation components are present in concentrations that are acceptable to the site of administration. For example, buffers are used to maintain the composition at physiological pH or at a slightly lower pH, typically within a pH range of from about 6 to about 8.68328856447vlAttorney Docket No: 243735.000512

[0284] When parenteral administration is contemplated, the therapeutic compositions of the inhibitors (e.g., therapeutic agents, receptor antagonists, and / or chemogenetic compounds described herein) for use in this invention can be in the form of a pyrogen-free, parenterally acceptable, aqueous solution comprising the desired inhibitors, therapeutic agents, and / or antagonists, in a pharmaceutically acceptable vehicle. A particularly suitable vehicle for parenteral injection is sterile distilled water in which an inhibitor (e.g., a therapeutic agent, a receptor antagonist, and / or a chemogenetic compound described herein), is formulated as a sterile, isotonic solution, properly preserved. Yet another preparation can involve the formulation of the desired inhibitors (e.g., therapeutic agents, receptor antagonists, and / or chemogenetic compounds described herein) with injectable microspheres, bio-erodible particles, polymeric compounds (such as polylactic acid or polyglycolic acid), beads, or liposomes, that provides for the controlled or sustained release of the product which can then be delivered via a depot injection. Hyaluronic acid can also be used, and this can have the effect of promoting sustained duration in the circulation. Other suitable means for the introduction of the desired molecule include implantable drug delivery devices.

[0285] In one embodiment, a pharmaceutical composition can be formulated for inhalation. For example, the pharmaceutical composition can be formulated as a dry powder for inhalation. Inhalation solutions can also be formulated with a propellant for aerosol delivery. In yet another embodiment, solutions can be nebulized. Pulmonary administration is further described in International Publication No. W01994020069 (incorporated herein by reference in its entirety), which describes the pulmonary delivery of chemically modified proteins.

[0286] It is also contemplated that certain formulations can be administered orally. In one embodiment of the present invention, formulations that are administered in this fashion can be formulated with or without those carriers customarily used in the compounding of solid dosage forms such as tablets and capsules. For example, a capsule can be designed to release the active portion of the formulation at the point in the gastrointestinal tract when bioavailability is maximized and pre-systemic degradation is minimized. Additional agents can be included to facilitate absorption. Diluents, flavorings, low melting point waxes, vegetable oils, lubricants, suspending agents, tablet disintegrating agents, and binders can also be employed.

[0287] Another pharmaceutical composition can involve an effective quantity of the inhibitor e.g., a therapeutic agent, a receptor antagonist, and / or a chemogenetic compound described69328856447vlAttorney Docket No: 243735.000512herein) in a mixture with non-toxic excipients that are suitable for the manufacture of tablets. By dissolving the tablets in sterile water, or another appropriate vehicle, solutions can be prepared in unit-dose form. Suitable excipients include, but are not limited to, inert diluents, such as calcium carbonate, sodium carbonate or bicarbonate, lactose, or calcium phosphate; or binding agents, such as starch, gelatin, or acacia; or lubricating agents such as magnesium stearate, stearic acid, or talc.

[0288] Additional pharmaceutical compositions include formulations involving inhibitors (e.g., therapeutic agents, receptor antagonists, and / or chemogenetic compounds described herein) in sustained- or controlled-delivery formulations. Techniques for formulating a variety of other sustained- or controlled-delivery means include the use of liposome carriers, bio-erodible microparticles or porous beads and depot injections (see, e.g., International Publication No. WO1993015722, which describes the controlled release of porous polymeric microparticles for the delivery of pharmaceutical compositions, and Wischke & Schwendeman, 2008, Int. J. Pharm. 364: 298-327, and Freiberg & Zhu, 2004, Int. J. Pharm. 282: 1-18, which discuss microsphere / microparticle preparation and use; each reference incorporated herein by reference in its entirety). As described herein, a hydrogel is an example of a sustained- or controlled-delivery formulation.

[0289] Additional examples of sustained-release preparations include semipermeable polymer matrices in the form of shaped articles, e.g., films, or microcapsules. Sustained release matrices can include polyesters, hydrogels, polylactides (U. S. Pat. No. 3,773,919 and European Patent No.0 058 481, each incorporated herein by reference in its entirety), copolymers of L-glutamic acid and gamma ethyl-L-glutamate (Sidman et ah, 1983, Biopolymers 22: 547-56), poly(2-hydroxyethyl-methacrylate) (Langer et ah, 1981, J. Biomed. Mater. Res. 15: 167-277 and Langer, 1982, Chem. Tech. 12: 98-105), ethylene vinyl acetate (Langer et al, supra) or poly-D(-)-3-hydroxybutyric acid (European Patent No. 0133988). Sustained-release compositions can also include liposomes, which can be prepared by any of several methods known in the art. See, e.g., Epstein et ah, 1985, Proc. Natl. Acad. Sci. U. S. A. 82: 3688-92; and European Patent Nos. 0036676, 0088046, and 0143949, each incorporated herein by reference in its entirety.

[0290] The pharmaceutical composition to be used for in vivo administration typically should be sterile. This can be accomplished by filtration through sterile filtration membranes. Where the composition is lyophilized, sterilization using this method can be conducted either prior to, or following, lyophilization and reconstitution. The composition for parenteral administration can be70328856447vlAttorney Docket No: 243735.000512stored in lyophilized form or in a solution. In addition, parenteral compositions generally are placed into a container having a sterile access port, for example, an intravenous solution bag or vial having a stopper pierceable by a hypodermic injection needle. The parenteral composition can be diluted into parenteral acceptable diluents (e.g., saline and 5% Dextrose).

[0291] Once the pharmaceutical composition has been formulated, it can be stored in sterile vials as a solution, suspension, gel, emulsion, solid, or as a dehydrated or lyophilized powder. Such formulations can be stored either in a ready-to-use form or in a form (e.g., lyophilized) requiring reconstitution prior to administration.

[0292] In some embodiments, the pharmaceutical compositions comprising one or more inhibitors (e.g., therapeutic agents, receptor antagonists, and / or chemogenetic compounds described herein) further comprises a PUFA. In some embodiments, the PUFA comprises an omega-3 PUFA. In some embodiments, the PUFA comprises eicosapentaenoic acid (EPA) and / or docosahexaenoic acid (DHA).

[0293] In some embodiments, the pharmaceutical compositions comprising one or more inhibitors (e.g., therapeutic agents, receptor antagonists, and / or chemogenetic compounds described herein) further comprises DHA and / or EPA.Kits

[0294] In one embodiment, the present invention is directed to kits for producing a single-dose administration unit. The kits can each contain both a first container having a dried protein and a second container having an aqueous formulation. Also included within the scope of this invention are kits containing single and multi-chambered pre- filled syringes (e.g., liquid syringes and dual chamber syringes).

[0295] In one embodiment, the present invention is directed to a pharmaceutical composition comprising an inhibitor (e.g., a therapeutic agent, a receptor antagonist, and / or a chemogenetic compound described herein) and optionally omega-3 PUFA formulated as a powder for injection after reconstitution to a solution for injection.Dosage and administration

[0296] Provided herein is a method of treating cachexia and / or sickness behavior in a subject having (i) a mutation in a liver kinase Bl (LKB1) gene and / or (ii) suppression of LKB1 -mediated 71328856447vlAttorney Docket No: 243735.000512signaling comprising administering to the subject an effective amount of one or more prostaglandin inhibitors (e.g., therapeutic agents described herein), optionally in combination with an omega-3 PUFA and / or a low-fat diet. Also provided herein is a method of treating cachexia and / or sickness behavior in a subject having a cancer and (i) a mutation in a liver kinase Bl (LKB1) gene and / or (ii) suppression of LKBl-mediated signaling comprising administering to the subject an effective amount of one or more prostaglandin inhibitors (e.g., therapeutic agents described herein), optionally in combination with an omega-3 PUFA and / or a low-fat diet. The prostaglandin inhibitors (e.g., therapeutic agents described herein) include but are not limited to, one or more prostaglandin synthase inhibitors.

[0297] In some embodiments, a method of treating cachexia and / or sickness behavior in a subject having (i) a mutation in a liver kinase Bl (LKB1) gene and / or (ii) suppression of LKB1-mediated signaling comprises administering to the subject an effective amount of one or more prostaglandin synthase inhibitors (e.g., therapeutic agents described herein), optionally in combination with an omega-3 PUFA and / or a low-fat diet. In some embodiments, a method of treating cachexia and / or sickness behavior in a subject having a cancer and (i) a mutation in a liver kinase Bl (LKB1) gene and / or (ii) suppression of LKBl-mediated signaling comprises administering to the subject an effective amount of one or more prostaglandin synthase inhibitors (e.g., therapeutic agents described herein), optionally in combination with an omega-3 PUFA and / or a low-fat diet.

[0298] In some embodiments, a method of treating cachexia and / or sickness behavior in a subject having (i) a mutation in a liver kinase Bl (LKB1) gene and / or (ii) suppression of LKB1-mediated signaling comprises administering to the subject an effective amount of one or more COX enzyme inhibitors (e.g., therapeutic agents described herein), optionally in combination with an omega-3 PUFA and / or a low-fat diet. In some embodiments, a method of treating cachexia and / or sickness behavior in a subject having a cancer and (i) a mutation in a liver kinase B 1 (LKB 1) gene and / or (ii) suppression of LKBl-mediated signaling comprises administering to the subject an effective amount of one or more COX enzyme inhibitors (e.g., therapeutic agents described herein), optionally in combination with an omega-3 PUFA and / or a low-fat diet.

[0299] Exemplary prostaglandin synthase inhibitors (e.g., therapeutic agents described herein) include, but are not limited to. ibuprofen, acetylsalicylic acid (ASA) diclofenac, diflunisal, etodolac, fenoprofen, flurbiprofen, indomethacin, ketoprofen, ketorolac, mefenamic acid,72328856447vlAttorney Docket No: 243735.000512meloxicam, nabumetone, naproxen, oxaprozin, piroxicam, sulindac, tolmetin, valdecoxib (Bextra), celecoxib (Celebrex), rofecoxib, zaloglanstat, pharmaceutically acceptable salts thereof, and any combinations thereof.

[0300] In some embodiments, a method of treating cachexia and / or sickness behavior in a subject having (i) a mutation in a liver kinase Bl (LKB1) gene and / or (ii) suppression of LKB1-mediated signaling comprises administering to the subject an effective amount of one or more PTGES inhibitors (e.g., therapeutic agents described herein), optionally in combination with an omega-3 PUFA and / or a low-fat diet. In some embodiments, a method of treating cachexia and / or sickness behavior in a subject having a cancer and (i) a mutation in a liver kinase Bl (LK. B1) gene and / or (ii) suppression of LKBl-mediated signaling comprises administering to the subject an effective amount of one or more PTGES inhibitors (e.g., therapeutic agents described herein), optionally in combination with an omega-3 PUFA and / or a low-fat diet. Exemplary PTGES inhibitors (e.g., therapeutic agents described herein) include, but are not limited to, zaloglanstat (ISC-27864; GRC-27864).

[0301] Provided herein is a method of treating cachexia and / or sickness behavior in a subject having (i) a mutation in a liver kinase Bl (LKB1) gene and / or (ii) suppression of LKBl-mediated signaling comprising administering to the subject an effective amount of one or more prostaglandin receptor inhibitors (e.g., receptor antagonists described herein), optionally in combination with an omega-3 PUFA and / or a low-fat diet. Also provided herein is a method of treating cachexia and / or sickness behavior in a subject having a cancer and (i) a mutation in a liver kinase Bl (LKB1) gene and / or (ii) suppression of LKBl-mediated signaling comprising administering to the subject an effective amount of one or more prostaglandin receptor inhibitors (e.g., receptor antagonists described herein), optionally in combination with an omega-3 PUFA and / or a low-fat diet.

[0302] In some embodiments, a method of treating cachexia and / or sickness behavior in a subject having (i) a mutation in a liver kinase Bl (LKB1) gene and / or (ii) suppression of LKBl-mediated signaling comprises administering to the subject an effective amount of an EPl receptor antagonist. In some embodiments, a method of treating cachexia and / or sickness behavior in a subject having (i) a mutation in a liver kinase Bl (LKB1) gene and / or (ii) suppression of LKBl-mediated signaling comprises administering to the subject an effective amount of an EP2 receptor antagonist. In some embodiments, a method of treating cachexia and / or sickness behavior in a subject having (i) a mutation in a liver kinase Bl (LKB1) gene and / or (ii) suppression of LKB1-73328856447vlAttorney Docket No: 243735.000512mediated signaling comprises administering to the subject an effective amount of an EP3 receptor antagonist. In some embodiments, a method of treating cachexia and / or sickness behavior in a subject having (i) a mutation in a liver kinase Bl (LKB1) gene and / or (ii) suppression of LKB1-mediated signaling comprises administering to the subject an effective amount of an EP4 receptor antagonist. In some embodiments, a method of treating cachexia and / or sickness behavior in a subject having a cancer and (i) a mutation in a liver kinase B 1 (LKB 1) gene and / or (ii) suppression of LKBl-mediated signaling comprises administering to the subject an effective amount of an EPl receptor antagonist. In some embodiments, a method of treating cachexia and / or sickness behavior in a subject having a cancer and (i) a mutation in a liver kinase Bl (LKB1) gene and / or (ii) suppression of LKBl-mediated signaling comprises administering to the subject an effective amount of an EP2 receptor antagonist. In some embodiments, a method of treating cachexia and / or sickness behavior in a subject having a cancer and (i) a mutation in a liver kinase Bl (LKB1) gene and / or (ii) suppression of LKBl-mediated signaling comprises administering to the subject an effective amount of an EP3 receptor antagonist. In some embodiments, a method of treating cachexia and / or sickness behavior in a subject having a cancer and (i) a mutation in a liver kinase Bl (LKB1) gene and / or (ii) suppression of LKBl-mediated signaling comprises administering to the subject an effective amount of an EP4 receptor antagonist.

[0303] Non-limiting examples of the prostaglandin receptor antagonists include SC-51322, GW-848687X, SC-19220, SC-51089, ONO-8713, ONO-8130, ONO-8711, PF-04418948, TG6-10-1, TG8-260, DG-041, L798-106, ONO-AE3-240, ONO-AE3-208, LY3127760, Grapiprant, AH6809, RQ-15986, and any combinations thereof. (Pain. 2011 Iun;152(6):1373-1381. doi: 10.1016 / j.pain.2011.02.019. Epub 2011 Mar 10.)

[0304] In some embodiments, the EPl receptor antagonist is selected from SC-51322, GW-848687X, SC-19220, SC-51089, ONO-8713, ONO-8130, ONO-8711, and any combination thereof. In some embodiments, the EP2 receptor antagonist is selected from PF-04418948. TG6-10-1, TG8-260, and any combination thereof. In some embodiments, the EP3 receptor antagonist is selected from DG-041, L798-106, ONO-AE3-240, and any combination thereof. In some embodiments, the EP4 receptor antagonist is selected from ONO-AE3-208, LY3127760, Grapiprant, AH6809, RQ-15986, and any combination thereof.74328856447vlAttorney Docket No: 243735.000512

[0305] Provided herein is a method of treating cachexia and / or sickness behavior in a subject having a cancer comprising administering to the subject an effective amount of one or more chemogenetic compounds, optionally in combination with an omega-3 PUFA and / or a low-fat diet.

[0306] In some embodiments, a method of treating cachexia and / or sickness behavior in a subject having (i) a mutation in a liver kinase Bl (LKB1) gene and / or (ii) suppression of LKB1-mediated signaling comprising administering to the subject an effective amount of one or more chemogenetic compounds, optionally in combination with an omega-3 PUFA and / or a low-fat diet. In some embodiments, a method of treating cachexia and / or sickness behavior in a subject having a cancer and (i) a mutation in a liver kinase Bl (LK. B1) gene and / or (ii) suppression of LK. B1-mediated signaling comprising administering to the subject an effective amount of one or more chemogenetic compounds, optionally in combination with an omega-3 PUFA and / or a low-fat diet. In some embodiments, the chemogenetic compound is clozapine-N-oxide.

[0307] In some embodiments, the method comprises administering to the subject an effective amount of one or more prostaglandin inhibitors, one or more prostaglandin receptor inhibitors, and / or one or more chemogenetic compounds. In some embodiments, the method comprises administering to the subject an effective amount of one or more prostaglandin inhibitors, one or more prostaglandin receptor inhibitors, and / or one or more chemogenetic compounds in combination with an omega-3 PUFA and / or a low-fat diet.

[0308] In certain embodiments, the method of treating disease is in a patient that has received no prior treatment. In certain embodiments, the method of treating disease is in a patient that has received a prior treatment with therapeutic agent(s), (e.g., chemotherapeutic agent(s) and / or immune checkpoint inhibitor(s), cytokine(s), tumor-associated antigen (TAA)- targeting agent(s), and immune agonist(s)). In certain embodiments, the patient has developed an acquired resistance to the previous treatment of one or more chemotherapeutic agents or immunotherapies. In further embodiments, the patient has developed bypass resistance to the previous treatment of one or more chemotherapeutic agents or immunotherapies.

[0309] A chemotherapeutic or chemotherapeutic agent ( e., an anti-cancer agent), is used according to its ordinary meaning, referring to a chemical composition, biologic, protein, nucleic acid, drug, inhibitor, antagonist, modulator, and / or compound having the ability to inhibit the growth or proliferation of cells and / or antineoplastic properties. In some aspects, an anti-cancer75328856447vlAttorney Docket No: 243735.000512agent is a therapeutic agent approved by the FDA or equivalent or similar regulatory agency, for treating cancer.

[0310] Chemotherapeutic agents with which the subject may have been treated prior to treatment with the treatments described herein, or with which the subject is concurrently being treated along with the treatments described herein, include but are not limited to, adrenocorticoids and corticosteroids, kinase inhibitors, androgens, alkylating agents, estrogens, peptide and peptidomimetic signal transduction inhibitors, aclamycin and aclamycin derivatives, pyrimidine analogs, purine analogs, platinum compounds, antiestrogens, antiandrogens, plant alkaloids, antimetabolites, microtubule inhibitors, amanitins, epothilones, mitomycins, discodermolides, dolastatins, inflammatory and proinflammatory agents, camptothecins, and / or immunotherapies.

[0311] In certain embodiments, the patient has been administered a prior treatment for NSCLC, or is being administered a treatment for NSCLC, such as platinum, abraxane, pembrolizumab, bevacizumab, pemetrexed, platinum doublet, paclitaxel, atezolizumab, carboplatin, and combinations thereof.

[0312] In certain embodiments, the patient has been administered a prior treatment for colorectal cancer, or is being administered a treatment for colorectal cancer, such as leucovorin, ramucirumab, cetuximab, bevacizumab, capecitabine, panitumumab, oxaliplatin, ziv-atlibercept, fluorouracil (5-FU), irinotecan, pemborlizumab, binimetinib, ipilimumab, nivolumab, encorafenib, amucirumab, and combinations thereof.

[0313] In certain embodiments, the patient has been administered a prior treatment for pancreatic cancer, or is being administered a treatment for pancreatic cancer, such as irinotecan, leucovorin, liposomal irinotecan, gemcitabine, erlotinib, abraxane, fluorouracil (5-FU), oxaliplatin, capecitabine, and combinations thereof.

[0314] In certain embodiments, the patient has been administered a prior treatment for uterine or cervical cancer, or is being administered a treatment for uterine or cervical cancer, such as cisplatin, doxorubicin, liposomal doxorubicin, docetaxel, trastuzumab, fulvestrant, topotecan, irinotecan, paclitaxel, bevacizumab, carboplatin, temsirolimus, tamoxifen, an aromatase inhibitor, and combinations thereof.

[0315] In the methods of treatment described herein, additional therapeutic agents can be used in combination with the inhibitors (e.g., therapeutic agents, receptor antagonists, and / or chemogenetic compounds described herein) that are suitable to the disease being treated (e.g.,76328856447vlAttorney Docket No: 243735.000512cancer). In some aspects, the provided methods of treatment further include administering an additional therapeutic agent to the subject. The additional therapeutic agent may be a drug, supplement such as an omega-3 PUFA, compound, inhibitor, modulator, or antagonist, having the ability to inhibit the growth or proliferation of cells and / or having antineoplastic properties. In some aspects, the additional therapeutic agent can be a chemotherapeutic agent. In further aspects, the additional therapeutic agent is a therapeutic agent approved by the FDA or an equivalent or similar regulatory agency, for treating cancer. In certain aspects, the additional therapeutic agent is radiation therapy. Suitable additional therapeutic agents include, but are not limited to anesthetics, anticonvulsants, analgesics, allosteric inhibitors, antihelmintics, analeptics, antifungals, antirheumatic agents, anticholinesterases, anticholinergic agents, antibiotics, antineoplastic agents, antimuscarinic agents, growth factors, anabolic steroids, hematological agents, antimycobacterial agents, psychotherapeutic agents, antiviral agents, neural blocking agents, immunological agents, anti-inflammatory agents, protease inhibitors, corticosteroids, anticoagulants, antihistamines, antiprotozoal agents, dopaminergics, muscarinics, vitamins, and hormones. The choice of agent and dosage can be determined by one of skill in the art based on several factors, primarily the given disease being treated.

[0316] Selecting an administration regimen for an inhibitor (e.g., a therapeutic agent, a receptor antagonist, and / or a chemogenetic compound described herein) depends on several factors, including the serum or tissue turnover rate of the entity, the level of symptoms, the immunogenicity of the entity, and the accessibility of the target cells in the biological matrix. In certain embodiments, an administration regimen maximizes the amount of an inhibitor (e.g., a therapeutic agent, a receptor antagonist, and / or a chemogenetic compound described herein) delivered to the patient consistent with an acceptable level of side effects. Accordingly, the amount of an inhibitor (e.g., a therapeutic agent, a receptor antagonist, and / or a chemogenetic compound described herein) delivered depends in part on the particular entity and the severity of the condition being treated. Guidance in selecting appropriate doses of antibodies, Fc fusion therapeutic proteins, cytokines, and small molecules are available (see, e.g., Wawrzynczak, 1996, Antibody Therapy, Bios Scientific Pub. Ltd, Oxfordshire, UK; Kresina (ed.), 1991, Monoclonal Antibodies, Cytokines and Arthritis, Marcel Dekker, New York, N. Y.; Bach (ed.), 1993, Monoclonal Antibodies and Peptide Therapy in Autoimmune Diseases, Marcel Dekker, New York, N. Y.; Baert, et al., 2003, New Engl. J. Med. 348:601-608; Milgrom, et al., 1999, New Engl. J. Med. 341:1966-1973;77328856447vlAttorney Docket No: 243735.000512Slamon, et al., 2001, New Engl. J. Med. 344:783-792; Beniaminovitz, et al., 2000, New Engl. J. Med. 342:613-619; Ghosh, et al., 2003, New Engl. J. Med. 348:24-32; Lipsky, et al., 2000, New Engl. J. Med. 343:1594-1602, each incorporated herein by reference in its entirety).

[0317] Determination of the appropriate dose is made by the clinician, e.g., using parameters or factors known or suspected in the art to affect treatment or predicted to affect treatment. Generally, the dose begins with an amount somewhat less than the optimum dose and it is increased by small increments thereafter until the desired or optimum effect is achieved relative to any negative side effects. Important diagnostic measures include those of symptoms of, e.g., increased serum phosphate or decreased phosphate excretion.

[0318] Actual dosage levels of the active ingredients such as inhibitors (e.g., therapeutic agents, receptor antagonists, and / or chemogenetic compounds described herein) in the pharmaceutical compositions of the present disclosure may be varied so as to obtain an amount of the active ingredient such as inhibitor (e.g., a therapeutic agent, a receptor antagonist, and / or a chemogenetic compound described herein) which is effective to achieve the desired therapeutic response for a particular patient, composition, and mode of administration, without being toxic to the patient. The selected dosage level will depend upon a variety of pharmacokinetic factors including the activity of the particular compositions of the present disclosure employed, or the ester, salt or amide thereof, the route of administration, the time of administration, the rate of excretion of the particular compound being employed, the duration of the treatment, other drugs, compounds and / or materials used in combination with the particular compositions employed, the age, sex, weight, condition, general health and prior medical history of the patient being treated, and like factors well known in the medical arts.

[0319] Compositions comprising the inhibitors (e.g., therapeutic agents, receptor antagonists, and / or chemogenetic compounds described herein) can be provided by continuous infusion, or by doses at intervals of, e.g., one day, one week, 1-7 times per week, or one month. Doses may be provided intravenously, subcutaneously, topically, orally, nasally, rectally, intramuscular, intrathecally, intracerebrally, or by inhalation. A specific dose protocol is one involving the maximal dose or dose frequency that avoids significant undesirable side effects. A total weekly dose may be at least 0.05 pg / kg, at least 0.2 pg / kg, at least 0.5 pg / kg, at least 1 pg / kg, at least 10 pg / kg, at least 100 pg / kg, at least 0.2 mg / kg, at least 1.0 mg / kg, at least 2.0 mg / kg, at least 10 mg / kg, at least 15 mg / kg, at least 20 mg / kg, at least 25 mg / kg, or at least 50 mg / kg body weight78328856447vlAttorney Docket No: 243735.000512(see, e.g., Yang, et al., 2003, New Engl. J. Med. 349:427-434; Herold, et al., 2002, New Engl. J. Med. 346:1692-1698; Liu, et al., 1999, J. Neurol. Neurosurg. Psych. 67:451-456; Portielji, et al., 2003, Cancer. Immunol. Immunother. 52: 133-144). The dose may be at least 15 pg, at least 20 pg, at least 25 pg, at least 30 pg, at least 35 pg, at least 40 jag, at least 45 jag, at least 50 jag, at least 55 jag, at least 60 pg, at least 65 pg, at least 70 jag, at least 75 jag, at least 80 jag, at least 85 jag, at least 90 jag, at least 95 jag, or at least 100 jag. The doses administered to a subject may number at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12, or more.

[0320] A “weight-based dose” (e.g., a dose measured in mg / kg) as used herein, is a dose of the inhibitors (e.g., therapeutic agents, receptor antagonists, and / or chemogenetic compounds described herein) that will vary depending on the subject’s weight.

[0321] For therapeutic inhibitors (e.g., therapeutic agents, receptor antagonists, and / or chemogenetic compounds described herein), the dosage administered to a patient may be 0.0001 mg / kg to 100 mg / kg of the patient’s body weight. The dosage may be between 0.0001 mg / kg and 20 mg / kg, 0.0001 mg / kg and 10 mg / kg, 0.0001 mg / kg and 5 mg / kg, 0.0001 mg / kg and 2 mg / kg, 0.0001 mg / kg and 1 mg / kg, 0.0001 mg / kg and 0.75 mg / kg, 0.0001 mg / kg and 0.5 mg / kg, 0.0001 mg / kg to 0.25 mg / kg, 0.0001 mg / kg to 0.15 mg / kg, 0.0001 mg / kg to 0.10 mg / kg, 0.001 mg / kg to 0.5 mg / kg, 0.01 mg / kg to 0.25 mg / kg or 0.01 mg / kg to 0.10 mg / kg of the patient’s body weight.

[0322] The dosage of the inhibitors (e.g., therapeutic agents, receptor antagonists, and / or chemogenetic compounds described herein) may be calculated using the patient’s weight in kilograms (kg) multiplied by the dose to be administered in mg / kg. The dosage of the inhibitors (e.g., therapeutic agents, receptor antagonists, and / or chemogenetic compounds described herein) of the disclosure may be 150 pg / kg or less, 125 pg / kg or less, 100 pg / kg or less, 95 pg / kg or less, 90 pg / kg or less, 85 pg / kg or less, 80 pg / kg or less, 75 pg / kg or less, 70 pg / kg or less, 65 pg / kg or less, 60 pg / kg or less, 55 pg / kg or less, 50 pg / kg or less, 45 pg / kg or less, 40 pg / kg or less, 35 pg / kg or less, 30 pg / kg or less. 25 pg / kg or less, 20 pg / kg or less, 15 pg / kg or less, 10 pg / kg or less, 5 pg / kg or less, 2.5 pg / kg or less, 2 pg / kg or less, 1.5 pg / kg or less, 1 pg / kg or less, 0.5 pg / kg or less, or 0.1 pg / kg or less of a patient’s body weight.

[0323] Unit dose of the inhibitors (e.g., therapeutic agents, receptor antagonists, and / or chemogenetic compounds described herein) may be 0.1 mg to 20 mg, 0.1 mg to 15 mg, 0.1 mg to 12 mg, 0.1 mg to 10 mg, 0.1 mg to 8 mg, 0.1 mg to 7 mg, 0.1 mg to 5 mg, 0.1 to 2.5 mg, 0.25 mg to 20 mg, 0.25 to 15 mg, 0.25 to 12 mg, 0.25 to 10 mg, 0.25 to 8 mg, 0.25 mg to 7 m g, 0.25 mg79328856447vlAttorney Docket No: 243735.000512to 5 mg, 0.5 mg to 2.5 mg, 1 mg to 20 mg, 1 mg to 15 mg, 1 mg to 12 mg, 1 mg to 10 mg, 1 mg to 8 mg, 1 mg to 7 mg, 1 mg to 5 mg, or 1 mg to 2.5 mg.

[0324] The dosage of the inhibitors (e.g., therapeutic agents, receptor antagonists, and / or chemogenetic compounds described herein) may achieve a serum titer of at least 0.1 pg / ml, at least 0.5 pg / ml, at least 1 pg / ml, at least 2 pg / ml, at least 5 pg / ml, at least 6 pg / ml, at least 10 pg / ml, at least 15 pg / ml, at least 20 pg / ml, at least 25 pg / ml, at least 50 pg / ml, at least 100 pg / ml, at least 125 pg / ml, at least 150 pg / ml, at least 175 pg / ml, at least 200 pg / ml, at least 225 pg / ml, at least 250 pg / ml, at least 275 pg / ml, at least 300 pg / ml, at least 325 pg / ml, at least 350 pg / ml, at least 375 pg / ml, or at least 400 pg / ml in a subject. Alternatively, the dosage of the inhibitors of the disclosure may achieve a serum titer of at least 0.1 pg / ml, at least 0.5 pg / ml, at least 1 pg / ml, at least, 2 pg / ml, at least 5 pg / ml, at least 6 pg / ml, at least 10 pg / ml, at least 15 pg / ml, at least 20 pg / ml, at least 25 pg / ml, at least 50 pg / ml, at least 100 pg / ml, at least 125 pg / ml, at least 150 pg / ml, at least 175 pg / ml, at least 200 pg / ml, at least 225 pg / ml, at least 250 pg / ml, at least 275 pg / ml, at least 300 pg / ml, at least 325 pg / ml, at least 350 pg / ml, at least 375 pg / ml, or at least 400 pg / ml in the subject.

[0325] In other embodiments, the inhibitors (e.g., therapeutic agents, receptor antagonists, and / or chemogenetic compounds described herein) is administered as a fixed dose. A “fixed dose” (e.g., a dose measured in mg) means that one dose of the inhibitors (e.g., therapeutic agents, receptor antagonists, and / or chemogenetic compounds described herein) is used consistently for all subjects regardless of any subject-specific factors, e.g., weight.

[0326] In some embodiments, the inhibitors (e.g., therapeutic agents, receptor antagonists, and / or chemogenetic compounds described herein) is administered at a dose of about 10 mg to about 100 mg, about 10 mg to about 98 mg, about 10 mg to about 95 mg, about 10 mg to about 92 mg, about 10 mg to about 90 mg, about 10 mg to about 88 mg, about 10 mg to about 85 mg, about 10 mg to about 82 mg, about 10 mg to about 80 mg, about 10 mg to about 78 mg, about 10 mg to about 75 mg, about 10 mg to about 72 mg, about 10 mg to about 70 mg, about 10 mg to about 68 mg, about 10 mg to about 65 mg, about 10 mg to about 62 mg, about 10 mg to about 60 mg, about 10 mg to about 58 mg, about 10 mg to about 55 mg, about 10 mg to about 52 mg, about 10 mg to about 50 mg, about 10 mg to about 48 mg, about 10 mg to about 45 mg, about 10 mg to about 42 mg, about 10 mg to about 40 mg, about 10 mg to about 38 mg, about 10 mg to about 35 mg, about 10 mg to about 32 mg, about 10 mg to about 30 mg, about 10 mg to about 28 mg, about 10 mg to80328856447vlAttorney Docket No: 243735.000512about 25 mg, about 10 mg to about 22 mg, about 10 mg to about 20 mg, about 10 mg to about 18 mg, about 10 mg to about 15 mg, about 10 mg to about 12 mg, about 15 mg to about 100 mg, about 15 mg to about 98 mg, about 15 mg to about 95 mg, about 15 mg to about 92 mg, about 15 mg to about 90 mg, about 15 mg to about 88 mg, about 15 mg to about 85 mg, about 15 mg to about 82 mg, about 15 mg to about 80 mg, about 15 mg to about 78 mg, about 15 mg to about 75 mg, about 15 mg to about 72 mg, about 15 mg to about 70 mg, about 15 mg to about 68 mg, about 15 mg to about 65 mg, about 15 mg to about 62 mg, about 15 mg to about 60 mg, about 15 mg to about 58 mg, about 15 mg to about 55 mg, about 15 mg to about 52 mg, about 15 mg to about 50 mg, about 15 mg to about 48 mg, about 15 mg to about 45 mg, about 15 mg to about 42 mg, about 15 mg to about 40 mg, about 15 mg to about 38 mg, about 15 mg to about 35 mg, about 15 mg to about 32 mg, about 15 mg to about 30 mg, about 15 mg to about 28 mg, about 15 mg to about 25 mg, about 15 mg to about 22 mg, about 15 mg to about 20 mg, about 15 mg to about 18 mg, about 20 mg to about 100 mg, about 20 mg to about 98 mg, about 20 mg to about 95 mg, about 20 mg to about 92 mg, about 20 mg to about 90 mg, about 20 mg to about 88 mg, about 20 mg to about 85 mg, about 20 mg to about 82 mg, about 20 mg to about 80 mg, about 20 mg to about 78 mg, about 20 mg to about 75 mg, about 20 mg to about 72 mg, about 20 mg to about 70 mg, about 20 mg to about 68 mg, about 20 mg to about 65 mg, about 20 mg to about 62 mg, about 20 mg to about 60 mg, about 20 mg to about 58 mg, about 20 mg to about 55 mg, about 20 mg to about 52 mg, about 20 mg to about 50 mg, about 20 mg to about 48 mg, about 20 mg to about 45 mg, about 20 mg to about 42 mg, about 20 mg to about 40 mg, about 20 mg to about 38 mg, about 20 mg to about 35 mg, about 20 mg to about 32 mg, about 20 mg to about 30 mg, about 20 mg to about 28 mg, about 20 mg to about 25 mg, about 20 mg to about 22 mg, about 25 mg to about 100 mg, about 25 mg to about 98 mg, about 25 mg to about 95 mg, about 25 mg to about 92 mg, about 25 mg to about 90 mg, about 25 mg to about 88 mg, about 25 mg to about 85 mg, about 25 mg to about 82 mg, about 25 mg to about 80 mg, about 25 mg to about 78 mg, about 25 mg to about 75 mg, about 25 mg to about 72 mg, about 25 mg to about 70 mg, about 25 mg to about 68 mg, about 25 mg to about 65 mg, about 25 mg to about 62 mg, about 25 mg to about 60 mg, about 25 mg to about 58 mg, about 25 mg to about 55 mg, about 25 mg to about 52 mg, about 25 mg to about 50 mg, about 25 mg to about 48 mg, about 25 mg to about 45 mg, about 25 mg to about 42 mg, about 25 mg to about 40 mg, about 25 mg to about 38 mg, about 25 mg to about 35 mg, about 25 mg to about 32 mg, about 25 mg to about 30 mg, about 25 mg to about 28 mg, about 30 mg to about 100 mg, about 30 mg to about 9881328856447vlAttorney Docket No: 243735.000512mg, about 30 mg to about 95 mg, about 30 mg to about 92 mg, about 30 mg to about 90 mg, about 30 mg to about 88 mg, about 30 mg to about 85 mg, about 30 mg to about 82 mg, about 30 mg to about 80 mg, about 30 mg to about 78 mg, about 30 mg to about 75 mg, about 30 mg to about 72 mg, about 30 mg to about 70 mg, about 30 mg to about 68 mg, about 30 mg to about 65 mg, about 30 mg to about 62 mg, about 30 mg to about 60 mg, about 30 mg to about 58 mg, about 30 mg to about 55 mg, about 30 mg to about 52 mg, about 30 mg to about 50 mg, about 30 mg to about 48 mg, about 30 mg to about 45 mg, about 30 mg to about 42 mg, about 30 mg to about 40 mg, about 30 mg to about 38 mg, about 30 mg to about 35 mg, about 30 mg to about 32 mg, about 35 mg to about 100 mg, about 35 mg to about 98 mg, about 35 mg to about 95 mg, about 35 mg to about 92 mg, about 35 mg to about 90 mg, about 35 mg to about 88 mg, about 35 mg to about 85 mg, about 35 mg to about 82 mg, about 35 mg to about 80 mg, about 35 mg to about 78 mg, about 35 mg to about 75 mg, about 35 mg to about 72 mg, about 35 mg to about 70 mg, about 35 mg to about 68 mg, about 35 mg to about 65 mg, about 35 mg to about 62 mg, about 35 mg to about 60 mg, about 35 mg to about 58 mg, about 35 mg to about 55 mg, about 35 mg to about 52 mg, about 35 mg to about 50 mg, about 35 mg to about 48 mg, about 35 mg to about 45 mg, about 35 mg to about 42 mg, about 35 mg to about 40 mg, about 35 mg to about 38 mg, about 40 mg to about 100 mg, about 40 mg to about 98 mg, about 40 mg to about 95 mg, about 40 mg to about 92 mg, about 40 mg to about 90 mg, about 40 mg to about 88 mg, about 40 mg to about 85 mg, about 40 mg to about 82 mg, about 40 mg to about 80 mg, about 40 mg to about 78 mg, about 40 mg to about 75 mg, about 40 mg to about 72 mg, about 40 mg to about 70 mg, about 40 mg to about 68 mg, about 40 mg to about 65 mg, about 40 mg to about 62 mg, about 40 mg to about 60 mg, about 40 mg to about 58 mg, about 40 mg to about 55 mg, about 40 mg to about 52 mg, about 40 mg to about 50 mg, about 40 mg to about 48 mg, about 40 mg to about 45 mg, about 40 mg to about 42 mg, about 45 mg to about 100 mg, about 45 mg to about 98 mg, about 45 mg to about 95 mg, about 45 mg to about 92 mg, about 45 mg to about 90 mg, about 45 mg to about 88 mg, about 45 mg to about 85 mg, about 45 mg to about 82 mg, about 45 mg to about 80 mg, about 45 mg to about 78 mg, about 45 mg to about 75 mg, about 45 mg to about 72 mg, about 45 mg to about 70 mg, about 45 mg to about 68 mg, about 45 mg to about 65 mg, about 45 mg to about 62 mg, about 45 mg to about 60 mg, about 45 mg to about 58 mg, about 45 mg to about 55 mg, about 45 mg to about 52 mg, about 45 mg to about 50 mg, about 45 mg to about 48 mg, about 50 mg to about 100 mg, about 50 mg to about 98 mg, about 50 mg to about 95 mg, about 50 mg to about 92 mg, about 50 mg to about 90 mg, about82328856447vlAttorney Docket No: 243735.00051250 mg to about 88 mg, about 50 mg to about 85 mg, about 50 mg to about 82 mg, about 50 mg to about 80 mg, about 50 mg to about 78 mg, about 50 mg to about 75 mg, about 50 mg to about 72 mg, about 50 mg to about 70 mg, about 50 mg to about 68 mg, about 50 mg to about 65 mg, about 50 mg to about 62 mg, about 50 mg to about 60 mg, about 50 mg to about 58 mg, about 50 mg to about 55 mg, about 50 mg to about 52 mg, about 55 mg to about 100 mg, about 55 mg to about 98 mg, about 55 mg to about 95 mg, about 55 mg to about 92 mg, about 55 mg to about 90 mg, about 55 mg to about 88 mg, about 55 mg to about 85 mg, about 55 mg to about 82 mg, about 55 mg to about 80 mg, about 55 mg to about 78 mg, about 55 mg to about 75 mg, about 55 mg to about 72 mg, about 55 mg to about 70 mg, about 55 mg to about 68 mg, about 55 mg to about 65 mg, about 55 mg to about 62 mg, about 55 mg to about 60 mg, about 55 mg to about 58 mg, about 60 mg to about 100 mg, about 60 mg to about 98 mg, about 60 mg to about 95 mg, about 60 mg to about 92 mg, about 60 mg to about 90 mg, about 60 mg to about 88 mg, about 60 mg to about 85 mg, about 60 mg to about 82 mg, about 60 mg to about 80 mg, about 60 mg to about 78 mg, about 60 mg to about 75 mg, about 60 mg to about 72 mg, about 60 mg to about 70 mg, about 60 mg to about 68 mg, about 60 mg to about 65 mg, about 60 mg to about 62 mg, about 65 mg to about 100 mg, about 65 mg to about 98 mg, about 65 mg to about 95 mg, about 65 mg to about 92 mg, about 65 mg to about 90 mg, about 65 mg to about 88 mg, about 65 mg to about 85 mg, about 65 mg to about 82 mg, about 65 mg to about 80 mg, about 65 mg to about 82 mg, about 65 mg to about 75 mg, about 65 mg to about 72 mg, about 65 mg to about 70 mg, about 65 mg to about 68 mg, about 70 mg to about 100 mg, about 70 mg to about 98 mg, about 70 mg to about 95 mg, about 70 mg to about 92 mg, about 70 mg to about 90 mg, about 70 mg to about 88 mg, about 70 mg to about 85 mg, about 70 mg to about 82 mg, about 70 mg to about 80 mg, about 70 mg to about 78 mg, about 70 mg to about 75 mg, about 70 mg to about 72 mg, about 75 mg to about 100 mg, about 75 mg to about 98 mg, about 75 mg to about 95 mg, about 75 mg to about 92 mg, about 75 mg to about 90 mg, about 75 mg to about 88 mg, about 75 mg to about 85 mg, about 75 mg to about 82 mg, about 75 mg to about 80 mg, about 75 mg to about 78 mg, about 80 mg to about 100 mg, about 80 mg to about 98 mg, about 80 mg to about 95 mg, about 80 mg to about 92 mg, about 80 mg to about 90 mg, about 80 mg to about 88 mg, about 80 mg to about 85 mg, about 80 mg to about 82 mg, about 85 mg to about 100 mg, about 85 mg to about 98 mg, about 85 mg to about 95 mg, about 85 mg to about 92 mg, about 85 mg to about 90 mg, about 85 mg to about 88 mg, about 90 mg to about 100 mg, about 90 mg to about 98 mg, about 90 mg to about 95 mg, about 90 mg to about 92 mg, about 95 mg to83328856447vlAttorney Docket No: 243735.000512about 100 mg, about 95 mg to about 98 mg, about 10 mg, about 12 mg, about 15 mg, about 18 mg, about 20 mg, about 22 mg, about 25 mg, about 28 mg, about 30 mg, about 32 mg, about 35 mg, about 38 mg, about 40 mg, about 42 mg, about 45 mg, about 48 mg, about 50 mg, about 52 mg, about 55 mg, about 58 mg, about 60 mg, about 62 mg, about 65 mg, about 68 mg, about 70 mg, about 72 mg, about 75 mg, about 78 mg, about 80 mg, about 82 mg, about 85 mg, about 88 mg, about 90 mg, about 92 mg, about 95 mg, about 98 mg, or about 100 mg.

[0327] Doses of inhibitors (e.g., therapeutic agents, receptor antagonists, and / or chemogenetic compounds described herein) may be repeated and the administrations may be separated by at least 1 day, 2 days, 3 days, 5 days, 10 days, 15 days, 30 days, 45 days, 2 months, 75 days, 3 months, or at least 6 months.

[0328] Dosage ranges and frequency of administration of inhibitors (e.g., therapeutic agents, receptor antagonists, and / or chemogenetic compounds described herein) as described herein can vary depending on the parameters of a specific subject, the route of administration, the type of medical condition, and / or the severity of the medical condition. A more accurate dose may depend on the subject in which it is administered, e.g., a lower dose may be used if the subject in which it is administered is juvenile and a higher dose may be used if the subject is adult. In some embodiments, a more accurate dose may depend on the subject weight.

[0329] In certain embodiments, multiple doses of inhibitors (e.g., therapeutic agents, receptor antagonists, and / or chemogenetic compounds described herein) are administered over a defined time course. In some embodiments, inhibitors (e.g., therapeutic agents, receptor antagonists, and / or chemogenetic compounds described herein) may be re-administered one time, two times, three times, four times, five times, six times, seven times, eight times, nine times, ten times, fifteen times, twenty times, or more, over the time course of treatment which may occur over any amount of time (e.g., days, weeks, or years). In certain embodiments, when the inhibitors (e.g., therapeutic agents, receptor antagonists, and / or chemogenetic compounds described herein) which is / are administered first in a repeat dosing regimen may comprise the same inhibitors (e.g., therapeutic agents, receptor antagonists, and / or chemogenetic compounds described herein) which is / are readministered second or thereafter in the regimen, for any number of subsequent times thereafter. In certain embodiments, when the inhibitors (e.g., therapeutic agents, receptor antagonists, and / or chemogenetic compounds described herein) which is / are administered first in a repeat dosing regimen may comprise a different inhibitors (e.g., therapeutic agents, receptor antagonists, and / or84328856447vlAttorney Docket No: 243735.000512chemogenetic compounds described herein) than is / are re-administered second or thereafter in the regimen, for any number of subsequent times thereafter.

[0330] In certain embodiments, the inhibitors (e.g., therapeutic agents, receptor antagonists, and / or chemogenetic compounds described herein) may be administered using a stepwise dosing regimen. Stepwise dosing can refer to dividing dosing of the same inhibitors e.g., therapeutic agents, receptor antagonists, and / or chemogenetic compounds described herein) over multiple administrations. In certain embodiments, the dosing of the same inhibitors (e.g., therapeutic agents, receptor antagonists, and / or chemogenetic compounds described herein) is / are broken up one time, two times, three times, four times, five times, six times, seven times, eight times, nine times, ten times, fifteen times, twenty times, or more, over the time course of the treatment which can occur over any period of time (e.g., over any number of days, weeks, or years). In certain embodiments, when a stepwise dose regimen is used in the administration of the inhibitors (e.g., therapeutic agents, receptor antagonists, and / or chemogenetic compounds described herein), the regimen may encompass an increase or decrease in dosage levels with each administration of the inhibitors (e.g., therapeutic agents, receptor antagonists, and / or chemogenetic compounds described herein).

[0331] In some embodiments, the inhibitors (e.g., therapeutic agents, receptor antagonists, and / or chemogenetic compounds described herein) are administered simultaneously. In some embodiments, the inhibitors (e.g., therapeutic agents, receptor antagonists, and / or chemogenetic compounds described herein) are administered simultaneously in one composition. In some embodiments, the inhibitors (e.g., therapeutic agents, receptor antagonists, and / or chemogenetic compounds described herein) are administered simultaneously in different compositions. In some embodiments, the inhibitors (e.g., therapeutic agents, receptor antagonists, and / or chemogenetic compounds described herein) are administered sequentially.

[0332] In certain embodiments, an inhibitor (e.g., a therapeutic agent, a receptor antagonist, and / or a chemogenetic compound described herein) is administered to a subject in combination with an omega-3 PUFA and / or a low-fat diet. The inhibitor (e.g., a therapeutic agent, a receptor antagonist, and / or a chemogenetic compound described herein) can be administered prior to, simultaneously with, and / or after an omega-3 PUFA and / or a low-fat diet.

[0333] In certain embodiments, when the inhibitor (e.g., a therapeutic agent, a receptor antagonist, and / or a chemogenetic compound described herein) is administered prior to, simultaneously with, and / or after an omega-3 PUFA and / or a low-fat diet, the inhibitor (e.g., a85328856447vlAttorney Docket No: 243735.000512therapeutic agent, a receptor antagonist, and / or a chemogenetic compound described herein) is administered one time, two times, three times, four times, five times, six times, seven times, eight times, nine times, ten times, twelve times, fourteen times, fifteen times, eighteen times, or twenty times or more, prior to, simultaneously with, and / or after the administration of an omega-3 PUFA and / or a low-fat diet. In certain embodiments, when an inhibitor (e.g., a therapeutic agent, a receptor antagonist, and / or a chemogenetic compound described herein) is administered with a repeat dosing regimen, an omega-3 PUFA and / or a low-fat diet may be administered once, twice, or any number of times prior to, simultaneously with, and / or after a first, second, and / or any number of subsequent administrations of the inhibitor (e.g., a therapeutic agent, a receptor antagonist, and / or a chemogenetic compound described herein) thereafter.

[0334] In some embodiments, an inhibitor (e.g., a therapeutic agent, a receptor antagonist, and / or a chemogenetic compound described herein) may be administered to a subject separately from an omega-3 PUFA and / or a low-fat diet.

[0335] In some embodiments, when an inhibitor (e.g., a therapeutic agent, a receptor antagonist, and / or a chemogenetic compound described herein) and an omega-3 PUFA and / or a low-fat diet are administered separately, the inhibitor (e.g., a therapeutic agent, a receptor antagonist, and / or a chemogenetic compound described herein) may also be administered simultaneously with an omega-3 PUFA and / or a low-fat diet. In certain embodiments, the inhibitor (e.g., a therapeutic agent, a receptor antagonist, and / or a chemogenetic compound described herein) is administered one or multiple times during the administration of an omega-3 PUFA and / or a low-fat diet. In another embodiment, an omega-3 PUFA and / or a low-fat diet is administered one or multiple times during the administration of the inhibitor (e.g., a therapeutic agent, a receptor antagonist, and / or a chemogenetic compound described herein).

[0336] In certain embodiments, an inhibitor (e.g., a therapeutic agent, a receptor antagonist, and / or a chemogenetic compound described herein) and an omega-3 PUFA and / or a low-fat diet may be administered separately over a defined time period. In some embodiments, multiple doses of an inhibitor (e.g., a therapeutic agent, a receptor antagonist, and / or a chemogenetic compound described herein) and / or an omega-3 PUFA optionally in combination with a low-fat diet may be administered to a subject through a defined time course. The methods may comprise sequentially administering to a subject multiple doses of an inhibitor (e.g., a therapeutic agent, a receptor antagonist, and / or a chemogenetic compound described herein) and / or an omega-3 PUFA86328856447vlAttorney Docket No: 243735.000512optionally in combination with a low-fat diet. Tn certain embodiments, when the inhibitor (e.g., a therapeutic agent, a receptor antagonist, and / or a chemogenetic compound described herein) and an omega-3 PUFA optionally in combination with a low-fat diet are administered sequentially, the inhibitor (e.g., a therapeutic agent, a receptor antagonist, and / or a chemogenetic compound described herein) can be administered either before and / or in between each of the administrations of the omega-3 PUFA and / or a low-fat diet.

[0337] The term “sequentially administering”, as used herein, means that each dose of the inhibitor (e.g., a therapeutic agent, a receptor antagonist, and / or a chemogenetic compound described herein) and / or an omega-3 PUFA optionally in combination with a low-fat diet is administered to the subject at various points in time, e.g., on different days separated by an interval that may comprise hours, days, weeks, months, or years. In certain embodiments, the methods comprise sequentially administering to the subject a single initial dose of the inhibitor (e.g., a therapeutic agent, a receptor antagonist, and / or a chemogenetic compound described herein) and / or an omega-3 PUFA optionally in combination with a low-fat diet, followed by one or multiple secondary doses of the inhibitor (e.g., a therapeutic agent, a receptor antagonist, and / or a chemogenetic compound described herein) and / or an omega-3 PUFA optionally in combination with a low-fat diet, and optionally followed by one or multiple tertiary doses of the inhibitor (e.g., a therapeutic agent, a receptor antagonist, and / or a chemogenetic compound described herein) and / or an omega-3 PUFA optionally in combination with a low-fat diet.

[0338] As used herein, the terms “initial dose,” “secondary dose(s),” and “tertiary dose(s)” refer to the sequential sequence of administration of the inhibitor (e.g., a therapeutic agent, a receptor antagonist, and / or a chemogenetic compound described herein) and / or an omega-3 PUFA optionally in combination with a low-fat diet. Thus, the “initial dose” is the dose administered at the beginning of the treatment regimen schedule (i.e., the “loading dose”), the “secondary dose(s)” is / are the dose(s) which are administered after the “initial dose”, and the “tertiary dose(s)” is / are the dose(s) which are administered after the “secondary dose(s)”.

[0339] In certain embodiments, the initial, secondary, and tertiary doses may all contain the same amount of the inhibitor (e.g., a therapeutic agent, a receptor antagonist, and / or a chemogenetic compound described herein) and / or an omega-3 PUFA optionally in combination with a low-fat diet but may differ from one another in the frequency of administration. In another embodiment, the amounts of the inhibitor (e.g., a therapeutic agent, a receptor antagonist, and / or87328856447vlAttorney Docket No: 243735.000512a chemogenetic compound described herein) and / or an omega-3 PUFA contained in the initial, secondary, and / or tertiary doses varies from one another (e.g., increased or decreased as appropriate) during the course of treatment. In some embodiments, one or multiple (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more) doses are administered in the beginning of the treatment regimen as loading doses (z.e., initial doses) followed by subsequent doses (e.g., secondary or tertiary doses) that are administered less frequently, known as “maintenance doses”. In certain embodiments, the initial dose and the one or more subsequent doses (i.e., secondary or tertiary doses) each contain the same amount of the inhibitor (e.g., a therapeutic agent, a receptor antagonist, and / or a chemogenetic compound described herein) and / or an omega-3 PUFA. In some embodiments, the initial dose comprises an initial amount of the Inhibitors (e.g., therapeutic agents, receptor antagonists, and / or chemogenetic compounds described herein) and / or an omega-3 PUFA optionally in combination with a low-fat diet and the one or multiple secondary doses each comprise a different amount of the inhibitor (e.g., a therapeutic agent, a receptor antagonist, and / or a chemogenetic compound described herein) and / or an omega-3 PUFA optionally in combination with a low-fat diet. In one embodiment, the first amount of the inhibitor (e.g., a therapeutic agent, a receptor antagonist, and / or a chemogenetic compound described herein) and / or an omega-3 PUFA optionally in combination with a low-fat diet can be 1.5x, 2x, 2.5x, 3x, 3.5x, 4x, 4.5x, 5x, lOx, or more than the second amount of the inhibitor (e.g., a therapeutic agent, a receptor antagonist, and / or a chemogenetic compound described herein) and / or an omega-3 PUFA.

[0340] In certain embodiments, each secondary dose(s) and / or tertiary dose(s) is / are administered 1 to 20 (e.g., 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9, 9.5, 10, 10.5, 11, 11.5, 12, 12.5. 13. 13.5. 14, 14.5, 15, 15.5, 16, 16.5. 17. 17.5, 18, 18.5, 19, 19.5, 20. 20.5 or more) weeks after the immediately preceding dose. As used herein, the phrase “the immediately preceding dose,” means, in a sequence of multiple administrations, the dose of the inhibitor (e.g., a therapeutic agent, a receptor antagonist, and / or a chemogenetic compound described herein) and / or an omega-3 PUFA optionally in combination with a low-fat diet that is administered to a subject before the administration of the very next subsequent dose in the sequence with no intervening doses.

[0341] The methods may comprise administering to a subject any number of secondary doses and / or tertiary doses of an inhibitor (e.g., a therapeutic agent, a receptor antagonist, and / or a chemogenetic compound described herein) and / or an omega-3 PUFA optionally in combination88328856447vlAttorney Docket No: 243735.000512with a low-fat diet. In some embodiments, only one secondary dose is administered to the subject. In certain embodiments, two or more secondary doses are administered to the subject. Likewise, in some embodiments, only one tertiary dose is administered to the subject. In some embodiments, two or more tertiary doses are administered to the subject.

[0342] In certain embodiments that involve multiple secondary doses, all secondary doses are administered at the same frequency as one another (e.g., each secondary dose may be administered 1, 2, 3, or 4 weeks, or some other frequency, after the immediately preceding dose. Similarly, in certain embodiments that involve multiple tertiary doses, all tertiary doses are administered at the same frequency as one another. Alternatively, the frequency at which the secondary doses and / or tertiary doses are administered can vary over the treatment regimen course. The frequency of administration may be adjusted during the treatment regimen course by a physician depending on the subject needs following clinical examination.

[0343] In certain embodiments, when an inhibitor (e.g., a therapeutic agent, a receptor antagonist, and / or a chemogenetic compound described herein) and / or an omega-3 PUFA and / or a low-fat diet are sequentially administered, an omega-3 PUFA and / or a low-fat diet may be a first component of the dosing regimen and the inhibitor (e.g., a therapeutic agent, a receptor antagonist, and / or a chemogenetic compound described herein) may be a second component of the dosing regimen (z.e., an omega-3 PUFA and / or a low-fat diet may be administered before the inhibitor (e.g., a therapeutic agent, a receptor antagonist, and / or a chemogenetic compound described herein)). In certain embodiments, an omega-3 PUFA and / or a low-fat diet may be a second component of the dosing regimen and the inhibitor e.g., a therapeutic agent, a receptor antagonist, and / or a chemogenetic compound described herein) may be a first component of a dosing regimen (i.e., an omega-3 PUFA and / or a low-fat diet may be administered after the inhibitor (e.g., a therapeutic agent, a receptor antagonist, and / or a chemogenetic compound described herein)). In other embodiments, an omega-3 PUFA and / or a low-fat diet and an inhibitor (e.g., a therapeutic agent, a receptor antagonist, and / or a chemogenetic compound described herein) may be sequentially administered, by using either of the above-described orders with variable time intervals between administrations. For example, the time interval between administration of an omega-3 PUFA and / or a low-fat diet and the inhibitor (e.g., a therapeutic agent, a receptor antagonist, and / or a chemogenetic compound described herein) may be at least about 30 seconds, at least about 45 seconds, at least about 1 minute, at least about 2 minutes, at least about 5 minutes,89328856447vlAttorney Docket No: 243735.000512at least about 10 minutes, at least about 15 minutes, at least about 20 minutes, at least about 30 minutes, at least about 45 minutes, at least about 1 hour, at least about 2 hours, at least about 3 to 4 hours, at least about 5 hours, at least about 6 to 7 hours, at least about 8 to 9 hours, at least about 10 hours, at least about 11 to 12 hours, at least about 13 to 14 hours, at least about 15 hours, at least about 16 to 17 hours, at least about 18 to 19 hours, at least about 20 hours, at least about 21 to 24 hours, at least about 1 day. at least about 2 days, at least about 3 to 4 days, at least about 5 days, at least about 6 to 7 days, at least about 8 to 9 days, at least about 10 days, at least about 11 to 12 days, at least about 13 to 14 days, at least about 15 days, at least about 16 to 17 days, at least about 18 to 19 days, at least about 20 days, at least about 21 to 25 days, at least about 26 to 31 days, at least about 1 month, at least about 2 to 5 months, at least about 6 months, at least about 7 to 11 months, at least about 1 year, at least about 2 to 4 years, at least about 5 years, at least about 6 to 9 years, at least about 10 years, or more.

[0344] Any of the methods of administration as described herein can further comprise any of various subsequent administration steps as described herein. For example, the subsequent administration step can comprise administering the inhibitor (e.g., a therapeutic agent, a receptor antagonist, and / or a chemogenetic compound described herein) and / or an omega-3 PUFA and / or a low-fat diet to the subject one or more subsequent times until a desired clinical outcome and / or measurement of interest is achieved in the subject.

[0345] For example, the subsequent administration step(s) can be at least about 1 week, at least about 2 to 4 weeks, at least about 5 weeks, at least about 6 to 9 weeks, at least about 10 weeks, at least about 11 to 15 weeks, or at least about 16 to 20 weeks after the initial dosing.

[0346] In some embodiments, the subsequent administration step can comprise administering a second inhibitor (e.g., a therapeutic agent, a receptor antagonist, and / or a chemogenetic compound described herein) and / or an omega-3 PUFA and / or a low-fat diet e.g., that is different from a first inhibitor (e.g., a therapeutic agent, a receptor antagonist, and / or a chemogenetic compound described herein) and / or an omega-3 PUFA and / or a low-fat diet administered in an initial administration step) to the subject one or more subsequent times until a desired clinical outcome and / or measurement of interest is achieved in the subject.

[0347] For example, the subsequent administration step(s) can be at least about 1 week, at least about 2 to 4 weeks, at least about 5 weeks, at least about 6 to 9 weeks, at least about 10 weeks, at least about 11 to 15 weeks, or at least about 16 to 20 weeks after the initial dosing.90328856447vlAttorney Docket No: 243735.000512

[0348] In some embodiments, the subsequently administered inhibitor (e.g., a therapeutic agent, a receptor antagonist, and / or a chemogenetic compound described herein) and / or an omega-3 PUFA and / or a low-fat diet is administered via the same administration route as the originally administered inhibitor (e.g., a therapeutic agent, a receptor antagonist, and / or a chemogenetic compound described herein) and / or an omega-3 PUFA and / or a low-fat diet.

[0349] In some embodiments, the subsequently administered inhibitor (e.g., a therapeutic agent, a receptor antagonist, and / or a chemogenetic compound described herein) and / or an omega-3 PUFA and / or a low-fat diet is administered via a different administration route as the originally administered inhibitor (e.g., a therapeutic agent, a receptor antagonist, and / or a chemogenetic compound described herein) and / or an omega-3 PUFA and / or a low-fat diet.

[0350] In certain embodiments, the inhibitor (e.g., a therapeutic agent, a receptor antagonist, and / or a chemogenetic compound described herein) is administered before the administration of an omega-3 PUFA and / or a low-fat diet.

[0351] In certain embodiments, the inhibitor (e.g., a therapeutic agent, a receptor antagonist, and / or a chemogenetic compound described herein) is administered simultaneously with the administration of an omega-3 PUFA and / or a low-fat diet.

[0352] In certain embodiments, the inhibitor (e.g., a therapeutic agent, a receptor antagonist, and / or a chemogenetic compound described herein) is administered after the administration of an omega-3 PUFA and / or a low-fat diet.

[0353] In some embodiments, an omega-3 PUFA and / or a low-fat diet are administered two or more times and the inhibitor (e.g., a therapeutic agent, a receptor antagonist, and / or a chemogenetic compound described herein) is administered before and / or between each of the administrations of an omega-3 PUFA and / or a low-fat diet.

[0354] In some embodiments, the inhibitor e.g., a therapeutic agent, a receptor antagonist, and / or a chemogenetic compound described herein) is administered simultaneously with an omega-3 PUFA and / or a low-fat diet or not simultaneously e.g., sequentially in any combination). For example, in a method comprising administering an inhibitor (e.g., a therapeutic agent, a receptor antagonist, and / or a chemogenetic compound described herein) and an omega-3 PUFA and / or a low-fat diet, they can be administered separately (e.g., the inhibitor (e.g., a therapeutic agent, a receptor antagonist, and / or a chemogenetic compound described herein) separately from an omega-3 PUFA and / or a low-fat diet). Further, the inhibitor (e.g., a therapeutic agent, a receptor91328856447vlAttorney Docket No: 243735.000512antagonist, and / or a chemogenetic compound described herein) can be administered prior to, subsequent to, prior to and subsequent to, or at the same time as an omega-3 PUFA and / or a low-fat diet.

[0355] In certain embodiments, the inhibitor (e.g., a therapeutic agent, a receptor antagonist, and / or a chemogenetic compound described herein) can be administered about 2 hours to about 72 hours, about 2 hours to about 48 hours, about 2 hours to about 24 hours, about 2 hours to about 12 hours, about 2 hours to about 6 hours, about 2 hours to about 4 hours, about 1 hour to about 72 hours, about 1 hour to about 48 hours, about 1 hour to about 24 hours, about 1 hour to about 12 hours, about 1 hour to about 6 hours, about 1 hour to about 4 hours, about 1 hour to about 2 hours, about 6 hours to about 48 hours, about 6 hours to about 24 hours, about 12 hours to about 48 hours, or about 24 hours to about 48 hours prior to and / or subsequent to administration of an omega-3 PUFA and / or a low-fat diet.

[0356] In some embodiments, the inhibitor (e.g., a therapeutic agent, a receptor antagonist, and / or a chemogenetic compound described herein) is administered at least about 2 hours, at least about 4 hours, at least about 6 hours, at least about 8 hours, at least about 12 hours, at least about 16 hours, at least about 18 hours, at least about 1 day, at least about 1.5 days, at least about 2 days, at least about 3 days, at least about 4 days, at least about 5 days, at least about 6 days, at least about 1 week, or at least about 2 weeks prior to administering an omega-3 PUFA and / or a low-fat diet. In another embodiment, the inhibitor (e.g., a therapeutic agent, a receptor antagonist, and / or a chemogenetic compound described herein) is administered about 2 hours to about 48 hours, about 4 hours to about 24 hours, about 4 hours to about 12 hours, about 8 hours to about 24 hours, about 12 hours to about 24 hours, about 1 day to about 14 days, about 1 day to about 7 days, about 1 day to about 6 days, about 1 day to about 5 days, about 1 day to about 3 days, about 1 day to about 2 days, about 2 days to about 7 days, about 4 days to about 7 days, or about 5 days to about 7 days prior to and / or subsequent to administering an omega-3 PUFA and / or a low-fat diet.

[0357] In some embodiments, the inhibitor (e.g., a therapeutic agent, a receptor antagonist, and / or a chemogenetic compound described herein) is administered at least about 2 hours, at least about 4 hours, at least about 6 hours, at least about 8 hours, at least about 12 hours, at least about 16 hours, at least about 18 hours, at least about 1 day, at least about 1.5 days, at least about 2 days, at least about 3 days, at least about 4 days, at least about 5 days, at least about 6 days, at least about 1 week, or at least about 2 weeks prior to and subsequent to administering an omega-3 PUFA92328856447vlAttorney Docket No: 243735.000512and / or a low-fat diet. In another embodiment, the inhibitor (e.g., a therapeutic agent, a receptor antagonist, and / or a chemogenetic compound described herein) is administered about 2 hours to about 48 hours, about 4 hours to about 24 hours, about 4 hours to about 12 hours, about 8 hours to about 24 hours, about 12 hours to about 24 hours, about 1 day to about 14 days, about 1 day to about 7 days, about 1 day to about 6 days, about 1 day to about 5 days, about 1 day to about 3 days, about 1 day to about 2 days, about 2 days to about 7 days, about 4 days to about 7 days, or about 5 days to about 7 days prior to and subsequent to administering an omega-3 PUFA and / or a low-fat diet.

[0358] In some embodiments, the inhibitor (e.g., a therapeutic agent, a receptor antagonist, and / or a chemogenetic compound described herein) is administered at least 2 hours, at least about 4 hours, at least 6 hours, at least about 8 hours, at least about 12 hours, at least 16 hours, at least about 18 hours, at least about 1 day, at least about 1.5 days, at least about 2 days, at least about 3 days, at least about 4 days, at least about 5 days, at least about 6 days, at least about 1 week, or at least about 2 weeks after administering an omega- 3 PUFA and / or a low-fat diet. In another embodiment, the inhibitor (e.g., a therapeutic agent, a receptor antagonist, and / or a chemogenetic compound described herein) is administered about 2 hours to about 48 hours, about 4 hours to about 24 hours, about 4 hours to about 12 hours, about 8 hours to about 24 hours, about 12 hours to about 24 hours, about 1 day to about 14 days, about 1 day to about 7 days, about 1 day to about 6 days, about 1 day to about 5 days, about 1 day to about 3 days, about 1 day to about 2 days, about 2 days to about 7 days, about 4 days to about 7 days, or about 5 days to about 7 days after administering an omega-3 PUFA and / or a low-fat diet.

[0359] Administration in vivo can be by any suitable route including, but not limited to, oral, parenteral, intrathecal, intra-arterial, intraperitoneal, intravenous, subcutaneous, topical, intracranial, intratumoral, intranasal, or intramuscular. Systemic modes of administration include, but are not limited to, parenteral and oral routes. Parenteral routes include, but are not limited to, subcutaneous, intraosseous, intravenous, intranasal, intradermal, intraarterial, intramuscular, and intraperitoneal routes. Some specific examples are intravenous infusion, nasal inhalation, and intravitreal injection. Local modes of administration include, but are not limited to, intracerebroventricular, intrathecal, intraparenchymal (e.g., localized intraparenchymal delivery to the cerebral cortex, temporal cortex, striatum, tegmentum, precentral gyrus, hippocampus, thalamus, frontal cortex, hypothalamus, cerebellum, amygdala, medulla, tectum, or substantia93328856447vlAttorney Docket No: 243735.000512nigra), intravitreal, subconjunctival, intraocular, subretinal, intraorbital, and transscleral routes. Significantly smaller amounts of the active components may elicit an effect(s) when administered locally (e.g., intravitreal or intraparenchymal) compared to when administered systemically (e.g., intravenously). Administration locally may also reduce or eliminate the prevalence of potentially toxic side effects that may occur when the component(s) are administered systemically.

[0360] Administration in vivo can be by any suitable route including, but is not limited to, intravenous, intracranial, subcutaneous, parenteral, intratumoral, intraperitoneal, oral, intraarterial, intranasal, intrathecal, topical, or intramuscular.

[0361] The number of dosages and the frequency of administration can depend on several factors. The administration of an inhibitor (e.g., a therapeutic agent, a receptor antagonist, and / or a chemogenetic compound described herein) and / or an omega-3 PUFA and / or a low-fat diet into the cell or subject can be performed one or more times over a specific period of time. In some embodiments, the administration can be performed only once over a period of time, at least two to three times over a period of time, at least four to five times over a period of time, at least six to seven times over a period of time, at least eight to nine times over a period of time, at least ten times over a period of time, at least eleven to twelve times over a period of time, at least thirteen to fourteen times over a period of time, at least fifteen times over a period of time, at least sixteen to nineteen times over a period of time, at least twenty times over a period of time, or at least twenty-two to thirty times over a period of time. In some embodiments, a single administration of the inhibitor (e.g., a therapeutic agent, a receptor antagonist, and / or a chemogenetic compound described herein) and / or an omega-3 PUFA and / or a low-fat diet, is sufficient to achieve the desired effect(s). In some embodiments, more than one administration may be beneficial to maximize desired therapeutic effect.

[0362] In some embodiments, the inhibitor (e.g., a therapeutic agent, a receptor antagonist, and / or a chemogenetic compound described herein) and / or an omega-3 PUFA and / or a low-fat diet is administered orally or intravenously.

[0363] In some embodiments, the inhibitor (e.g., a therapeutic agent, a receptor antagonist, and / or a chemogenetic compound described herein) and / or an omega-3 PUFA and / or a low-fat diet may be carried out in combination with one or more of a known therapy including, but not limited to, surgery, gene therapy, altering vagal activity, radiation therapy, chemotherapy,94328856447vlAttorney Docket No: 243735.000512photodynamic therapy, and / or immunotherapy. Tn some embodiments, the surgery is vagotomy, including unilateral vagotomy.

[0364] An effective amount for a particular patient may vary depending on factors such as the condition being treated, the overall health of the patient, the method route and dose of administration and the severity of side effects (see, e.g.. Maynard, et al., 1996, A Handbook of SOPs for Good Clinical Practice, Interpharm Press, Boca Raton, Fla.; Dent, 2001, Good Laboratory and Good Clinical Practice, Urch Publ, London, UK).

[0365] The route of administration may be by, e.g., topical or cutaneous application, injection or infusion by intravenous, intraperitoneal, intracerebral, intramuscular, intrathecal, intraocular, intraarterial, in tracerebro spinal, intralesional, or by sustained release systems or an implant (see, e.g., Sidman et al., 1983, Biopolymers 22:547-556; Langer, et al., 1981. J. Biomed. Mater. Res.15: 167-277; Langer, 1982, Chem. Tech. 12:98-105; Epstein, et al., 1985, Proc. Natl. Acad. Sci. USA 82:3688-3692; Hwang, et al., 1980, Proc. Natl. Acad. Sci. USA 77:4030-4034; U. S. Pat. Nos. 6,350.466 and 6,316.024). Where necessary, the composition may also include a solubilizing agent and a local anesthetic such as lidocaine to ease pain at the site of the injection. In addition, pulmonary administration can also be employed, e.g., by use of an inhaler or nebulizer, and formulation with an aerosolizing agent. See, e.g., U. S. Pat. Nos. 6,019,968, 5,985,320, 5,985,309, 5,934,272, 5,874,064, 5,855,913, 5,290,540, and 4,880,078; and PCT Publication Nos. WO 92 / 19244, WO 97 / 32572, WO 97 / 44013, WO 98 / 31346, and WO 99 / 66903, each of which is incorporated herein by reference their entirety. In one embodiment, an inhibitor (e.g., a therapeutic agent, a receptor antagonist, and / or a chemogenetic compound described herein), combination therapy such as an inhibitor (e.g., a therapeutic agent, a receptor antagonist, and / or a chemogenetic compound described herein) and / or an omega-3 PUFA, or a composition of the disclosure is administered using Alkermes AIR™ pulmonary drug delivery technology (Alkermes, Inc., Cambridge, Mass.).

[0366] The frequency of dosing will depend upon the pharmacokinetic parameters of the inhibitor (e.g., a therapeutic agent, a receptor antagonist, and / or a chemogenetic compound described herein) in the formulation being used. Typically, a clinician will administer the composition until a dosage is reached that achieves the desired effect. The composition can therefore be administered as a single dose, as two or more doses (which may or may not contain the same amount of the desired molecule) over time, or as a continuous infusion via an95328856447vlAttorney Docket No: 243735.000512implantation device or catheter. Further refinement of the appropriate dosage is routinely made by those of ordinary skill in the art and is within the ambit of tasks routinely performed by them. Appropriate dosages can be ascertained through use of appropriate dose-response data.

[0367] The route of administration of the pharmaceutical composition is in accord with known methods, e.g., orally; through injection by subcutaneous, intravenous, intraperitoneal, intracerebral (intraparenchymal), intrathecal, intracerebroventricular, intramuscular, intraocular, intraarterial, intraportal, or intralesional routes; by sustained release systems (which may also be injected); or by implantation devices. Where desired, the compositions can be administered by bolus injection or continuously by infusion, or by implantation device.

[0368] Alternatively or additionally, the composition can be administered locally via implantation of a membrane, sponge, or other appropriate material onto which the desired molecule has been absorbed or encapsulated. Where an implantation device is used, the device can be implanted into any suitable tissue or organ, and delivery of the desired molecule can be via diffusion, timed- release bolus, or continuous administration. In order to deliver drug, e.g., an inhibitor (e.g., a therapeutic agent, a receptor antagonist, and / or a chemogenetic compound described herein), at a predetermined rate such that the drug concentration can be maintained at a desired therapeutically effective level over an extended period, a variety of different approaches can be employed. In one example, a hydrogel comprising a polymer such as a gelatin (e.g., bovine gelatin, human gelatin, or gelatin from another source) or a naturally-occurring or a synthetically generated polymer can be employed. Any percentage of polymer (e.g., gelatin) can be employed in a hydrogel, such as 5, 10, 15, or 20%. The selection of an appropriate concentration can depend on a variety of factors, such as the therapeutic profile desired and the pharmacokinetic profile of the therapeutic molecule.

[0369] Examples of polymers that can be incorporated into a hydrogel include polyethylene glycol (“PEG”), polyethylene oxide, polyethylene oxide-co-polypropylene oxide, co-polyethylene oxide block or random copolymers, polyvinyl alcohol, poly(vinyl pyrrolidinone), poly(amino acids), dextran, heparin, polysaccharides, polyethers, and the like.

[0370] Another factor that can be considered when generating a hydrogel formulation is the degree of crosslinking in the hydrogel and the crosslinking agent. In one embodiment, crosslinking can be achieved via a methacrylation reaction involving methacrylic anhydride. In some situations, a high degree of cross-linking may be desirable while in other situations a lower degree96328856447vlAttorney Docket No: 243735.000512of crosslinking is preferred. In some cases, a higher degree of crosslinking provides a longer sustained release. A higher degree of crosslinking may provide a firmer hydrogel and a longer period over which drug is delivered. Any ratio of polymer to crosslinking agent (e.g., methacrylic anhydride) can be employed to generate a hydrogel with desired properties. For example, the ratio of polymer to crosslinker can be, e.g., 8:1, 16:1, 24:1, or 32:1. For example, when the hydrogel polymer is gelatin and the crosslinker is methacrylate, ratios of 8:1. 16:1, 24:1, or 32:1 methyacrylic anhydride: gelatin can be employed.

[0371] One skilled in the art recognizes that different methods of delivery may be utilized to administer a polynucleotide (e.g., an mRNA) or vector into a cell. Examples include: (1) methods utilizing physical means, such as electroporation (electricity), a gene gun (physical force) or applying large volumes of a liquid (pressure); and (2) methods wherein the vector is complexed to another entity, such as a liposome, aggregated protein, or transporter molecule.

[0372] Furthermore, the actual dose and schedule can vary depending on whether the compositions are administered in combination with other compositions, or depending on interindividual differences in pharmacokinetics, drug disposition, and metabolism. Similarly, amounts can vary in in vitro applications depending on the particular cell line utilized (e.g., based on the number of vector receptors present on the cell surface, or the ability of the particular vector employed for gene transfer to replicate in that cell line). Furthermore, the amount of polynucleotide or vector to be added per cell will likely vary with the length and stability of the therapeutic gene inserted in the polynucleotide or vector, as well as also the nature of the sequence, and is particularly a parameter which needs to be determined empirically, and can be altered due to factors not inherent to the methods of the present invention (for instance, the cost associated with synthesis). One skilled in the art can easily make any necessary adjustments in accordance with the exigencies of the particular situation.

[0373] The polynucleotide molecule may also contain a suicide gene i.e., a gene which encodes a product that can be used to destroy the cell. In many gene therapy situations, it is desirable to be able to express a gene for therapeutic purposes in a host cell but also to have the capacity to destroy the host cell at will. The therapeutic agent can be linked to a suicide gene, whose expression is not activated in the absence of an activator compound. When death of the cell in which both the agent and the suicide gene have been introduced is desired, the activator compound is administered to the cell thereby activating expression of the suicide gene and killing97328856447vlAttorney Docket No: 243735.000512the cell. Examples of suicide gene / prodrug combinations which may be used are herpes simplex virus -thymidine kinase (HSV-tk) and ganciclovir, acyclovir; oxidoreductase and cycloheximide; cytosine deaminase and 5 -fluor ocy to sine; thymidine kinase thymidilate kinase (Tdk;: Tmk) and AZT; and deoxycytidine kinase and cytosine arabinoside.Subjects

[0374] Provided herein are methods of treating a subject having (i) a mutation in a liver kinase Bl (LKB1) gene and / or (ii) suppression of LKBl-mediated signaling. In some embodiments, provided herein are methods of treating a subject having a cancer. In some embodiments, provided herein are methods of treating a subject having a cancer and (i) a mutation in a liver kinase Bl (LKB1) gene and / or (ii) suppression of LKBl-mediated signaling. In some embodiments, provided herein are methods of treating a subject having germline mutations in Peutz-Jeghers syndrome (PJS). In some embodiments, provided herein are methods of treating a subject at risk of developing a cancer.

[0375] In some embodiments, the subject is a human. In some embodiments, the subject is a veterinary animal (e.g., cats, dogs, cows, horses, sheep, pigs, etc.) or an experimental animal model.

[0376] The subject of the present disclosure may include a subject having germline mutations in Peutz-Jeghers syndrome (PJS), a cancer, and / or a risk of developing cancer.

[0377] A cancer as described herein may include any cancer or tumor condition which, upon treatment with any or all of the methods of the present disclosure, results in improvement or shows a sign of improvement in the cancer or tumor condition. The improvement or sign of improvement may include, but is not limited to, a tumor reduction, a prevention of tumor progression, an increase in the effect of the other treatment(s) in combination (e.g., a pre-treatment, a concurrent treatment, and / or a post-treatment of a cancer or a tumor condition). A cancer as described herein may include any cancer or tumor condition in which LKB1 (also known as STK11) is mutated and / or LKBl-mediated signaling is inhibited. Mutations of LKB1 gene and LKB-1 mediated signaling phenomena are described herein. In some embodiments, the cancer is pancreatic cancer, lung cancer, cervical cancer, and / or cholangiocarcinoma. In some embodiments, the lung cancer is nonsmall cell lung cancer (NSCLC) or small cell lung cancer (SCLC). In some embodiments, the lung cancer is selected from adenocarcinoma, squamous cell carcinoma, large cell carcinoma,98328856447vlAttorney Docket No: 243735.000512adenosquamous carcinoma, and sarcomatoid carcinoma. Tn some embodiment, the cancer is lung adenocarcinoma (LUAD). In some embodiments, the lung adenocarcinoma may be characterized by signaling inhibition of or a genetic mutation in the following genes: TP53, KRAS, KEAP1, and / or CDKN2A.Non-limiting Embodiments1. A method of treating cachexia and / or sickness behavior in a subject having a cancer and (i) a mutation in a liver kinase Bl (LKB1) gene and / or (ii) suppression of LKB1 -mediated signaling, the method comprising:a) inhibiting synthesis and / or activity and / or function of one or more prostaglandins; b) inhibiting one or more prostaglandin receptors; and / orc) inhibition of sensory neurons.2. The method of embodiment 1, wherein the cancer comprises a lung cancer, a pancreatic cancer, a cervical cancer, and / or a cholangiocarcinoma.3. The method of embodiment 1 or embodiment 2, wherein the cancer is non-small cell lung cancer.4. The method of any one of embodiments 1-3, wherein the LKB1 mutation comprises a loss of function mutation.5. The method of embodiment 4, wherein the LKB1 mutation comprises a point mutation, a frameshift mutation, a splice mutation, an insertion mutation, a deletion mutation, a mis sense mutation, a nonsense mutation, a chromosomal arm deletion, and / or a focal deletion.6. The method of embodiment 4 or embodiment 5, wherein the LKB1 mutation comprises a G251V mutation, a G251R mutation, a G251C mutation, a S216F mutation, a D194H mutation, a D194Y mutation, a G242W mutation, a G242V mutation, a W239C mutation, a Q220* mutation, a R86* mutation, a Y60* mutation, a E165* mutation, a P281Rfs*6 mutation, a L282Afs*3 mutation, a K84* mutation, a E223* mutation, a E33* mutation, D53Tfs*l 1 mutation, a K78N mutation, a E199* mutation, a G56V mutation, a E57Kfs*7 mutation, a D53Gfs*l 10 mutation, a G56W mutation, a E70* mutation, a K62* mutation, a A43Pfs*8 mutation, a E65* mutation, a Y60* mutation, a K146* mutation, a K175* mutation, a K262* mutation, a K235* mutation, a K78E mutation, a T250Rfs*37 mutation, a N259Kfs*28 mutation, a D176A mutation, a L228Rfs*33 mutation, a D30Gfs*133 mutation, a E265Gfs*1999328856447vlAttorney Docket No: 243735.000512mutation, a S69* mutation, a KI 08* mutation, a El 38* mutation, a V77Sfs*19 mutation, a Q37Pfs*123 mutation, a Q220Pfs*46 mutation, a M136K mutation, a M136I mutation, a STK11-ARHGAP45 Fusion mutation, a STK11-SRFBP1 Fusion mutation, a ARHGAP45-STK11 Fusion mutation, a TNRC6B-STK11 Fusion mutation, a Q137H mutation, a E245F mutation, a H168R mutation, a Q170P mutation, a Y118H mutation, a M129I mutation, a I224V mutation, a X200_splice mutation, a X155_splice mutation, a X245_splice mutation, a X288_splice mutation, and / or a X97_splice mutation.7. The method of any one of embodiments 1-6, wherein the suppression of EKBl-mediated signaling includes a mutation in a salt-inducible kinase (SIK) gene.8. The method of embodiment 7, wherein the SIK is SIK1, SIK2, and / or SIK3.9. The method of embodiment 7 or embodiment 8, wherein the SIK mutation comprises a loss of function mutation.10. The method of any one of embodiments 1-9, wherein the prostaglandin is prostaglandin E2 (PGE2).11. The method of any one of embodiments 1-10, wherein the synthesis of the one or more prostaglandins is inhibited by decreasing activity and / or function of a prostaglandin synthase. 12. The method of embodiment 11, wherein the prostaglandin synthase is a cyclooxygenase (COX) enzyme, phospholipase A2, and / or prostaglandin E synthase (PTGES).13. The method of embodiment 12, wherein the COX enzyme is COX-1 or COX-2.14. The method of any of embodiments 11-13, wherein the activity and / or function of the COX enzyme is decreased by administering a therapeutic agent.15. The method of embodiment 14, wherein the therapeutic agent that decreases the activity and / or function of the COX enzyme comprises a competitive inhibitor, a non-competitive inhibitor, an uncompetitive inhibitor, a reversible inhibitor, and / or an irreversible inhibitor. 16. The method of embodiment 14 or embodiment 15, wherein the therapeutic agent comprises a small molecule.17. The method of embodiment 16, wherein the small molecule comprises a COX-1 inhibitor and / or a COX-2 inhibitor.18. The method of embodiment 17, wherein the COX-1 inhibitor is a selective COX-1 inhibitor or a non- selective COX-1 inhibitor.100328856447vlAttorney Docket No: 243735.00051219. The method of embodiment 17, wherein the COX-2 inhibitor is a selective COX-2 inhibitor or a non-selective COX-2 inhibitor, optionally wherein the selective COX-2 inhibitor comprises celecoxib (Celebrex), NS-398 (N-[2-(cyclohexyloxy)-4-nitrophenyl]-methanesulfonamide). and / or valdecoxib (Bextra).20. The method of any one of embodiments 14-19, wherein the therapeutic agent that decreases the activity and / or function of the COX enzyme comprises a non-steroidal anti-inflammatory drug (NSAID).21. The method of embodiment 20, wherein the NSAID is ibuprofen or acetylsalicylic acid. 22. The method of embodiment 14 or embodiment 15, wherein the therapeutic agent that decreases the activity and / or function of the COX enzyme is an antibody.23. The method of embodiment 14 or embodiment 15, wherein the therapeutic agent that decreases the activity and / or function of the COX enzyme comprises a polyunsaturated fatty acid (PUFA).24. The method of embodiment 23, wherein the PUFA comprises an omega-3 PUFA.25. The method of embodiment 23 or embodiment 24, wherein the PUFA comprises eicosapentaenoic acid (EPA) and / or docosahexaenoic acid (DHA).26. The method of embodiment 25, wherein the EPA is administered in an amount of 250 mg / day to 3000 mg / day.27. The method of embodiment 25, wherein the DHA is administered in an amount of 250 mg / day to 3000 mg / day.28. The method of any one of embodiments 25-27, wherein the ratio of EPA to DHA is 2:1. 29. The method of embodiment 11, wherein the prostaglandin synthase is prostaglandin E synthase (PTGES).30. The method of embodiment 29. wherein the PTGES is microsomal PTGES.31. The method of embodiment 29 or embodiment 30, wherein the activity and / or function of PTGES is decreased by administering a therapeutic agent.32. The method of embodiment 31, wherein the therapeutic agent that decreases the activity and / or function of PTGES is a small molecule.33. The method of embodiment 32, wherein the small molecule is selected from crisdesalazine (AAD-2004), compound III (N-cyclopentyl-l-[5,6-dimethyl-l-(l-methylethyl)-lH-benzimidazol-2-yl]-4-piperidinecarboxamide; mPGES-1 Inhibitor III), LY3023703 (2-101328856447vlAttorney Docket No: 243735.000512(difluoromethyl)-5-[[(2-methyl-l-oxopropyl)amino]methyl]-N-[4-methyl-5-[4-(trifluoromethyl)phenyl]- lH-imidazol-2-yl] -3 -pyridinecarboxamide), AF3485 (N-[9-(2-hydroxyethyl)-9H-carbazol-3-yl]-2-(trifluoromethyl)-benzamide). MF63 (2-(6-chloro-lH-phenanthro[9,10-d]imidazol-2-yl)-isophthalonitrile), AF3442 (N-(9-ethyl-9H-carbazol-3-yl)-2-(trifluoromethyl)benzamide), PF-9184 (N-(3',4'-dichloro[l,l'-biphenyl]-4-yl)-4-hydroxy-2H-l,2-benzothiazine-3-carboxamide 1,1-dioxide), PF-4693627 (l-[5-chloro-6-(4-chlorophenyl)-2-benzoxazolyl] -N- [ ( 1 S,3 S )- 3 - (hydroxymethyl)cyclohexyl] -4-piperidinecarb oxamide), LY3031207 (2-chloro-N-(lH-imidazol-2-yl)-5-(pivalamidomethyl)benzamide), YS121 (2-(4-chloro-6-(2,3-dimethylphenylamino)pyrimidin-2-ylthio)octanoic acid), MK.-886 (l-[(4-chlorophenyl)methyl]-3- [( 1, 1 -dimethylethyl)thio]-alpha,alpha-dimethyl-5-( 1 -methylethyl)- 1H-indole-2-propanoic acid), and dexamethasone, or derivative(s) thereof.34. The method of embodiment 31, wherein the therapeutic agent that decreases the activity and / or function of PTGES is an antibody.35. The method of any one of embodiments 1-10. wherein the activity and / or function of a prostaglandin is inhibited by increasing activity and / or function of a different prostaglandin. 36. The method of embodiment 35, wherein the activity and / or function of PGE2 is inhibited by increasing activity and / or function of prostaglandin E3 (PGE3), optionally by administering a PUFA, preferably an omega-3 PUFA, alone or in combination with a low-fat diet, for example simultaneously with a meal of the low-fat diet, before a meal of the low-fat diet, or after a meal of the low-fat diet.37. The method of embodiment 36, wherein the PUFA comprises eicosapentaenoic acid (EPA) and / or docosahexaenoic acid (DHA).38. The method of embodiment 37, wherein the EPA is administered in an amount of 250 mg / day to 3000 mg / day.39. The method of embodiment 37, wherein the DHA is administered in an amount of 250 mg / day to 3000 mg / day.40. The method of any one of embodiments 37-39, wherein the ratio of EPA to DHA is 2:1. 41. The method of any one of embodiments 13-22 and 29-34, wherein the therapeutic agent is administered in combination with a PUFA, preferably an omega-3 PUFA.42. The method of embodiment 41, wherein the PUFA comprises eicosapentaenoic acid (EPA) and / or docosahexaenoic acid (DHA).102328856447vlAttorney Docket No: 243735.00051243. The method of embodiment 42, wherein the EPA is administered in an amount of 250 mg / day to 3000 mg / day.44. The method of embodiment 42, wherein the DHA is administered in an amount of 250 mg / day to 3000 mg / day.45. The method of any one of embodiments 42-44, wherein the ratio of EPA to DHA is 2:1. 46. The method of any one of embodiments 13-33 and 41-45, wherein the therapeutic agent, optionally in combination with the PUFA, is administered with a low-fat diet.47. The method of embodiment 46, wherein the therapeutic agent, optionally in combination with the PUFA, is administered simultaneously with a meal of the low-fat diet, before a meal of the low-fat diet, or after a meal of the low-fat diet.48. The method of any one of embodiments 1-10, wherein the one or more prostaglandin receptors are selected from the group consisting of prostaglandin E2 receptor 1 (EPl), prostaglandin E2 receptor 2 (EP2), prostaglandin E2 receptor 3 (EP3), and prostaglandin E2 receptor 4 (EP4).49. The method of embodiment 48, wherein the one or more prostaglandin receptors are EPl receptors.50. The method of embodiment 48 or embodiment 49, wherein the activity and / or function of the one or more prostaglandin receptors is inhibited by an antagonist.51. The method of embodiment 50, wherein the antagonist is a competitive antagonist, a noncompetitive antagonist, an uncompetitive antagonist, a reversible antagonist, and / or an irreversible antagonist.52. The method of embodiment 50 or embodiment 51, wherein the antagonist is a small molecule.53. The method of any one of embodiments 48-52, wherein the one or more prostaglandin receptors are EPl receptors and the antagonist comprises SC-51322, GW-848687X, SC-19220, SC-51089, ONO-8713, ONO-8130, and / or ONO-8711.54. The method of any one of embodiments 48-51, wherein the one or more prostaglandin receptors are EP2 receptors and the antagonist comprises PF-04418948, TG6-10-1, and / or TG8-260.103328856447vlAttorney Docket No: 243735.00051255. The method of any one of embodiments 48-51, wherein the one or more prostaglandin receptors are EP3 receptors and the antagonist comprises DG-041, L798-106, and / or 0N0-AE3-240.56. The method of any one of embodiments 48-51, wherein the one or more prostaglandin receptors are EP4 receptors and the antagonist comprises ONO-AE3-208, LY3127760, Grapiprant. AH6809, and / or RQ- 15986.57. The method of embodiment 50 or embodiment 51, wherein the antagonist is an antibody. 58. The method of any one of embodiments 50-57, wherein the antagonist is administered in combination with a PUFA, preferably an omega-3 PUFA.59. The method of embodiment 58, wherein the PUFA comprises eicosapentaenoic acid (EPA) and / or docosahexaenoic acid (DHA).60. The method of embodiment 59, wherein the EPA is administered in an amount of 250 mg / day to 3000 mg / day.61. The method of embodiment 59, wherein the DHA is administered in an amount of 250 mg / day to 3000 mg / day.62. The method of any one of embodiments 59-61, wherein the ratio of EPA to DHA is 2:1. 63. The method of any one of embodiments 50-62, wherein the antagonist, optionally in combination with the PUFA, is administered with a low-fat diet.64. The method of embodiment 63, wherein the antagonist, optionally in combination with the PUFA, is administered simultaneously with a meal of the low-fat diet, before a meal of the low-fat diet, or after a meal of the low-fat diet.65. The method of any one of embodiments 1-10. wherein the sensory neurons are inhibited by a chemogenetic compound, blocking or stimulating a vagal nerve in the subject, or by vagotomy.66. The method of embodiment 65. wherein the sensory neurons are adjacent to the cancer in the subject.67. The method of embodiment 66, wherein the sensory neurons are in a lung of the subject. 68. The method of any one of embodiments 65-67, wherein the chemogenetic compound comprises clozapine-N-oxide (CNO).69. The method of any one of embodiments 65-67, wherein the vagotomy is unilateral.70. The method of any one of embodiments 65-67, wherein blocking the vagal nerve comprises an intermittent vagal blockade, optionally via an implanted device.104328856447vlAttorney Docket No: 243735.00051271. The method of any one of embodiments 65-67, wherein the vagal nerve is stimulated via an implanted device.72. The method of any one of embodiments 65-67, the method further comprising:(i) administering a therapeutic agent according to the method of any one of embodiments 14-34 or 41-47,(ii) increasing activity and / or function of the different prostaglandin according to the method of any one of embodiments 35-40, and / or(iii) administering an antagonist according to the method of any one of embodiments 50-64.73. The method of any one of embodiments 1-72, wherein the subject is a mammal.74. The method of any one of embodiments 1-73, wherein the subject is a human.EXAMPLES

[0378] The following examples are provided to further describe some of the embodiments disclosed herein. The examples are intended to illustrate, not to limit, the disclosed embodiments.Example 1: Loss of Lkbl promotes cancer-associated cachexia

[0379] Cachexia is highly prevalent in non-small cell lung cancer (NSCLC) patients, including lung adenocarcinoma (LU AD), the most common subtype of NSCLC28. LU AD displays a high degree of mutational heterogeneity28and it remains unknown how common tumor mutations impact the development of cachexia. It was hypothesized that common genetic mutations in lung cancer would influence the propensity for a tumor to disrupt organismal homeostasis and promote cachexia. To examine the interaction between tumor genotype and cachexia in lung cancer, three genetically engineered mouse models (GEMMs) of ra.s-driven lung adenocarcinoma (LU AD) were generated utilizing CRISPR / Cas9 to inactivate the Lkbl (KL), Cdkn2a / 2b (KCC), or p53 (KP) locus29'31. These models were selected as they represent the three major genetic subtypes of k' / v / .y-d riven LUAD and exhibit distinct transcriptional, inflammatory, and metabolic programs based on profiling of tumor biopsies28. To generate these models, tumors were initiated in mice carrying Cre-inducible germline alleles of KraS (,l2l) / +and Rosa26LSL'Cas9'P2A'GFP / LSL'Cas9'P2A'GFPvia intratracheal delivery of lentiviruses constitutively expressing Cre-recombinase and sgRNAs targeting Lkbl (KL) or the Cdkn2a / b (KCC) loci (Fig. 5A)24,29’32. KP tumors were generated105328856447vlAttorney Docket No: 243735.000512through infection of Kr(i '(,l-l) / +- p53fl / fland Rosa26LSL-Cas9-P2A-GFP / LSL-Cas9-P2A-GFPanimals with lentiviruses constitutively expressing Cre-recombinase and control non-targeting sgRNAs (Fig.5A) whereas KLP tumors were generated through inactivating both Lkbl and p53 tumor suppressor genes (Fig. 19). Tumors were allowed to progress for 10 weeks before mice were transferred to metabolic cages for one week to examine systemic physiological changes associated with cachexia (Fig. 1A), with a similar tumor burden between each genotype observed at this matched time point (Figs. IB and 18). While KL mice demonstrated features of cachexia, including weight loss, decreased skeletal and adipose tissue, and decreased lean muscle mass (Figs. 1C, 1G-1I, and 5B-5D); changes in diet did not affect tumor burden (Fig. 6L). Further, KL mice demonstrated decreased relative iWAT and gastrocnemius weight (Figs. 5E-5F), and reduced energy expenditure (Fig. 5G). Upon diet swap to HFD on Day 7. KPL mice demonstrated marked reduction in food and water consumption (Fig. 19). Thus, the mouse models harboring NSCLC with mutation in Lkbl displayed canonical features of sickness behavior,33-35including reduced relative weight, food and water intake, and decreased activity (Figs. 1C, II, and 19). This cancer-associated sickness was not observed in tumors with mutations in p53 or Cdk2na / 2b (Figs. 1D-1F) alone, suggesting the specific loss of Lkbl promotes cachexia in NSCLC.Example 2: High dietary fat exacerbates features of cachexia in / A / U-mutant lung cancer (NSCLC)

[0380] It was hypothesized that the reduced food intake in KL GEMMs was the main contributor to the weight-loss in these animals, given that energy expenditure was similar or decreased in KL GEMMs as compared to other tumor genotypes (Figs. 5D and 5G). Mice given ad libitum access to a high-fat diet (HFD) spontaneously overeat and gain weight36. It was investigated whether placing KL GEMMs on HFD would rescue their deficits in caloric intake and consequent weight loss. Tumors were initiated in GEMMs of NSCLC, and tumors were allowed to progress for 4 weeks before mice were switched to a high-fat diet (HFD), ketogenic diet (KD), or maintained on standard chow (Fig. 2A). These diets were chosen as both HFD and KD are calorically dense and derive the majority of their calories from lipids (Figs. 6A-6B) yet differ in their ability to modulate insulin signaling and ketogenesis37, with recent studies implicating the ketogenic diet in modulating cancer-cell growth38-40and worsening cachexia in some tumor models27. Upon diet swap to HFD, KL mice demonstrated marked weight-loss while KCC and KP106328856447vlAttorney Docket No: 243735.000512animals rapidly gained weight upon consumption of HFD (Fig. 2B). This weight-loss was also observed in KL animals consuming ketogenic diet (Fig. 6C). In line with this rapid reduction in weight, KL mice demonstrated a dramatic reduction in overall survival when placed on a ketogenic or high-fat diet (Fig.2C). These survival differences were observed in both male and female mice (Figs.6D-6E).

[0381] Lkbl regulates the activity of 14 downstream kinases belonging to the AMP-activated protein kinase (AMPK) and AMPK-related kinase (ARK) families21with recent studies demonstrating that the salt-inducible kinases (SIKs) mediate induction of an immunosuppressive microenvironment and promote LU AD development in a manner similar to loss of LKB120,21. Therefore, HFD was fed to animals harboring k' / rzs-driven tumors with mutations in SIK1 / 3 to determine if the cachectic response was dependent on these downstream signaling components. The results recapitulated the accelerated cachexia phenotype observed in KL animals, displaying similar weight-loss and decreased survival upon HFD feeding as compared to animals fed normal chow (Figs. 14A-14B). Strikingly, KCC and KP mice showed no meaningful change in overall survival on either diet (Figs. 2D-2E), with these survival differences being observed in both male and female mice (Figs.6D-6E). The consumption of the ketogenic diet led to an increase in blood ketone levels and corresponding decrease in blood glucose levels (Figs. 6F-6K). It was hypothesized that the decreased survival of KL animals on KD or HFD was due to increased tumor progression and growth. However, no differences were found in primary tumor burden in KL-GEMMs upon the manifestation of cachexia in HFD or ketogenic diet-fed animals (Fig. 6L), suggesting the decreased survival seen in KL-GEMMs is due to a systemic effect.

[0382] The high-fat diet used in the study described herein was more similar in macronutrient composition and caloric density to more traditional western-diets41as compared to the ketogenic diet (Figs. 6A-6B). Additionally, the high lipid content of ketogenic diets prevents them from being pelleted, which could make food intake studies inaccurate. Given the greater translational potential and technical considerations, remaining studies focused on the impact of only HFD on Lkbl -mutant LU AD.

[0383] To determine whether the decreased survival in KL mice was due to disruption of systemic physiology, tumor-bearing animals were placed in metabolic cages for one week and then swapped animals to HFD or maintained them on chow. In line with previous experiments, animals quickly began to lose weight once switched to HFD (Fig. 2F). Strikingly, consumption of HFD107328856447vlAttorney Docket No: 243735.000512reduced locomotion in KL GEMMs and reduced food and water intake in both KL and KPL GEMMs within two days after dietary swap (Figs. 2G-2I) without affecting energy expenditure (Figs.2G-2I, and 7A), indicating that the decrease in food and water intake was dependent on loss of Lkbl (Figs. 7B-7C). No significant changes in energy expenditure were observed between KL GEMMs fed chow or HFD (Fig. 7A). In line with decreases in food intake, the consumption of HFD in KL GEMMs led to a marked increase in levels of the early activation marker cFos in the area postrema (AP) and nucleus tractus solitarii (NTS) of the caudal brainstem (Figs. 2J-2K), a key brain region involved in feeding behavior12 15 17 18’33’42'44, and its activation is associated with a reduction in food intake in nausea and sickness44. Anorexigenic factors in cachexia, such as IL-61226and GDF1515 17 18-435have been demonstrated to activate neurons in the area postrema1226, a key brain region involved in feeding behavior12 15 17 18’33’42'44.

[0384] Skeletal muscle breakdown and lipolysis of fat stores are key drivers of cachexia, contributing to impaired quality of life and weight-loss2. To further characterize cachexia in KL GEMMS, metabolic tissues were harvested three weeks post-diet swap, at the point where HFD-induced weight loss has begun to manifest (Fig. 2B). A decrease in the mass of inguinal white adipose tissue (iWAT) was observed in KL GEMMs fed high dietary fat with a corresponding decrease in adipocyte size without an increase of mRNA levels of uncoupling protein 1 {Ucpl) and iodothyronine deiodinase type II (I)io2). canonical markers of adipose tissue browning and thermogenesis45(Figs. 7D-7F). Conversely, no differences were seen in the mass and muscle fiber size of gastrocnemius in KL GEMMs following diet swap, including a lack of induction of genes associated with activation of the autophagy machinery associated with cachexia (Figs. 7G-7I)3, suggesting decreases in adiposity may precede losses in lean mass. Together, these data suggest that loss of Lkbl in parallel with consumption of energy (lipid) rich diets accelerates cachexia in NSCLC that is mainly driven by reductions in food intake.Example 3: Localized signals and cachexiaIL6 and GDF15 are not required for HFD-induced sickness in Lkbl -mutant lung cancer.

[0385] C ancer associated cachexia (CAC) is associated with the production of inflammatory mediators and other signaling molecules10’12’15’17’18’2''’42’43by tumor cells or components of the tumor microenvironment. Secreted inflammatory factors, including IL-611 12’27, LIF10, and GDF-1515,17,18,42,43^ promote white adipose tissue lipolysis and muscle protein degradation to provide108328856447vlAttorney Docket No: 243735.000512metabolic substrates for growing tumors and act on the central nervous system to induce sickness behaviors such as anorexia, driving a negative energy balance and weight loss. Additionally, loss of Lkbl is known to regulate the production of a host of proinflammatory cytokines in NSCLC19’21’23, including IL-6 and LIF, which have defined roles in causing cachexia. To identify potential mediators of sickness (cachexia) in KL GEMMS fed HFD, both expression and circulating levels of pro-inflammatory cytokines and secreted factors previously linked to cachexia were profiled in both healthy and tumor bearing animals fed chow or HFD. An increases in both gene expression and circulating levels of both IL-6 (Fig.8A) and GDF-15 (Fig.8D) in KL GEMMs was observed, which have been previously implicated in driving decreases in food intake and weight loss in cachexia. Use of a neutralizing antibody towards IL-6 failed to rescue features of cachexia in KL GEMMs consuming HFD (Figs. 8B-8C and 8J), while whole-body Gdfl5 knockout mice harboring Kras-Lkbl mutant NSCLC (Fig.8E) still demonstrated features of accelerated cachexia upon switching to HFD (Figs. 8F-8H), including reduction in survival probability (Fig. 81).Changes in other circulating factors previously shown to be increased in circulation upon loss of Lkbl and linked to cachexia, including LIF, IL-la / p, TNF-a, and IFN-y, were not significantly altered at this time point (Figs. 15A-15F), while levels of other factors, such as plasma PTHrP8and LCN271were elevated in KL GEMMs independent of dietary intervention (Figs. 15G-15H).These data suggest that common circulating factors do not play a role in diet-induced cachexia in KL GEMMs.Localized signals promote sickness behavior CAC in Lkbl -mutant lung cancer

[0386] The rapid decrease in food intake, water intake, motility, and weight in KL GEMMs fed HFD mirrors the phenotypes of sickness behaviors in models of infection. Sickness behaviors describe stereotyped behavioral and physiological responses that overlap with features of cachexia, including decreases in food and water intake, cognitive impairment, and catabolism of tissues such as skeletal muscle33’35. Inflammatory factors and immune stimuli are capable of inducing sickness behaviors when administered peripherally, yet recent studies have highlighted how localized signals may induce sickness behaviors in infection models through detection by sensory neurons. For example, in influenza infections of the lung, local production of prostaglandins signal through specific populations of sensory neurons of the vagus nerve to promote sickness26, while lipopolysaccharide is detected by TRPV1+ sensory neurons in the lung to induce sickness in mouse models of bacterial pneumonia25. Tumors are densely innervated and highly inflammatory46,109328856447vlAttorney Docket No: 243735.000512producing both localized and circulating mediators with significant overlap between the immune phenotype between tumors and infections47. Given a lack of candidate circulating mediators in the diet-induced cachexia model described herein, it was hypothesized that local signaling may be contributing to cachexia (sickness) in KL GEMMs.

[0387] Bronchoalveolar lavage fluid (BALF) was collected from tumor bearing animals subjected to different dietary interventions and performed Luminex profiling of 44 cytokines / chemokines (including IL-6, ILl-a / p, TNF-a, IFNy, CCL2, LIF) to detect local signals that may be driving decreased consumption of high-fat diet. Of the cytokines previously implicated in cachexia and demonstrated to reduce food intake, only IL-6 was found to be significantly increased in BALF upon consumption of HFD (Figs. 9A-9G), yet its neutralization had shown to be ineffective in alleviating HFD induced sickness (Figs.8A-8C and 8J).

[0388] It was hypothesized that other locally acting molecules could be driving HFD-induced sickness behaviors. Prostaglandins are a group of locally acting lipid mediators produced by cyclooxygenase enzymes34(Fig. 3A) and mediate a diverse range of actions, including vasodilation, promotion of inflammation, and platelet aggregation48. Prostaglandin E2 (PGE2), an omega-6-eicosanoid produced from arachidonic acid, has been demonstrated to promote sickness behaviors when administered systemically34,48and has recently been demonstrated to signal to specific sensory neurons in the lung to promote sickness behaviors following influenza infection26. This pleiotropic lipid mediator has also been implicated in driving neural inflammation, reductions in food intake, and muscle protein degradation in cachexia72-78. Additionally, consumption of high-fat diet has been implicated in changes in prostaglandin signaling and the development of diet-induced obesity49. To detect disturbances (changes) in prostaglandin signaling that promote sickness behaviors in the diet-induced cachexia model of the present disclosure, polyunsaturated fatty acid (PUFA) metabolomics was performed on BALF isolated from tumor bearing animals fed either chow or HFD. PGE2 levels were measured in BALF from mice harboring loss of Lkbl compared to p53 or Cdkn2a / 2b by ELISA. A significant increase in the levels of PGE2 in KL-tumors upon consumption of HFD was detected (Figs. 3B and 13B), with higher levels of PGE2 detected in BALF in tumors harboring loss of Lkbl as detected by ELISA. KP and KCC tumorbearing animals displayed no significant increase in PGE2 when fed a HFD (Fig. 13A). Expression of microsomal prostaglandin E synthase (Ptges), the enzyme responsible for production of PGE2 and PGE3 from prostaglandin H2 and Hj, respectively, was found to be increased in tumor cells110328856447vlAttorney Docket No: 243735.000512upon loss of Lkbl and upon consumption of HFD (Figs. 3C-3D). Additionally, loss of Lkbl was demonstrated to increase levels of prostaglandin synthesis enzymes in human NSCLC cell-lines (Figs. 10B-10E) and Ptges expression levels in Lkbl knockout mice (Figs. 13D and 10B-10E).Indeed, treatment of Lkbl-mutant cell lines with linoleic acid, an 18:2 (n-6) polyunsaturated fatty acid that is highly enriched in lard, the main component of HFD, resulted in significant increases in the production of PGE2 (Figs. 10F-10G). These results suggest that loss of Lkbl leads to an increase in production of PGE2 that is exacerbated upon increased dietary consumption of precursors to prostaglandin synthesis.

[0389] To investigate whether PGE2 plays a role in human cachexia, BALF PGE2 levels were measured in patients with NSCLC who had experienced >5% weight loss over 6 months, or >2% weight loss if BMI was <20, and compared them with weight-stable patients. PGE2 was significantly higher in the patients with weight loss (Figs. 16G and 16H). Furthermore, a transcriptomic analysis of BALF cells from the tumor area of patients with cachexia showed upregulation of prostaglandin signaling pathways (Fig. 161), suggesting local prostaglandin signaling may contribute to the development of cachexia.

[0390] How Lkbl loss leads to increased production of PGE2 was explored by assessing the expression and protein levels of microsomal prostaglandin E synthase (Ptges), the enzyme responsible for production of PGE2 and PGE3 from prostaglandin H2 and H3, respectively. Ptges levels were increased in tumor cells upon loss of Lkbl (Fig. 16A) and further elevated upon consumption of HFD (Fig. 16B), but remained unchanged in the context of KP and KCC tumors (Figs.l3B, 13C, 16C, and 16D). Additionally, the loss of Lkbl increased levels of prostaglandin synthesis enzymes in human NSCLC cell-lines (Figs. 16E-16G and 10B). Treatment of LKB1-mutant cell lines with linoleic acid, an 18:2 (n-6) polyunsaturated fatty acid that is highly enriched in lard, the main component of HFD, resulted in significant increases in the production of PGE2 (Fig. 10C). In contrast Kras-WT, EGFR-mutant NSCLC cell lines produce low levels of PGE2 both in presence and absence of linoleic acid (Fig.10D). In line with the diet-exacerbated cach...

Claims

Attorney Docket No: 243735.000512Claims1. A method of treating cachexia and / or sickness behavior in a subject having a cancer and (i) a mutation in a liver kinase Bl (LKB1) gene and / or (ii) suppression of LKBl-mediated signaling, the method comprising:a) inhibiting synthesis and / or activity and / or function of one or more prostaglandins; b) inhibiting one or more prostaglandin receptors; and / orc) inhibition of sensory neurons.

2. The method of claim 1, wherein the cancer comprises a lung cancer, a pancreatic cancer, a cervical cancer, and / or a cholangiocarcinoma.

3. The method of claim 1 or claim 2, wherein the cancer is non-small cell lung cancer.

4. The method of any one of claims 1-3, wherein the LKB1 mutation comprises a loss of function mutation.

5. The method of claim 4, wherein the LKB1 mutation comprises a point mutation, a frameshift mutation, a splice mutation, an insertion mutation, a deletion mutation, a missense mutation, a nonsense mutation, a chromosomal arm deletion, and / or a focal deletion.

6. The method of claim 4 or claim 5, wherein the LKB1 mutation comprises a G251V mutation, a G251R mutation, a G251C mutation, a S216F mutation, a D194H mutation, a D194Y mutation, a G242W mutation, a G242V mutation, a W239C mutation, a Q220* mutation, a R86* mutation, a Y60* mutation, a E165* mutation, a P281Rfs*6 mutation, a L282Afs*3 mutation, a K84* mutation, a E223* mutation, a E33* mutation, D53Tfs*ll mutation, a K78N mutation, a E199* mutation, a G56V mutation, a E57Kfs*7 mutation, a D53Gfs*110 mutation, a G56W mutation, a E70* mutation, a K62* mutation, a A43Pfs*8 mutation, a E65* mutation, a Y60* mutation, a K146* mutation, a K175* mutation, a K262* mutation, a K235* mutation, a K78E mutation, a T250Rfs*37 mutation, a N259Kfs*28 mutation, a D176A mutation, a L228Rfs*33 mutation, a D30Gfs*133 mutation, a E265Gfs*19 mutation, a S69* mutation, a KI 08* mutation, a El 38* mutation, a V77Sfs*19 mutation, a Q37Pfs*123 mutation, a Q220Pfs*46 mutation, a M136K mutation, a M136I mutation, a STK11-ARHGAP45 Fusion mutation, a STK11-SRFBP1 Fusion mutation, a ARHGAP45-STK11 Fusion mutation, a TNRC6B-STK11 Fusion mutation, a Q137H mutation, a L245F mutation, a H168R mutation, a Q170P mutation, a Y118H mutation, a M129I 134328856447vlAttorney Docket No: 243735.000512mutation, a I224V mutation, a X200_splice mutation, a X155_splice mutation, a X245_splice mutation, aX288_splice mutation, and / or a X97_splice mutation.

7. The method of any one of claims 1-6, wherein the suppression of LKBl-mediated signaling includes a mutation in a salt-inducible kinase (SIK) gene.

8. The method of claim 7, wherein the SIK is SIK1, SIK2, and / or SIK3.

9. The method of claim 7 or claim 8, wherein the SIK mutation comprises a loss of function mutation.

10. The method of any one of claims 1-9, wherein the prostaglandin is prostaglandin E2 (PGE2).

11. The method of any one of claims 1-10, wherein the synthesis of the one or more prostaglandins is inhibited by decreasing activity and / or function of a prostaglandin synthase.

12. The method of claim 11, wherein the prostaglandin synthase is a cyclooxygenase (COX) enzyme, phospholipase A2, and / or prostaglandin E synthase (PTGES).

13. The method of claim 12, wherein the COX enzyme is COX-1 or COX-2.

14. The method of any of claims 11-13, wherein the activity and / or function of the COX enzyme is decreased by administering a therapeutic agent.

15. The method of claim 14, wherein the therapeutic agent that decreases the activity and / or function of the COX enzyme comprises a competitive inhibitor, a non-competitive inhibitor, an uncompetitive inhibitor, a reversible inhibitor, and / or an irreversible inhibitor.

16. The method of claim 14 or claim 15, wherein the therapeutic agent comprises a small molecule.

17. The method of claim 16, wherein the small molecule comprises a COX-1 inhibitor and / or a COX-2 inhibitor.

18. The method of claim 17, wherein the COX-1 inhibitor is a selective COX-1 inhibitor or a non-selective COX- 1 inhibitor.

19. The method of claim 17, wherein the COX-2 inhibitor is a selective COX-2 inhibitor or a non-selective COX-2 inhibitor, optionally wherein the selective COX-2 inhibitor comprises celecoxib (Celebrex), NS-398 (N-[2-(cyclohexyloxy)-4-nitrophenyl]-methanesulfonamide), and / or valdecoxib (Bextra).135328856447vlAttorney Docket No: 243735.00051220. The method of any one of claims 14-19, wherein the therapeutic agent that decreases the activity and / or function of the COX enzyme comprises a non-steroidal anti-inflammatory drug (NSAID).

21. The method of claim 20, wherein the NSAID is ibuprofen or acetylsalicylic acid.

22. The method of claim 14 or claim 15, wherein the therapeutic agent that decreases the activity and / or function of the COX enzyme is an antibody.

23. The method of claim 14 or claim 15, wherein the therapeutic agent that decreases the activity and / or function of the COX enzyme comprises a polyunsaturated fatty acid (PUFA).

24. The method of claim 23, wherein the PUFA comprises an omega-3 PUFA.

25. The method of claim 23 or claim 24, wherein the PUFA comprises eicosapentaenoic acid (EPA) and / or docosahexaenoic acid (DHA).

26. The method of claim 25, wherein the EPA is administered in an amount of 250 mg / day to 3000 mg / day.

27. The method of claim 25, wherein the DHA is administered in an amount of 250 mg / day to 3000 mg / day.

28. The method of any one of claims 25-27, wherein the ratio of EPA to DHA is 2: 1.

29. The method of claim 11, wherein the prostaglandin synthase is prostaglandin E synthase (PTGES).

30. The method of claim 29, wherein the PTGES is microsomal PTGES.

31. The method of claim 29 or claim 30, wherein the activity and / or function of PTGES is decreased by administering a therapeutic agent.

32. The method of claim 31, wherein the therapeutic agent that decreases the activity and / or function of PTGES is a small molecule.

33. The method of claim 32, wherein the small molecule is selected from crisdesalazine (AAD-2004), compound III (N-cyclopentyl-l-[5,6-dimethyl-l-(l-methylethyl)-lH-benzimidazol-2-yl]-4-piperidinecarboxamide; mPGES-1 Inhibitor III), LY3023703 (2-(difluoromethyl)-5-[[(2-methyl- 1 - oxopropyl) amino] methyl] -N- [4-methyl- 5 - [4- (trifluoromethyl)phenyl] - 1 H-imidazol- 2-136328856447vlAttorney Docket No: 243735.000512yl]-3-pyridinecarboxamide), AF3485 (N-[9-(2-hydroxyethyl)-9H-carbazol-3-yl]-2-(trifluoromethyl)-benzamide), MF63 (2-(6-chloro- lH-phenanthro[9,10-d]imidazol-2-yl)-isophthalonitrile), AF3442 (N-(9-ethyl-9H-carbazol-3-yl)-2-(trifluoromethyl)benzamide), PF-9184 (N-(3',4'-dichloro[ 1, 1 ’-biphenyl] -4-yl)-4-hydroxy-2H- 1,2-benzothiazine-3-carboxamide 1,1-dioxide), PF-4693627 (l-[5-chloro-6-(4-chlorophenyl)-2-benzoxazolyl]-N-[(lS,3S)-3-(hydroxymethyl)cyclohexyl]-4-piperidinecarboxamide), LY3031207 (2-chloro-N-(lH-imidazol- 2-yl)-5-(pivalamidomethyl)benzamide), YS 121 (2-(4-chloro-6-(2,3-dimethylphenylamino)pyrimidin-2-ylthio)octanoic acid), MK-886 (l-[(4-chlorophenyl)methyl]- 3-[(l,l-dimethylethyl)thio]-alpha,alpha-dimethyl-5-(l-methylethyl)-lH-indole-2-propanoic acid), and dexamethasone, or derivative(s) thereof.

34. The method of claim 31, wherein the therapeutic agent that decreases the activity and / or function of PTGES is an antibody.

35. The method of any one of claims 1-10. wherein the activity and / or function of a prostaglandin is inhibited by increasing activity and / or function of a different prostaglandin.

36. The method of claim 35, wherein the activity and / or function of PGE2 is inhibited by increasing activity and / or function of prostaglandin E3 (PGE3), optionally by administering a PUFA, preferably an omega-3 PUFA, alone or in combination with a low-fat diet, for example simultaneously with a meal of the low-fat diet, before a meal of the low-fat diet, or after a meal of the low-fat diet.

37. The method of claim 36, wherein the PUFA comprises eicosapentaenoic acid (EPA) and / or docosahexaenoic acid (DHA).

38. The method of claim 37, wherein the EPA is administered in an amount of 250 mg / day to 3000 mg / day.

39. The method of claim 37, wherein the DHA is administered in an amount of 250 mg / day to 3000 mg / day.

40. The method of any one of claims 37-39, wherein the ratio of EPA to DHA is 2: 1.

41. The method of any one of claims 13-22 or 29-34, wherein the therapeutic agent is administered in combination with a PUFA, preferably an omega-3 PUFA.137328856447vlAttorney Docket No: 243735.00051242. The method of claim 41, wherein the PUFA comprises eicosapentaenoic acid (EPA) and / or docosahexaenoic acid (DHA).

43. The method of claim 42, wherein the EPA is administered in an amount of 250 mg / day to 3000 mg / day.

44. The method of claim 42, wherein the DHA is administered in an amount of 250 mg / day to 3000 mg / day.

45. The method of any one of claims 42-44, wherein the ratio of EPA to DHA is 2:

146. The method of any one of claims 13-33 or 41-45, wherein the therapeutic agent, optionally in combination with the PUFA, is administered with a low-fat diet.

47. The method of claim 46. wherein the therapeutic agent, optionally in combination with the PUFA, is administered simultaneously with a meal of the low-fat diet, before a meal of the low-fat diet, or after a meal of the low-fat diet.

48. The method of any one of claims 1-10, wherein the one or more prostaglandin receptors are selected from the group consisting of prostaglandin E2 receptor 1 (EPl), prostaglandin E2 receptor 2 (EP2), prostaglandin E2 receptor 3 (EP3), and prostaglandin E2 receptor 4 (EP4).

49. The method of claim 48, wherein the one or more prostaglandin receptors are EPl receptors.

50. The method of claim 48 or claim 49, wherein the activity and / or function of the one or more prostaglandin receptors is inhibited by an antagonist.

51. The method of claim 50, wherein the antagonist is a competitive antagonist, a non-competitive antagonist, an uncompetitive antagonist, a reversible antagonist, and / or an irreversible antagonist.

52. The method of claim 50 or claim 51, wherein the antagonist is a small molecule.

53. The method of any one of claims 48-52, wherein the one or more prostaglandin receptors are EPl receptors and the antagonist comprises SC-51322, GW-848687X, SC-19220, SC-51089, ONO-8713, ONO-8130, and / or ONO-8711.

54. The method of any one of claims 48-51, wherein the one or more prostaglandin receptors are EP2 receptors and the antagonist comprises PF-04418948, TG6-10-1, and / or TG8-260.138328856447vlAttorney Docket No: 243735.00051255. The method of any one of claims 48-51, wherein the one or more prostaglandin receptors are EP3 receptors and the antagonist comprises DG-041, E798-106, and / or ONO-AE3-240.

56. The method of any one of claims 48-51, wherein the one or more prostaglandin receptors are EP4 receptors and the antagonist comprises ONO-AE3-208, LY3127760. Grapiprant, AH6809, and / or RQ-15986.

57. The method of claim 50 or claim 51, wherein the antagonist is an antibody.

58. The method of any one of claims 50-57, wherein the antagonist is administered in combination with a PUFA, preferably an omega-3 PUFA.

59. The method of claim 58, wherein the PUFA comprises eicosapentaenoic acid (EPA) and / or docosahexaenoic acid (DHA).

60. The method of claim 59, wherein the EPA is administered in an amount of 250 mg / day to 3000 mg / day.

61. The method of claim 59, wherein the DHA is administered in an amount of 250 mg / day to 3000 mg / day.

62. The method of any one of claims 59-61, wherein the ratio of EPA to DHA is 2:1.

63. The method of any one of claims 50-62, wherein the antagonist, optionally in combination with the PUFA, is administered with a low-fat diet.

64. The method of claim 63, wherein the antagonist, optionally in combination with the PUFA, is administered simultaneously with a meal of the low-fat diet, before a meal of the low-fat diet, or after a meal of the low-fat diet.

65. The method of any one of claims 1-10, wherein the sensory neurons are inhibited by a chemogenetic compound, blocking or stimulating a vagal nerve in the subject, or by vagotomy.

66. The method of claim 65, wherein the sensory neurons are adjacent to the cancer in the subject.

67. The method of claim 66, wherein the sensory neurons are in a lung of the subject.

68. The method of any one of claims 65-67, wherein the chemogenetic compound comprises clozapine-N-oxide (CNO).

69. The method of any one of claims 65-67, wherein the vagotomy is unilateral.139328856447vlAttorney Docket No: 243735.00051270. The method of any one of claims 65-67, wherein blocking the vagal nerve comprises an intermittent vagal blockade, optionally via an implanted device.

71. The method of any one of claims 65-67, wherein the vagal nerve is stimulated via an implanted device.

72. The method of any one of claims 65-67, the method further comprising:(i) administering a therapeutic agent according to the method of any one of claims 14-34 or 41-47,(ii) increasing activity and / or function of the different prostaglandin according to the method of any one of claims 35-40, and / or(iii) administering an antagonist according to the method of any one of claims 50-64.

73. The method of any one of claims 1-72, wherein the subject is a mammal.

74. The method of any one of claims 1-73, wherein the subject is a human.140328856447vl